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Summary 
 
Liposomes remain at the forefront of vaccine design due to their well documented abilities 
to act as delivery vehicles and adjuvants. Liposomes have been described to initiate an 
antigen depot-effect, thereby increasing antigen exposure to circulating antigen-
presenting cells. More recently, in-depth reviews have focussed on inherent 
immunostimulatory abilities of various cationic lipids, the use of which is consequently of 
interest in the development of subunit protein vaccines which when delivered without an 
adjuvant are poorly immunogenic.  
The importance of liposomes for the mediation of an antigen depot-effect was examined 
by use of a dual-radiolabelling technique thereby allowing simultaneous detection of 
liposomal and antigenic components and analysis of their pharmacokinetic profile. In 
addition to investigating the biodistribution of these formulations, their physicochemical 
properties were analysed and the ability of the various liposome formulations to elicit 
humoral and cell-mediated immune responses was investigated. 
Our results show a requirement of cationic charge and medium/strong levels of antigen 
adsorption to the cationic liposome in order for both a liposome and antigen depot-effect 
to occur at the injection site. The choice of injection route had little effect on the 
pharmacokinetics or immunogenicity observed. In vitro, cationic liposomes were more 
cytotoxic than neutral liposomes due to significantly enhanced levels of cell uptake. With 
regards to the role of bilayer fluidity, liposomes expressing more rigid bilayers displayed 
increased retention at the injection site although this did not necessarily result in 
increased antigen retention. Furthermore, liposome bilayer rigidity did not necessarily 
correlate with improved immunogenicity. In similar findings, liposome size did not appear 
to control liposome or antigen retention at the injection site. However, a strong liposome 
size correlation between splenocyte proliferation and production of IL-10 was noted; 
specifically immunisation with large liposomes lead to increased levels of splenocyte 
proliferation coupled with decreased IL-10 production.  
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1.1 The History of Vaccination 
The origins of vaccination lie with smallpox, a disease which once ravaged most, if not all 
parts of the world. Initial descriptions of smallpox stem from as early as 1122 BC from 
texts originating in China. Smallpox was known to spread rapidly and resulted in 
disfigurement, blindness and death. It was also known that smallpox was infectious and 
early reports dating from 430 BC describe survivors of smallpox being used to treat those 
infected in a process known as inoculation (Gross and Sepkowitz, 1998). Over many 
hundreds of years the concept of inoculation began to take form and involved a small 
swab of infectious material (otherwise known as pus) being placed on the skin of non-
infected persons. However, it was not until 1722, when members of the English Royal 
Family were successfully immunised against smallpox using this method, that inoculation 
was accepted in the scientific community of the western-world (Riedel, 2005). For the 
following 70 years many people were inoculated against smallpox using infected material 
derived from those infected with smallpox. One such person was Edward Jenner, born in 
1749 in Gloucestershire, UK. He developed a strong interest in science and after 
overhearing a young dairymaid claim that she may never have smallpox as she had had 
cowpox, he decided to investigate further. In 1796 Jenner successfully inoculated a young 
boy with infectious material from a dairymaid who had cowpox lesions; two months later 
he exposed the boy to smallpox and no disease resulted. This was the beginning of what 
we now term vaccination. 
 
1.2 Current Vaccination Campaigns with Focus on Tuberculosis 
The process of vaccination is now commonplace in the western world where drugs and 
medical treatment are relatively accessible. Whilst vaccination is of principle benefit to the 
individual receiving the vaccine, the concept of herd immunity is possibly more important 
as vaccination campaigns are dependent on the development of herd immunity to 
successfully eradicate disease. This was classically seen in 1980 when the world was 
declared free of smallpox and likewise plans have played a primary role in the success of 
diminishing polio cases. The World Health Organisation (WHO) campaign to eradicate 
polio has however been blighted by political instabilities with consequential poor vaccine 
uptake and poor herd immunity. To date, polio remains endemic in four countries (India, 
Pakistan, Afghanistan and Nigeria) and in 2009 there were just 1604 cases worldwide, a far 
cry from the 350,000 cases in 1988 when the worldwide vaccination campaign began (The 
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Global Polio Eradication Initiative, 2010). In addition to polio, elimination of the diseases 
measles and tetanus by vaccination is also being actively supported by the WHO (The 
World Heath Organisation, 2009).   
 
We have now entered ‘the decade of vaccines’ (The Lancet Infectious Diseases, 2010) in 
which many of the obstacles faced in bringing vaccines from the laboratory to the clinic 
will hopefully be addressed. Possibly the most important aspect is funding for the 
discovery and development of vaccines, however the financial gain of vaccine production 
to companies obviously remains an important issue. In 2008 the vaccine market was 
estimated to be worth €11.5 billion and substantial expansion is predicted (Taylor et al., 
2009), especially from developing country manufactures (Milstien and Kaddar, 2010). 
However, unlike drug development, vaccine development does not offer the same 
financial gain, especially for the development of vaccines against diseases of the 
developing world. Approaches such as those applied by GlaxoSmithKline (GSK) Biologicals 
in collaboration with The Global Alliance for Vaccines and Immunisation (GAVI) have 
resulted in the provision of vaccines to the world’s poorest countries at prices typically 10 
- 25 % of those paid by the developed world (Taylor et al., 2009). Strategies such as these 
are the only way in which vaccination can be offered to everyone and therefore help in the 
worldwide aim to eradicate particularly infectious and debilitating diseases.  
 
With regards to funding of vaccine research and development, there still remains a 
significant lack of cash inflow for diseases of the developing world, aptly termed neglected 
diseases. With the celebration of GAVI’s 10th birthday also arrived a $10 billion payment 
from the Bill and Melinda Gates foundation, a sum which will significantly help in the 
distribution of the vaccines it disburses against diphtheria, tetanus, pertussis, hepatitis B 
and Haemophilus influenzae type b (The Lancet Infectious Diseases, 2010). However, $10 
billion represents just a small amount when one considers that an estimated $2 billion is 
needed every year for the continuing discovery and development of a vaccine against 
tuberculosis (TB) alone (Kaufmann et al., 2010). Although the current TB vaccine funding is 
significantly lower than required, the first decade of the millennia has still been an 
relatively productive period (Table 1.1); in 2009 there were 10 vaccines undergoing clinical 
trials with a further 6 in preclinical studies and over 22 candidate formulations (Stop TB 
Partnership, 2009). Interestingly, and discussed in detail later, there remains huge scope in 
the type of vaccine, proposed vaccine schedule and antigen/adjuvant selected, all of which 
20 
 
further highlight the complexity of designing vaccines against TB and other diseases 
(Kaufmann et al., 2010). 
 
Underlined components are antigens requiring adjuvants. Data collected from (Stop TB 
Partnership, 2009). 
 
 
The current vaccination campaign in the UK recommends vaccination against the 
diphtheria, measles, mumps, rubella, tetanus, polio, Haemophilus influenzae type b (Hib), 
pneumococcal, meningitis C and human papillomavirus types 16 and 18. Non-routine 
vaccines include the Bacillus Calmette-Guérin (BCG) and hepatitis B vaccines for those who 
are high-risk individuals (National Health Service, 2010). Between 1953 and 2005 it was 
national policy to vaccinate against TB using the BCG vaccine. However, the BCG vaccine 
was removed from the recommended immunisation schedule in the UK as it was no longer 
cost effective in a country which saw so few cases of TB. Furthermore, side-effects of the 
vaccine such as abscesses outweighed the preventative role of the vaccine. Importantly, 
numerous studies have shown huge variance in the efficacy of the BCG vaccine with values 
ranging from 0 – 80 % quoted. With regards to this, it is surprising that the BCG vaccine 
remains the most commonly used vaccine worldwide with over 3 billion people having 
received it (Andersen and Doherty, 2005). Although very successful as a vaccine to prevent 
21 
 
TB in newborn infants, the pitfalls of the BCG include its poor ability to maintain long term 
immunity and poor efficiency at preventing establishment of latent TB (Andersen, 2007). 
The most recent report on the number of TB cases in the UK shows the incidence of TB to 
be increasing (Moore et al., 2009). In 2008 there were 8,655 cases of TB diagnosed, 
equivalent to an increase of 2.9 % in the number of cases since 2007. The number of cases 
in the under 5 age group (which is often used as an indicator of recent transmission) has 
remained stable at approximately 5 in 100,000 since 2000 (Moore et al., 2009). However, 
an interesting finding in the demographics of TB incidence show that whilst the majority of 
cases in UK-born persons are in the 85 - 89 year age group (10 in 100,000), in non-UK born 
persons this figure is over 10-fold higher (123 in 100,000) and principally affected those 
between 25 - 29 years of age. Assuming that all UK-born persons received the BCG, this 
data would support the poor long-term immunising ability of the BCG vaccine with active 
TB posing a significant problem in immunocompromised ageing populations. In contrast, 
non-UK born persons show increased rates of TB at a young age when the immune system 
should be able to prevent onset of disease (assuming they had been vaccinated and it had 
been successful). Therefore with regards to tackling TB in the UK, there are two target 
groups: those who have previously been vaccinated against TB with a vaccine that does 
not confer life-long protection, and those that have not previously been vaccinated and 
act as a disease reservoir. The WHO estimates the number of new cases of TB in 2007 to 
be 9.27 million with a mortality of nearly 1.4 million (Bauquerez et al., 2009). In relation to 
global HIV incidence (2.7 million) in the same year, the scale of the TB pandemic is clear. It 
is now accepted that the previous long-term goal to reduce TB incidence to less than one 
case per million by 2050 (Dye et al., 2006) will now not be accomplished, and an 
intensified research vaccine development strategy with increases in funding is required 
(Kaufmann et al., 2010; Lönnroth et al., 2010). It should be noted that global vaccine 
research has intensified over the last 13 years with dramatic increases in the number of 
companies developing vaccines as well as the number of vaccines entering pre-clinical 
trials (Davis et al., 2010). 
 
1.3 Overview of the Immune System 
The immune system comprises many cellular and humoral components which must be 
able to protect the host from disease, a term which includes infection, autoimmune 
syndromes, injury and mutations. To do so, the host has acquired the ability to evolve to 
its environment, a classic example being the gut whereby commensal microbes live in 
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harmony with the host. The immune system can be divided into innate and acquired parts 
although interplay between the two is vital and there are many crossover components. 
The innate immune system can be described as the non-specific and rapid response to 
infection but the results are short lived and non-protective against future infection. In 
contrast, the acquired immune system is specific and long-term but equally takes time to 
establish. The aim of a vaccine is to mimic the immune response provoked by primary 
infection (hence the innate immune response) of a pathogenic substance but without 
causing the associated pathogenicity and eliciting significantly strong memory responses 
to protect the host upon future infection (hence the adaptive immune system). To do so 
both innate and acquired immune systems, comprising cellular and humoral components, 
must be stimulated in a process that involves recognition, uptake and presentation of 
antigen with subsequent establishment of a population of memory T and B cells (a concise 
review is given in (McCullough and Summerfield, 2005). The general processes involved in 
pathogen recognition through to antigen presentation to T cells are explained below.  
 
1.3.1 Recognition of pathogenic material 
Primary exposure to a pathogen results in a rapid non-specific response including the 
production of complement proteins and cytokines, both of which are capable of alerting 
circulating granulocytes (neutrophils, eosinophils and basophils) and mononuclear 
phagocytes (monocytes and macrophages) of a potential infection. The production of 
cytokines by granulocytes and mononuclear phagocytes results in local inflammation 
characterised by vasodilation, increased blood supply and initiation of a positive feedback 
loop with high amounts of pro-inflammatory cytokines, chemokines and phagocytes.  
Whilst local tissue damage plays an important role in the production of the humoral 
substances, pathogen derived factors such as toxins (e.g. from pathogens such as 
Corynebacterium diphtheriae, causing diphtheria, or Clostridium tetani, causing tetanus) or 
structural components such as bacterial flagella or surface glycoproteins may also initiate 
activation of the innate immune response. Pathogen association with host humoral 
(complement and antibodies) and cellular components initiates a series of events leading 
to pathogen uptake and consequent processing.   
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1.3.2 Mechanisms of uptake 
Endocytosis is an umbrella term to describe the uptake of both host and pathogen derived 
macromolecules (Khalil et al., 2006). Endocytosis can be divided into phagocytosis (cell 
eating) and pinocytosis (cell drinking) depending on factors such as the size of the 
substance being uptaken, the receptors or ligands (if any) required and the components of 
the cells intracellular matrix (e.g. actin cytoskeleton) involved (Figure 1.1).  
 
 
 
Figure 1.1 Mechanisms of endocytosis. Depicted here are phagocytosis used to clear dead 
cells and large pathogens (> 0.5 μm), macropinocytosis stimulated by mitogens to uptake 
pathogens of <5 μm, clathrin-mediated endocytosis involving uptake of small (~ 50 nm) 
pathogens and finally caveolae-mediate endocytosis which mediates uptake of pathogens 
in the size range of 100 - 150 nm. Only the latter mechanism does not result in vesicle-
lysosome association with consequent degradation by lysosomal enzymes. Adapted from 
(Khalil et al., 2006). 
 
 
Whilst it is generally considered that the consequence of endocytosis is lysosomal 
degradation of the pathogenic substance, as noted in Figure 1.1 this is not always the case 
as some intracellular vesicles are ‘leaky’ whilst others do not deliver their contents to 
lysosomes, instead targeting the endoplasmic reticulum and the Golgi apparatus 
(caveolae-mediated endocytosis). Larger (> 0.5 μm) pathogens are taken up by 
phagocytosis after binding with specific cell surface receptors such as Fcγ receptors. In this 
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case the pathogen must have encountered the opsonin system which comprises 
circulating antibodies and complement proteins that can bind pathogens. Macrophages 
are considered to be the professional phagocytic cell and are avid scavengers for both 
pathogenic substances and host infected cells expressing ‘eat-me’ signals (Hume, 2008). 
Pathogens of < 5 μm can be taken up by macropinocytosis or clathrin/caveolae mediated 
endocytosis (Khalil et al., 2006). For uptake routes in which endosome-lysosome fusion 
can occur, there is a decrease in pH as the endosomes matures. This feature has been 
used by pathogens such as Listeria and Shigella as a method to escape lysosomal 
degradation (Cossart and Roy, 2010).  
 
It is postulated that such a variety of uptake mechanisms evolved to activate different 
downstream targets – knowledge of these different mechanisms is therefore of particular 
interest to vaccine development as it offers the possibility of selective targeting of specific 
immune responses depending on the antigen uptake route. The downstream target for 
the host is the processing and presentation of pathogen-derived antigens to T cells so that 
‘Memory’ can be formed. Pathogens entering the cell via endocytosis are presented on 
MHC Cl II molecules whilst cytoplasmic pathogens are presented on MHC Cl I molecules. 
Whilst MHC Cl II molecules present antigens to CD4 expressing T cells (or Th cells), and 
MHC Cl I molecules present to CD8 expressing T cells (Tc cells), there is an additional 
mechanism known as cross-presentation whereby exogenous antigen can avoid MHC Cl II 
loading and instead be processed by proteasomes with subsequent MHC Cl I presentation. 
This mechanism has been attributed to DCs (Belz et al., 2002; den Haan and Bevan, 2001) 
and macrophages, albeit to a lesser ability (Trombetta and Mellman, 2005) and is of 
interest to vaccine design concerned with pathogens that do not directly infect APCs 
(Bhardwaj, 2001). 
 
1.3.3 Antigen presentation and activation of T cells 
T cells emerging from the thymic cortex and medulla are naïve until exposed to antigen 
and it is not until T cell receptor (TCR):antigen:MHC association with the relevant co-
stimulatory molecules are T cells activated to become ‘effector’ T cells. T cells which have 
already encountered antigen can be successfully activated without the requirement of 
relevant co-stimulatory signals. Figure 1.2 outlines the different methods in which T and B 
cells become activated.  
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Figure 1.2 Mechanisms of T cell activation upon uptake and presentation of antigen (Ag) 
by APCs. A; Exogenous antigens are uptaken by APCs and processed for display on MHC Cl 
II molecules. CD4+ T cells recognise antigen via their T cell receptor (TCR) and with co-
stimulation from CD80-CD28 interactions, intracellular signalling pathways leading to CD4+ 
T cell activation can occur. B; In a similar mechanism to ‘A’ but involving endogenous 
antigen, CD8+ T cells can become activated by antigen presented on MHC Cl I molecules. C; 
B cells are also APCs however they require CD40-CD40L interactions in addition to CD80-
CD28 for effective CD4+ T cell activation to occur. Furthermore, antigen uptake is mediated 
by association with surface bound membrane IgM antibodies (mIgM). 
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Both MHC Cl II:CD4+ T cell and MHC Cl I:CD8+ T cell antigen presentation follows a similar 
mechanism: associated with the TCR are the relevant CD4 or CD8 molecules which are 
capable of binding protein tyrosine kinases (PTK), and the intracellular domains of the TCR 
itself contain ITAMs which can be phosphorylated. This TCR complex forms signal 1 of the 
activation process but for successful activation a co-stimulatory signal known as signal 2 is 
also required (lack of signal 2 leads to peripheral tolerance and anergy of the T cell 
whereby it is incapable of responding to self or non-self antigen). Binding of co-stimulatory 
molecules CD80 (on the APC) and CD28 (on the T cell) form signal 2, the strength of which 
is increased upon activation of signal 1. This immunological synapse is bought into play by 
adhesion molecules such as DC-SIGN, ICAM-3 and LFA-1, all of which rearrange to stabilise 
the clustering of TCR:MHC molecules.  
 
Whilst DCs constitutively express CD80, macrophages and B cells must become activated 
for the expression of CD80. For this reason DCs are known as professional APCs however 
their phenotype is dependent on their location; within the peripheral tissues or the site of 
antigen uptake they are relatively poor at antigen presentation however upon their 
migration to the lymph nodes there is upregulation of co-stimulatory and MHC molecules 
so that in the lymph nodes they mature into potent APCs.                 
 
1.3.3.1 Activating intracellular pathways 
The series of intracellular events that are initiated by association of the MHC:TCR synapse 
involves PTKs, autophosphorylation of ITAMs and activation of the intracellular PTK Zap70. 
Zap70 activates two routes, the first involving the molecule IP3 and calcium release from 
the intracellular Ca2+ pool, and the second involving the signalling cascade DAG-PKC-
CARMA1-Bcl10-MALT1 eventual NFκB mediated gene transcription (Ruland and Mak, 
2003; Schmitz et al., 2003). Ca2+ acts as an activational secondary-signalling molecule and 
can induce exocytosis of granules acting as alarmins. Whilst this series of events relates to 
T cells during presentation of antigen, there are also numerous intracellular signalling 
pathways which occur in the APC which lead to upregulation of co-stimulatory molecules 
such as CD80 and CD40, upregulation of MHC molecules and production of chemokines, 
cytokines and other soluble factors which are all involved in the immune response. 
Initiation of such signalling pathways involves the binding of pathogenic components with 
numerous cellular receptors found on both myeloid and lymphoid cells. The best 
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described group of receptors are the Toll like receptors (TLRs) which are present on both 
the cell surface (TLRs 1, 2, 4, 5 and 6) and within the endosomal compartment (TLRs 3, 7, 8 
and 9). TLRs are known to signal via intracellular MyD88 or Trif adapter proteins followed 
by activation of either the IRF3 or TRAF6 pathways; there are numerous in depth reviews 
focussing on TLR signalling pathways (see (Harding and Boom, 2010; Kawai and Akira, 
2010; Monie et al., 2009)). Non-TLR receptors are also involved in pathogen recognition; 
these include C-type lectins such as Dectin-1, mannose, DC-SIGN and Mincle which signal 
via the CARD9-Bcl10-MALT10 pathway (Gregorio et al., 2009; Gross et al., 2006; 
Werninghaus et al., 2009). The role of these receptor-pathogen interactions with regards 
to vaccines and targeting the immune response are discussed in further detail in sections 
1.4 and 1.5.  
 
1.3.3.2 Localisation of responses 
As mentioned briefly above, DCs only become efficient APCs upon entering the lymph 
nodes – in the periphery they do not express sufficient MHC or co-stimulatory molecules 
to successfully present antigen and activate T cells. Figure 1.3 shows a schematic of the 
lymph node. The lymph nodes, which drain circulating lymph from the tissues unlike the 
spleen which is involved in filtering blood-borne antigen, are placed strategically around 
the body to maximise their chances of encountering pathogens. The highly organised 
nature of the lymph node involves regions of APC:T cell interactions (the paracortex), 
areas of antibody production by plasma cells (the medulla) and the outermost ‘cortex’ 
layer in which memory B cells form (Figure 1.3). By having such an organisation it allows 
naïve T cell interactions with APCs to occur in the T cell rich paracortex area whilst effector 
T (and B) cells which are involved in secondary responses lie in the follicle rich cortex. 
Primary follicles form secondary follicles upon antigen exposure and are composed of 
germinal centres in which memory T and B cells form. 
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Figure 1.3 Lymph node organisation : the lymph node comprises three layers, the cortex, 
paracortex and medulla. Lymph flowing inwards via the afferent lymphatic vessels filters 
through the tiered structure and leaves via the efferent lymphatic vessel. Primary and 
secondary follicles (where memory T and B cells form) are found in the cortex. 
 
1.3.4 T cell subsets 
As mentioned above, CD4+ T cells are typically depicted as being presented exogenous 
antigen on MHC Cl II molecules whilst CD8+ T cells are presented antigen from MHC Cl I 
molecules. CD8+ T cells are also termed cytotoxic T cells for their ability to initiate cell-
mediated killing of pathogen-infected or tumour cells. For this reason, initiation of CD8+ T 
cell immune responses during vaccination is especially important for vaccines targeting 
intracellular pathogens or cancer. CD8+ T cells are also sentinel in antigen cross-
presentation which allows exogenous antigen to stimulate CD8+ T cell mediated immune 
responses (den Haan and Bevan, 2001). CD4+ T cells can be further subdivided into 
numerous subsets initially chosen on the basis of their cytokine production (Mosmann et 
al., 1986). Today we recognise two traditionally distinct subsets of Th cells: Th1 and Th2 
originally segregated based on their production of IFN-γ and IL-4 respectively. However 
there are also at least three further subsets of Th cells (Th17 (Dong, 2008), TFH (Fazilleau et 
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al., 2009) and TReg (Piccirillo and Shevac, 2004)) which show considerable plasticity and 
have raised the question of whether T cells can be subdivided from a specific lineage 
(Bluestone et al., 2009). The variation in these numerous Th cell subsets further 
complicates our understanding of how TCR activation can lead to the T cell responses 
which are critical for immunity against pathogens.  
 
It is known that immunity relies on the production of memory T cells which includes both 
CD4+ and CD8+ T cell subsets. These memory cells must be capable of rapidly becoming 
effector cells with the capacity to recognise previously encountered antigen and initiate its 
removal or breakdown (Kaech et al., 2002). More recent techniques have allowed cytokine 
profiling of Th and Tc cell subsets at different stages in their development to create a 
timeframe profile of cellular development (Seder et al., 2008). Using multiparameter flow 
cytometry, the model produced (Figure 1.4) shows how exposure of naïve T cells to 
antigen results in a progressive increase in cytokine production until a stage is reached 
whereby the cytokines produced are optimal for the cells function as an effector cell. 
During this process the cells are termed ‘central memory’ cells or TCM cells and are positive 
for the cell surface homing receptor CCR7 indicating their ability to migrate to secondary 
lymphoid organs. Further exposure to antigenic stimuli results in a loss of CCR7 and 
cytokine production leading to decreased effector functions and ultimately apoptosis. The 
cytokines investigated for the purpose of developing this model were IFN-γ, TNF-α and IL-2 
as they are all relevant cytokines in the development of immunity against many pathogens 
to which vaccine formulations are required (for example IFN-γ and TNF-α are both 
commonly used parameters to assess vaccine-related immune responses against 
pathogens such as M. tuberculosis and Leishmania major, whilst IL-2 has a role in T cell 
expansion). Multiparameter flow cytometry has been extensively implemented to assess T 
cell differentiation in studies involving development of vaccines against HIV (Kloverpris et 
al., 2009; Steers et al., 2009), urothelial carcinoma (Sharma et al., 2008), advanced stage 
melanoma (Perales et al., 2008) and TB (Duffy et al., 2009; Elvang et al., 2009; Kamath et 
al., 2009; Kamath et al., 2008a; Linderstrøm et al., 2009). 
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Figure 1.4 Schematic defining T cell function based on their ability to produce TNF-α, IL-2 
and/or IFN-γ at periodic intervals during antigenic exposure. T cell progress from naïve 
CD4+ T cells (TNF-α- IL-2- IFN-γ-) towards IFN-γ+ T cells results in their progression from 
CCR7 expressing TCM (central memory) cells towards TEM (effector memory) cells which 
loose the cell surface homing receptor CCR7. Adapted from (Seder et al., 2008). 
 
1.4 Vaccines 
1.4.1 Types of vaccines 
The Collins English dictionary defines a vaccine as ‘a suspension of dead, attenuated, or 
otherwise modified microorganisms (viruses, bacteria, or rickettsiae) for inoculation to 
produce immunity to a disease by stimulating the production of antibodies’. This definition 
has somewhat changed recently with the development of cancer vaccines and vaccines 
against autoimmune diseases. Therefore, a more appropriate, simple and modern 
definition could be a substance which improves immunity to a certain disease. In their 
traditional organisation, vaccines are grouped into three categories: killed, attenuated or 
subunit vaccines. Killed vaccines contain chemically or heat-inactivated organisms which 
are unable to replicate or produce toxins. They structurally resemble their live 
counterparts however their genetic material is no longer functional. Typical examples of 
killed vaccines include inactivated polio vaccine (IPV) and the hepatitis A vaccine. Within 
the attenuated group are vaccines against yellow fever, mumps and TB. Attenuation is a 
method to weaken the pathogenic effects of a microorganism, either by altering its growth 
abilities or physically/chemically changing it so that it presents less of a danger to the host. 
31 
 
The final group comprises subunit vaccines which are composed of the antigenic unit of 
the pathogen. The principle benefits of subunit vaccines are their inability to revert to a 
pathogenic form, decreased toxicity, reproducible production and improved antigen 
specificity. Examples of subunit vaccines include vaccines against hepatitis B and influenza. 
In addition to this simplified list, vaccine development also includes toxoid based vaccines 
(against tetanus and diphtheria), peptide vaccines against autoimmune diseases (such as 
asthma and allergies), therapeutic cancer vaccines and DNA vaccines (whereby the host 
synthesises the antigenic proteins themselves).  
 
As highlighted in Table 1.1, there is no clear rule as to which type of vaccine 
(recombinant/killed/attenuated etc) may be superior against a certain disease. Certainly 
the present aim of vaccinologists is to focus on safety, including low toxicity and 
prevention of reversion to virulence. However immunogenicity obviously plays a major 
role. With regards to smallpox, whilst the live attenuated composition of the vaccine led to 
the successful eradication of the disease, there were numerous other factors which 
certainly contributed including the lack of an animal reservoir, non-zoonotic disease, 
stability of the vaccine formulation and clear disease symptoms. However it is interesting 
to note that the side effects from this vaccine were also sufficiently damaging for the 
vaccination campaign in the US to be halted in 1972, 8 years prior to the declaration by 
the WHO that the world was free from smallpox (Kennedy et al., 2009). Therefore even 
the only vaccine to have ever led to the eradication of a disease had its faults and it is 
most probable that if the smallpox vaccine was still required today, it would not be used as 
it would fail clinical trials.  
 
1.4.2 Improving subunit vaccine efficiency with adjuvants 
1981 marked the appearance of the first marketed subunit vaccine against Hepatitis B 
(Hilleman, 2000). Therefore in terms of arrivals onto the vaccine market, the subunit 
vaccines are latecomers with development rather than discovery being hindered by their 
poor immunogenic profile. However they have the very important advantage over 
attenuated or killed vaccines in that there is no chance of reversion to a virulent form. 
Subunit vaccines are based on solely the antigenic epitopes originally derived from a 
virulent organism; there is a total loss of the molecules which would have typically alerted 
the host to the dangerous nature of the pathogen, in addition to the loss of particulate 
nature. This appears to be the downfall of subunit vaccines – they are simply too ‘clean’ 
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and do not resemble pathogens. Therefore in an effort to improve the immune responses 
to subunit antigens, adjuvants are included in the formulation.  
 
Adjuvants, whose name stems from the Latin ‘adjuvare’ meaning to aid, come in such a 
wide range of shapes and sizes that even though documentation on adjuvants has existed 
for nearly 100 years, there is still no universally approved grouping system. One of the first 
papers published by Ramon described the adjuvant effect of a range of compounds 
including tapioca, agar and starch oil (Ramon, 1925). Following this, the use of inorganic 
compounds including aluminium phosphate and aluminium hydroxide were documented 
(Glenny et al., 1926) and these aluminium based compounds became the first licensed 
adjuvants in commercial vaccines. Until late 2009, aluminium based compounds remained 
the only US-licensed adjuvants whilst in Europe a wider scope of adjuvants had been 
recognised (Table 1.2). However, adjuvant development from bench to marketed vaccines 
has been slow with the first non-aluminium salt adjuvant being licensed less than 15 years 
ago (Mbow et al., 2010; O’Hagan and Gregorio, 2009). The slow output and lack of 
successful licensing is due to numerous reasons including poor scale-up and inflexibility 
with regards to the scope of antigens with which they can be administered (O’Hagan and 
Gregorio, 2009). However when the varied immunising abilities of different vaccine 
adjuvants bearing remarkably similar structure and composition are considered, their slow 
development is hardly surprising. For these reasons, adjuvants are licensed in individual 
vaccines as opposed to being considered a separate entity. Some of the more common 
adjuvants are discussed in detail below.  
 
Table 1.2 European licensed adjuvants for inclusion in vaccines 
GSK, GlaxoSmithKline; MPL, monophosphoryl lipid A; HPV, human papillomavirus; HBV, 
hepatitis B virus; HAV, hepatitis A virus. Adapted from (Friede, 2009; Mbow et al., 2010). 
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1.4.2.1 ‘Alum’ and other mineral salts 
‘Alum’ is a collective term often used to refer to a group of aluminium salts including 
aluminium hydroxide, aluminium phosphate and aluminium potassium sulphate which are 
present in half of the vaccines currently in use in the US (National Center for Immunization 
and Respiratory Diseases. Centers for Disease Control and Prevention, 2009). The correct 
term for this group of adjuvants is aluminium salts; Alum actually refers solely to 
aluminium potassium sulphate (Marrack et al., 2009). The widespread use of aluminium 
salts as vaccine adjuvants is due to a combined ability to (generally speaking) improve 
vaccine immune responses as well as provide an excellent safety profile. Whilst occasional 
local reactions including inflammation, erythrema, subcutaneous nodules and allergic 
reactions are reported, when the numbers of people who have been vaccinated are 
considered, aluminium salts are exemplary adjuvants (Clements and Griffiths, 2002). The 
major downfall of aluminium salts is the polarised immune response which they activate 
being predominate activators of Th2 biased immunity. Aluminium salts are therefore ideal 
adjuvants in vaccines requiring strong humoral immunity with high levels of IgG1 
antibodies and cytokines such as IL-4. Examples of this include vaccines against 
extracellular pathogens such as parasitic diseases (e.g. leishmaniasis) or toxoid-producing 
pathogens (e.g. diphtheria, tetanus). Among the methods used to mediate the Th1/Th2 
balance, one has involved combining aluminium salts with adjuvants known as strong 
stimulators of Th1 responses. Examples include aluminium hydroxide combined with 
cationic liposomes (Agger et al., 2008a) or monophosphoryl lipid A (MPL), the latter of 
which is now a licensed adjuvant (AS04, GSK Biologicals).  
 
It is only recently that the mechanisms by which aluminium salt adjuvants act have started 
to be uncovered, challenging the previous dogma that adjuvanticity was simply due to 
longer retention of antigen at the injection site, also known as the depot-effect (Marrack 
et al., 2009). The importance and mechanisms of antigen association to aluminium 
adjuvants remains debated (Iyer et al., 2003; Iyer et al., 2004; Morefield et al., 2005a; 
Morefield et al., 2005b) however it is clear that aluminium salts prevent the rapid removal 
and degradation of antigen normally seen upon injection of free antigen. There is a now a 
wide range of literature on the mechanisms of aluminium action (for in-depth reviews see 
(Brewer, 2006; Marrack et al., 2009)) which strongly suggest a role for the inflammasome 
and uric acid release upon local tissue damage (Kool et al., 2008; Marrack et al., 2009; 
O’Hagan and Gregorio, 2009). Briefly, injection of aluminium salts is known to cause tissue 
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damage and cell death with release of alarmins such as endogenous uric acid, infiltration 
of neutrophils and inflammatory mediators. Uric acid is capable of activating caspase 1, a 
component of the inflammasome, which can subsequently cleave pro-units of IL-1β and IL-
18 to their active forms (Kool et al., 2008; Mariathasan, 2007; Martinon et al., 2002; Monie 
et al., 2009) (Figure 1.5). What is interesting is that aluminium salts are unable to activate 
monocytes and DCs in vitro (Kool et al., 2008; Sun et al., 2003), a property also seen by 
certain liposomal adjuvant formulations (Korsholm et al., 2006) (see Section 1.6 for an 
outline of liposomes).  
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Figure 1.5 Mechanisms of immunological action of aluminium salts: downstream signalling 
events after activation of Toll like receptors (TLR) and the inflammasome. (i) Pathogens are 
endocytosed and activate TLRs via their pathogen associated molecular patterns (PAMPs) 
resulting in the initiation of intracellular events including release of alarmins and activation 
of MyD88 adapter proteins respectively (ii). The TRAF6 signalling pathway becomes 
activated leading to cleavage of IκB and activation of the transcription factor NFκB with 
production of pro-inflammatory cytokines such as IL-1β and IL-18, both of which are 
produced with ‘pro’ inhibitory domains (iii). Endogenous ATP can act as an alarmin to 
activate the P2X7 receptor leading to potassium efflux from the cell (iv). The combination 
of potassium efflux and TLR activation lead to cleavage of the active caspase component of 
inflammasomes which is then able to cleave pro-domains of the cytokines IL-1β and IL-18 
(v).    
35 
 
1.4.2.2 o/w emulsions: the success of MF59®  
In 1997 the first emulsion adjuvant MF59® (Novartis, Italy) was licensed in Europe in the 
influenza vaccine Fluad®; to date more than 50 million people have been vaccinated 
against seasonal influenza with this vaccine (O’Hagan and Gregorio, 2009). MF59® is an oil 
in water (o/w) emulsion composed of 5 % squalene (naturally occurring oil) combined with 
surfactants sorbitan trioleate (Span 85) and polyoxyethylenesorbitan monooleate (Tween 
80). Despite concerns regarding its safety due to the occurrence of autoimmune 
dysfunctions in rats (Carlson et al., 2000), the adjuvant has a established safety profile in 
humans of good-health and immunocompromised populations (Black et al., 2010; Donatoa 
et al., 1999). It is interesting to note that MF59® is not the first emulsion to be licensed for 
human use; the well-known experimental adjuvant Incomplete Freund’s adjuvant (ICF) 
(Freund et al., 1948) was once used in human influenza vaccines (Chang et al., 1998). In 
contrast to MF59®, ICF is a water in oil (w/o) emulsion composed of a light mineral oil 
(such as Bayol F) and the emulsifier mannide monooleate (Aracel A™), combined in a 9:1 
volume ratio (Lindblad, 2000). Whilst it has been withdrawn from human use due to 
occasional serious local reactions, it remains an experimental “gold-standard” adjuvant in 
immunisation protocols. MF59® has now been in use for over 10 years with its success 
being attributed to the rendering of soluble antigen to particulate form, improved cell 
recruitment to the injection site and antigen uptake with transport to local lymph nodes 
(Mosca et al., 2008). Similar to aluminium salts, no direct activation of DCs has been noted 
although improved trafficking and antigen uptake by macrophages and DCs respectively 
has been noted,  and expression of soluble activation factors may indeed lead to indirect 
DC activation (Dupuis et al., 2001; Mosca et al., 2008). Currently MF59® is only used in 
influenza vaccination, however, a recent report combining MF59® with enveloped 
glycoproteins from hepatitis C virus (HCV) has shown success in human Phase I clinical 
trials (Frey et al., 2010).    
 
1.4.2.3 Taking tips from pathogens with MPL 
Monophosphoryl lipid A (MPL) is the first licensed adjuvant containing bacterial analogues 
which are known to act via TLRs. Derived from lipopolysaccharide (LPS) covered Gram 
negative bacterial cell surfaces, MPL is a synthetic and slightly modified version of the 
anchor moiety of LPS, ‘lipid A’ (Alving and Rao, 2008). MPL has been licensed by GSK 
Biologicals for use in its ‘Adjuvant Systems’ including AS01, AS02 and AS04, all of which 
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contain MPL (Casella and Mitchell, 2008). In terms of development, the most successful 
Adjuvant System is AS04 which was successfully licensed in the US in October 2009 in the 
vaccine Ceravix™ targeting human papillomavirus (HPV) types 16 and 18. AS04 is also 
included as an adjuvant in recombinant hepatitis B (HBV) vaccine Fendrix™ (although this 
is not licensed in the US yet) and is in Phase III clinical trials in a herpes simplex 2 virus 
(HSV) vaccine (Didierlaurent et al., 2009). It is important to note however that in all of the 
above mentioned adjuvant systems, MPL is combined with a secondary adjuvant, namely 
liposomes and QS21 (AS01), QS21 alone (AS02) or aluminium hydroxide (AS04). The 
inclusion of these secondary adjuvants is due to the requirement of MPL and especially 
the antigen to have a delivery system which MPL alone cannot contribute.  
 
MPL, and its natural analogues lipid A and LPS, act via TLR4 present on the cell surface 
with resulting activation of a series of intracellular pathways including MyD88 and NFκB, 
finally resulting in transcription of co-stimulatory molecules, chemokines and cytokines 
which express a predominantly Th1 phenotype (Didierlaurent et al., 2009). The finding 
that MPL could be used and indeed licensed as an adjuvant has been very important for 
the development of novel adjuvants as it has led to the active pursuit of molecules that 
are ligands for TLRs and other cellular receptors. By purposefully activating such receptors 
the adjuvant is mimicking pathogenic actions and therefore if the ligand:receptor 
combination is carefully selected, a similar immune response that would normally be 
initiated against the pathogen of interest can be mounted. The different TLRs and their 
intracellular signalling pathways will be discussed in further detail in Section 1.5, however, 
on a very general note it can be said that their activation leads to initiation of important 
innate immune responses that can mature APCs and consequently drive acquired 
immunity.  
 
1.4.2.4 Antigen delivery with vesicular systems 
There are numerous lipid and polymer based delivery systems which exhibit a spherical or 
vesicular form, thereby allowing antigens to be entrapped or surface-associated 
depending on the physicochemical properties of each component. Examples of such 
include microspheres, nanoparticles, virosomes, immune-stimulating complexes (ISCOMS), 
liposomes and bilosomes among others. By associating antigens with such delivery 
systems, the antigen can be protected from the extracellular milieu thereby limiting 
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peptide/protein and nucleic antigen breakdown by enzymes, as well as preventing the 
rapid removal of such small compounds by the mononuclear phagocytic system (MPS).  
 
Nucleic antigens are especially prone to enzymatic degradation by nucleases and the poor 
transfection noted upon application of free DNA to cells led Felgner and colleagues to 
develop Lipofectin™ as a transfection agent (Felgner et al., 1987). Whilst Lipofectin™ 
makes use of liposomes (discussed in detail in section 1.6) as a method to condense, 
associate with and deliver DNA intracellularly, other particulate systems exist which 
conduct a similar role as antigen/drug delivery vehicles. Nanoparticles (named as such due 
to their sub-micron size) and microspheres are both spherical particles used extensively as 
drug delivery systems as they reduce drug-associated toxicity, improve drug solubility and 
can improve bioavailability (Perrie and Rades, 2010). In addition, both nanoparticles and 
microspheres can be used for vaccine antigen delivery (Kirby et al., 2008b; Mohanan et al., 
2010) although the small solid nature of nanoparticles restricts antigen association to the 
surface of the vesicles. Nanoparticles and microspheres are commonly composed of 
biodegradable polymers such as poly(D,L-lactide-co-glycolide) (PLGA) or polylactic acid 
(PLA) which can also be combined with poly(ethyleneglycol) (PEG) to form ‘stealth’ vesicles 
capable of avoiding removal by the MPS. Other particulate delivery systems capable of 
associating with drugs and vaccine antigens include dendrimers which are composed of a 
polymeric spherical lattice (Dutta et al., 2010) and ISCOMS composed of phospholipid, 
cholesterol and saponins which form cage-like structures (Myschik et al., 2006). 
 
1.5 Improving our Understanding of How Adjuvants Work 
1.5.1 Diverse substances with a diverse classification  
Generally speaking, adjuvants can be divided into groups relating to their physical 
properties, such as inorganic salts, liposomes, oil in water (o/w) emulsions, surfactants etc. 
This classification poses the problem that the method in which the adjuvant acts is 
unknown and therefore does not help with eliminating or identifying future adjuvant 
candidates. Another classification which will become more complex with time is proposed 
by O’Hagen and De Gregorio (O’Hagan and Gregorio, 2009) whereby adjuvants are classed 
as 1st or 2nd generation adjuvants. In this system a 1st generation adjuvant refers to one of 
the more traditional substances normally composed of one immunostimulatory 
compound. These include aluminium salts, liposomes and MF59. Addition of further 
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immunostimulatory compounds to these existing 1st generation adjuvants results in a 2nd 
generation adjuvant such as the aforementioned adjuvant systems (GSK Biologicals), IC-
31® (Intercell, Austria) and ISCOMS. Whilst the possibility exists to extend the system to 3rd 
generation adjuvants (and 4th and 5th etc), the system becomes increasingly awkward and 
does not give any indication as to how the adjuvants may work. In 2000 Virgil Schijns 
proposed a system whereby adjuvants can be divided into groups depending on their 
method of immunostimulatory action (Schijns, 2000). Whilst five groups were suggested, it 
is possible that further mechanisms may be deduced in the future, in addition to the 
difficulty in classification when one adjuvant has more than one mode of action. Finally 
and possibly the simplest involves a classification system based on whether the adjuvant 
works via TLRs or not (Mosca et al., 2008). In this instance only two groups exist (TLR-
dependent and TLR-independent) however for adjuvants containing two or more 
immunogenic components (such as GSK’s AS04 adjuvant containing aluminium hydroxide 
and MPL), they may act via both TLR-dependent and TLR-independent mechanisms further 
complicating matters. For the purposes of identifying the mechanisms of action of present 
and future adjuvants, the classification system by Schijns is the most appropriate and the 
basis of how these adjuvants will be described herein.  
 
1.5.2 Concepts of adjuvant mediated immunogenicity  
According to Schijns classification, there are five methods in which adjuvants may be 
immunostimulatory. Highlighted in Figure 1.6, these methods provide an ideal way to 
explain the immune system with relevance to systemic delivery of vaccines.  
 
Upon parental vaccine delivery there is localised tissue damage which results from the 
physical insertion of the needle and vaccine components into the tissue milieu. Cells will 
inevitably be ruptured releasing their intracellular contents including mitochondria, uric 
acid and heat shock proteins (HSPs), all of which are termed ‘alarmins’ (Bianchi, 2007). 
Alarmins are host-derived substances released upon non-intentional cell death (in contrast 
to apoptosis) and, unsurprisingly signal to the host that there is a problem such as tissue 
destruction or stress. This can be considered the first mechanism of adjuvant action (Shi et 
al., 2000) and is termed the danger signal, in reference to the ‘danger model’ originally 
described by Matzinger (Matzinger, 1994). The danger model assumes that the host can 
differentiate between harmless and harmful as opposed to self and non-self (the later 
model originally described by Metchnikoff and thoroughly reviewed by Janeway (Janeway, 
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1992)). Overlapping with the danger model is the concept of signal 0, the second class by 
which adjuvants act. Signal 0 can include alarmins but with respect to adjuvant 
composition and formulation, the signal 0 group principally includes exogenous pathogen 
associated molecular patterns (PAMPs). Importantly the signal 0 concept is the physical 
binding of alarmins or PAMPS (collectively termed danger associated molecular patterns, 
or DAMPS (Bianchi, 2007)) to pathogen recognition receptors (PRRs) and the resulting 
intracellular signalling cascade leading to activation of the cell (see Figure 1.7 for a 
schematic of DAMPS and their TLRs). PRRs are constitutively expressed on or within cells 
of the innate immune system (Schijns, 2000) and include, among others, TLRs, 
inflammasomes, integrins, c-type lectins and antibody Fc receptors. The specific signalling 
cascades initiated by these DAMP-PRR interactions will be discussed later but some of the 
resulting actions include the production of pro-inflammatory cytokines, chemokines and 
co-stimulatory molecules required for the productive activation of the T cell upon antigen 
presentation. In fact, antigen presentation without simultaneous co-stimulatory molecule 
interactions has been shown to lead to tolerance. Co-stimulatory molecules such as CD80 
and CD86 are consequently very important for successful T cell activation and whilst being 
expressed constitutively on DCs, they are only expressed on other APCs including 
macrophages and B cells upon activation. Adjuvants which are able to activate 
macrophages and B cells to induce expression of CD80 or CD86, and those able to 
upregulate expression of the said markers on DCs can be grouped under the third 
adjuvantal category, ‘recombinant signal 2’. The principle adjuvants in this group are 
cytokines which can be considered as endogenous adjuvants and have also been 
administered with vaccines experimentally (see (Boyaka and McGhee, 2001; Egan and 
Israel, 2002; Heath and Playfair, 1992) for review articles), as well as TLR-signalling 
adjuvants.  
 
The final two adjuvantal categories relate more to the physical structure of the adjuvant 
and its physical localisation in vivo. As discussed previously, there is much diversity in the 
structures of adjuvants although many of them are based on emulsions or vesicular 
structures. The benefits of vesicular structures are two-fold; firstly they can be used to 
‘carry’ antigen, either by entrapment or adsorption; secondly vesicles are naturally 
occurring and appropriately sized structures that can be endocytosed by cells depending 
on their composition and size (see section 1.3.2 and Figure 1.1), making them ideal 
intracellular delivery systems. This paradigm of assisting antigen uptake is the fourth 
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adjuvantal category and principally concerns liposomes, nanoparticles, microspheres, 
virosomes, emulsions and ISCOMs, all of which are able to package antigen into a delivery 
vehicle. The final concept is the idea that antigen held at the injection site for a long 
period of time results in lengthy presentation of antigen to innate immune cells. Known as 
the depot-effect, it refers to localisation of antigen (with or without adjuvant) at the 
injection site and not in the lymphoid organs (although increased presentation of antigen 
in the lymphoid organs may be a direct consequence of the depot effect and is often the 
desired effect). The depot-effect is therefore dependent on numerous factors such as the 
route of injection, the tissue found at the injection site and characteristics associated with 
the formulation itself such as viscosity and particulate size. 
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1. Danger
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4. Antigen delivery
5. Depot-effect
Infiltrating phagocytes
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Increase in co-stimulatory 
molecules
Adjuvant:antigen
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Figure 1.6 Classification of adjuvants: the five steps of adjuvant action are described in the 
text. APC, antigen presenting cells; MØ, macrophage; PRR, pathogen recognition 
receptors; PAMP, pathogen associated molecular patterns.  
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Figure 1.7 Flow chart showing pathogen associated molecular patterns (PAMP) and 
alarmins which are known to bind Toll like receptors (TLRs). Synthetic analogues known to 
target specific TLRs are bold underlined. R-837, Imiquimod; R-838, resiquimod; HSP, heat 
shock protein; HMGB1, high motility group box 1; ECM, extracellular matrix. Data obtained 
from a range of sources including (Bianchi, 2007; Dockrell and Kinghorn, 2001; Monie et 
al., 2009; O’Hagan and Gregorio, 2009) 
 
1.5.3 Defining the ideal adjuvant 
From this analysis of different ‘types’ of adjuvants, it is clear that there are still many 
overlaps between groupings however the system devised by Schijns does help to define 
the mechanisms by which adjuvants work. With this in mind, it is possible to envisage how 
the perfect adjuvant would work. Firstly, it must contain a sufficient amount of PAMPs to 
alert the immune system of danger but without causing hyper-immunostimulation which 
may result in anaphylactic shock or local tissue damage by excess of inflammatory 
mediators. Too few PAMPs or PAMPs without sufficient toxicity may not stimulate 
sufficient production of pro-inflammatory molecules or chemokines which are vital to alert 
circulating APCs. It may just be that a certain degree of local tissue damage is also 
beneficial as it allows the release of alarmins, further promoting APC influx to the injection 
site (Shi et al., 2000). The adjuvant should also ideally stay associated with the antigen 
until uptaken by APCs so that the immune system can make a collective association of 
both components. Free antigen, in the form of nucleic material or small peptide antigens, 
is rapidly degraded by extracellular enzymes and many subunit protein vaccine antigens 
are themselves immunogenically inert. Protein and peptide antigens undergo rapid 
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removal via the circulatory or lymphatic system and without any danger signals attached, 
the protein may simply be removed before antigen uptake and presentation can occur. 
Whilst it appears important for adjuvant and antigen to stay associated until arrival of 
APCs, whether antigen uptake should occur simultaneously with the adjuvant is unknown 
and is discussed in more detail in Chapter 5.  
 
1.6 Liposomes: The Ideal Adjuvant?  
1.6.1 Liposomes as delivery systems 
Originally discovered in 1965 by the late Alex Bangham, liposomes are essentially 
bilayered vesicles composed of lipids, with or without additional lipophilic components, 
which form upon exposure to aqueous media (Bangham et al., 1965). Since their 
discovery, liposomes have been recognised as efficient drug and vaccine antigen delivery 
systems due to their ability to encapsulate or surface adsorb a wide variety of molecules. 
Much of the pioneering work on the subject of liposomes was undertaken by Gregoriadis 
who highlighted the ability of liposomes to entrap drugs (Gregoriadis, 1973), described 
methods to improve liposomal stability (Gregoriadis and Davis, 1979) and discussed the 
problems associated with liposomal clearance in vivo (Gregoriadis, 1995a, b; Gregoriadis 
and Senior, 1980). Furthermore, many of the positive aspects of liposomes as drug 
delivery vehicles can also be applied to vaccine antigen delivery. Firstly liposomes can 
protect antigen from extracellular degradation via either entrapment or surface 
adsorption (Gregoriadis et al., 1999). Secondly liposomes can be formulated to have an 
anionic, neutral or cationic surface charge which will determine what type of antigens may 
associate, in addition to how the liposome will interact with soluble and cellular 
components of the host (discussed in detail in Chapter 4). Thirdly liposomes are incredibly 
flexible systems as their ampiphilic structure allows for incorporation of both hydrophilic 
and lipophilic molecules. For example, whilst anionic nucleic acids and peptides/proteins 
can be surface adsorbed to cationic vesicles, soluble antigens can be encapsulated in uni- 
or multilamellar vesicles and lipophilic glycolipids and bacterial cell wall derivatives are 
able to insert into the bilayered membrane (Figure 1.8). 
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Figure 1.8 Schematic of liposome types including multilamellar vesicles (MLVs), small 
unilamellar vesicles (SUVs) and large unilamellar vesicles (LUVs). A further type of 
liposome can be described as a dehydration-rehydration vesicle (DRV) which forms after 
freeze-drying and is used to encapsulate antigen.  
 
1.6.2 Cationic liposomes expressing immunostimulatory properties 
In addition to being successful drug and antigen delivery systems, liposomes expressing a 
positive charge have also been shown to have specific immunostimulatory abilities, 
independent from their delivery vehicle properties (Figure 1.9 shows a selection of 
cationic lipids commonly used in liposome formation). The immunostimulatory properties 
of cationic lipids were originally documented in a screening study by Gall (Gall, 1966). 
Within this study a wide range of compounds were investigated for their ability to 
adjuvant diphtheria or tetanus toxoids in guinea pigs. Compounds included non-ionic, 
anionic and cationic surface acting agents, amines, guanidines, benzamidines, thioureas, 
thiosemicarbazides, thiosemicarbazones, thiouroniums and various nitrogenous bases. 
With regard to the group of surface acting agents, or more commonly termed surfactants, 
Gall observed increased adjuvanticity for those expressing cationic quaternary ammonium 
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head groups and long alkyl chains (Gall, 1966). These lipids are able to form bilayered 
vesicles upon exposure to aqueous environments, a process which is attributed to the 
geometry of the lipid known as the critical packing parameter (CPP). The CPP defines the 
final lipid-structure that will form and is dependent on the length and saturation of the 
lipid hydrocarbon chains, as well as the size of the lipid head group (Perrie and Rades, 
2010). The majority of immunostimulatory cationic lipids form liposomes alone, or with 
the inclusion of a neutral helper lipid primarily included to stabilise the membrane 
(discussed in further detail in Chapter 3). Such cationic liposomes are of principle 
importance in gene delivery and experimental vaccines involving both nucleic acid antigen 
(termed lipoplexes when associated with the surface of liposomes) and peptide/protein 
antigens.  
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Figure 1.9 Commonly used cationic lipids expressing transfection or immunostimulatory 
abilities. A, dimethyldioactadecylammonium (DDA); B, N,N-dioleyl-N,N 
dimethylammonium (DODA); C, DiC14-amidine; D, 1,2-dioleoyl-3-dimethylammonium-
propane (DODAP); E, 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA); F, 
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP); G, 3β-[N-(N',N'-
dimethylaminoethane)-carbamoyl] cholesterol hydrochloride (DC-Chol). Diagrams were 
obtained from www.avantilipids.com. 
 
1.6.3 Liposomal adjuvants 
Although there are no liposomal adjuvanted vaccines currently on the market, their use in 
laboratory transfection (e.g. Lipofectamine™) is commonplace (see (McNeil and Perrie, 
2006) for a review on liposomal gene delivery) and there also exists numerous liposomal 
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formulations designed as delivery systems for chemotherapeutic and antimicrobial agents 
(Gregoriadis, 1973, 1985, 1995a; Perrie, 2005).  
 
The lack of liposomal adjuvants on the market is not without trying however and again 
there is a wealth of research dating from the 1980’s and 1990’s based on improving 
immune responses with the aid of liposomes (Bakouche and Gerlier, 1986; dal Monte and 
Jr, 1989; Gregoriadis, 1985, 1994; Gregoriadis et al., 1996; Nakanishi et al., 1997; Oussoren 
et al., 1997). It was not however until the mid- 1990’s that the importance of liposomal 
cationic charge was noted for the induction of strong immune responses. Since then 
research on cationic liposomal adjuvants has also diversified towards cationic structures 
such as ISCOMS/PLUSCOMS (Lendemans et al., 2007; McBurney et al., 2008) and the 
cationic peptide KLKL5KLK, a component of IC31® adjuvant (Schellack et al., 2006). IC31® is 
currently in Phase I and Phase II clinical trials (Table 1.1) due to its success with the 
tuberculosis antigens Ag85B-TB10.4 and Ag85B-ESAT-6 respectively (Agger et al., 2006; 
Kamath et al., 2008a; Kamath et al., 2008b).  
 
Returning to cationic liposomes, much focus has been in trying to elucidate the 
mechanisms by which these vesicles confer significantly enhanced immune responses 
compared with controls such as aluminium salts or ICF. Whilst the cationic lipids 1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP) and 3β-[N-(N’,N’-
dimethylaminoethane)-carbomyl] cholesterol (DC-Chol) will be focussed on in greater 
detail in Chapter 5, a brief point to make with regards to their mechanisms of action would 
be that nothing is as simple as it would seem! Whilst DOTAP, DC-Chol and many other 
cationic lipids share numerous physicochemical properties, there is great variation in their 
immunogenic abilities and methods by which they target the immune system. The focus 
here, and indeed throughout this thesis, is on dimethyldioctadecylammonium bromide 
(DDA) which was initially noted for its immunogenic abilities in the aforementioned study 
by Gall (Gall, 1966). DDA is a rather simple quaternary ammonium lipid possessing two 
saturated 18-carbon lipophilic tails which promote bilayer formation in aqueous solution. 
The head group is also relatively small when compared to DOTAP, DC-Chol and other 
cationic lipids with documented immunostimulatory action (Figure 1.9). DDA liposomes 
have been tested in combination with a wide range of additional molecules used either to 
stabilise the vesicles or to increase the immunogenic responses towards the vaccine 
antigen; this forms the basis and is discussed in detail in Chapter 3. With respect to 
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liposomes composed solely of DDA, improved immunogenicity in response to vaccine 
antigen has been noted in numerous disease models including TB (Andersen, 1994; 
Davidsen et al., 2005; Holten-Andersen et al., 2004; Lindblad et al., 1997; Rosenkrands et 
al., 2005), malaria (Desowitz and Barnwell, 1980), tetanus (Stanfield et al., 1973) and 
listeriosis (Van der Meer et al., 1979). The adjuvant action noted by DDA liposomes is 
understood to be due to a combination of the following: a strong antigen depot-effect, 
rendering antigen to a particulate form, improving antigen delivery to secondary 
lymphatic organs and promoting antigen uptake by APCs (Hilgers and Snippe, 1992; 
Korsholm et al., 2006). Whilst a specific cellular receptor for DDA liposomes capable of 
initiating an intracellular activation pathways has yet to be discovered, it is 
comprehendible that cell surface receptors play an important role in liposome uptake via 
endocytotic mechanisms.  
 
1.7 Aims of Work 
As discussed above, there is a considerable lack of effective vaccines to target the most 
significant causes of infectious disease. Furthermore, despite the many decades of 
research into the mechanism of adjuvantal action, we still do not have a clear and 
complete understanding into how these substances can make the host mount a 
sufficiently strong immune response against a small peptide/protein/nucleic acid to 
consequently protect from infectious disease. By gaining a better understanding into the 
mechanisms by which adjuvants act it is hoped that improved adjuvant and vaccine design 
with a more structured approach may lead to more productive formulations going into 
clinical trials.  
 
One of the lead TB adjuvants is a cationic liposome formulation ‘CAF01’ composed of DDA 
and trehalose 6,6’-dibehenate (TDB) (Table 1.1). Little is known however about the way in 
which this adjuvant is effective. Focusing on this formulation and other cationic liposomes 
sharing properties with CAF01, the aim of this work was to investigate further how CAF01 
acts as an adjuvant. To achieve this aim the overall objectives of the work were: 
 Screen a range of cationic liposome formulations to investigate the 
immunogenicity of these cationic liposomes thereby allowing further optimisation 
of the systems.  
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 Measure the key pharmaceutical properties including physicochemical 
characteristics and stability.  
 Investigate the biodistribution of liposomes and their associated antigens with the 
aim to correlate these to their physicochemical properties and immunological 
function. 
 Use of cell lines to investigate the immunostimulatory effects of various cationic 
liposomes in vitro and correlate these with in vivo responses.  
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Chapter 2: Materials and Methods 
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2.1 Materials 
AbD Serotec, Oxford, UK: Goat anti-mouse IgG1:HRP (STAR132P), goat anti-mouse 
IgG2a:HRP (STAR133P), goat anti-mouse IgG2b:HRP (STAR134P), goat anti-mouse IgG:HRP 
(STAR77), murine monoclonal isotyping test strips (MMT1) 
American type culture collection (ATCC): J774.1 and RAW264.7γNO(-) 
monocyte/macrophage cell lines 
Avanti Polar Lipids, Alabaster, US: Dimethyldioctadecylammonium bromide (DDA), 1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP), 3β-[N-(N’,N’-dimethylaminoethane)-
carbomyl] cholesterol (DC-Chol), distearoyl-glycero-phosphatidylcholine (DSPC), trehalose 
6,6’-dibehenate (TDB), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) (Rho-DPPE) 
Beckman Coulter, High Wycombe, UK: OptiLyse®C Lysing solution 
BioRad, Hemel Hempstead, UK: Silver stain kit 
Biosera, Leicestershire, UK: Dulbecco’s modified Eagle’s medium (DMEM), RPMI 1640, 
foetal bovine serum (FBS), penicillin-streptomycin-glutamine (PSG) 
Enzo Life Sciences, Exeter, UK: Vitamin D3 (VD3), Phorbol 12-myristate 13-acetate (PMA) 
Fisher Scientific, Leicestershire, UK: Methanol and chloroform (both HPLC grade)  
GE Healthcare, Amersham, UK: 1,2-dipalmitoyl L-3-phosphatidyl[N-methyl-3H]choline (3H-
DPPC), [methyl-3H]Thymidine 
Geneflow, Staffordshire, UK: EZ-PCR Mycoplasma test kit 
Greiner, Stonehouse, UK: Plasticwear for cell culture experiments 
IDN Biomedical Inc, Aurora, Ohio, US:  Tris-base  
Invitrogen, Paisley, UK: Tris-glycine gels (12 %), broad range molecular marker  
Medicell International Ltd, UK: Dialysis membrane (12-14 kDa pore size)  
Merck Chemicals Ltd, Nottingham, UK: Ovalbumin, 5X crystalline 
Perkin Elmer, Waltham, MA, US: 125I (NaI in NaOH solution), Solvable™, Ultima Gold 
scintillation fluid 
Pierce Biotechnology, Rockford, IL: Pierce iodination tubes containing Pierce iodination 
reagent (formally known as IODO-GEN®) 
Promega, Southhampton, UK: CellTiter 96 AQueous non-radioactive cell proliferation 
assay (MTS assay), CytoTox 96 non-radioactive cytotoxicity assay (LDH assay) 
R+D, Abingdon, UK: Mouse DuoSet capture ELISA IL-2 (DY402), IL-5 (DY405), IL-6 (DY406), 
IL-10 (DY417), IFN-γ (Dy485) 
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Sigma-Aldrich, Poole, UK: Cholesterol (Chol), PBS tablets, ovalbumin (OVA), bovine serum 
albumin (BSA), lysozyme (from hen egg white), bicinchoninic acid (BCA) protein assay kit, 
Triton® X-100, hydrogen peroxide, Sephadex™ G-75, 2’2 azino-bis(3-ethylbenzthiazoline-6-
sulfonic) acid, concanavalin A (ConA ), β-N-Acetylglucosaminidase Assay kit (NAG assay), 
fluorescein isothiocyanate (FITC), bromophenol blue, β-mecaptoethanol, glycerol, sodium 
dodecyl sulphate (SDS), glycine, brilliant blue R, pontamine blue, neutral red, sodium 
azide, citric acid, dimethyl sulphoxide (DMSO), tryphan blue, ethylenediaminetetra-acetic 
acid (EDTA), heparin, Incomplete Freund’s Adjuvant (IFA), potassium chloride, potassium 
phosphate, sodium chloride, sodium phosphate dibasic, sulphuric acid, 
tetramethylbenzidine, Trizma base, Tween-20 
Statens Serum Institute, Copenhagen, Denmark: Non-His-tagged protein Ag85B-ESAT-6 
was produced as described by Olsen et al., (Olsen et al., 2001) , CTH1 was kindly donated 
by Frank Follmann, N,N-dioleyl-N,N dimethylammonium Chloride (DODA) 
VWR International, Leicestershire, UK: Terumo Insulin needles 
 
Ethics Approvals for in vivo studies 
All experimentation undertaken at Aston University strictly adhered to the 1986 Scientific 
Procedures Act (UK). All protocols have been subject to ethical review and were carried 
out in a designated establishment. Mice were obtained from Charles River. 
   
All experimentation undertaken at Statens Serum Institute, Denmark strictly adhered to 
the regulations of the Danish Ministry of Justice and animal protection committees and 
was in compliance with European Community Directive 86/609.  All protocols have been 
subject to ethical review and were carried out in a designated establishment. Mice were 
obtained from Harlan Scandinavia, Allerod, Denmark. 
 
2.2 Methods: Preparation of Liposomes 
2.2.1 The lipid-film hydration method 
Liposomes were produced using the lipid-film hydration method originally described by 
Bangham (Bangham et al., 1965). This relatively simple method was chosen based on 
previous work by Davidsen et al. in which the vesicle size of liposomes produced by the 
lipid-film hydration and aqueous heat methods was investigated (Davidsen et al., 2005). 
Addition of the stabilizing and immunostimulatory component trehalose 6,6’-dibehenate 
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(TDB), in addition to antigen, had no effect on the size of vesicles produced by the lipid-
film hydration method. In contrast, those produced by the aqueous heat method showed 
significant increases in size upon addition of either component (Davidsen et al., 2005). 
 
To produce liposomes, lipids at appropriate ratios were first dissolved in solvent 
(chloroform:methanol 9:1) in a round-bottom flask (rbf); throughout these studies lipids 
stocks were made to 10 mg/ml whereas TDB was made to 2 mg/ml.  The organic solvent 
was then evaporated on a rotary evaporator (Buchi rotavapor-R) to obtain a dry film. 
Residual solvent was removed using a stream of N2 after which the lipid-film was hydrated 
using buffer at a temperature dependent on the lipid transition temperature and at least 
10°C above it. Table 2.1 presents the transition temperatures of the lipids used. For most 
work Tris buffer (10 mM, pH 7.4) was used to rehydrate lipid films however occasionally 
PBS buffer was used and is marked as appropriate. Rbfs were sealed with parafilm to 
prevent buffer evaporation. The lipids were hydrated for approximately 20 mins with 
frequent vortexing to encourage lipid mixing and vesicle formation.  
 
When TDB was incorporated into formulations, the ratio of lipid:TDB used was 5:1 
(weight) or 8:1 (molarity). In characterisation studies the lipid concentration was 1.25 
mg/ml however for various other applications (indicated as appropriate) the concentration 
of liposomes was increased to as much as 10 mg/ml.  
 
To reduce the size of liposomes produced by the lipid-hydration method, liposomes were 
sonicated at 4 microns for between 30-120 seconds, depending on the volume of 
liposomes used. For studies in which antigen was added to the liposomes, sonication took 
place prior to addition of antigen.  
 
A novel method was used to produce ‘big’ liposomes; a high amount of lipid (10-fold more 
than normal) was placed in a very small rbf (5 ml volume) and a lipid film produced using 
the lipid-film hydration method. The lipid film was hydrated in a volume of buffer 10-fold 
less than usual and vortexed. Preliminary studies showed that the combination of small 
rbf, high amount of lipid and low rehydrating buffer were all required for the successful 
formation of large liposomes. 
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Table 2.1 Transition temperatures of lipids used for the formation of liposomes 
Lipid Transition temperature (°C) 
Dimethyldioctadecylammonium bromide (DDA) + 47 (Davidsen et al., 2005) 
N,N-dioleyl-N,N dimethylammonium chloride (DODA) n.a 
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) - 12 (Zuidam et al., 1999) 
3β-[N-(N’,N’-dimethylaminoethane)-carbomyl] cholesterol 
(DC-Chol) 
n.a 
Distearoyl-glycero-phosphatidylcholine (DSPC) + 55 (www.avantilipids.com)  
n.a; not available.  
 
 
2.2.2 Production of radiolabelled liposomes 
In order to track the movement of liposomes in vivo, liposomes were radiolabelled by 
incorporating tritiated lipid 1,2-dipalmitoyl L-3-phosphatidyl[N-methyl-3H]choline (3H-
DPPC) which is readily incorporated into the bilayer of liposomes (Henriksen-Lacey et al., 
2010a). Liposomes including 3H-DPPC were produced using the lipid-film hydration 
method described in section 2.2.1 with the addition of 3H-DPPC (supplied in solvent) to the 
lipid mixture prior to solvent removal. The amount of 3H-DPPC added was based on the 
radioactivity (3H) and the concentration of DPPC in the liposomes so that the 
physicochemical liposomal properties were not altered. The specific activity of 3H-DPPC 
was 2.85 TBq/mmol with a radioactive concentration or 37 MBq/ml. This high ratio of 
3H:DPPC was ideal for biodistribution work as both factors - high radioactivity and low 
DPPC  - were fulfilled. 3H-DPPC was incorporated into liposomes at 3H-DPPC:lipid weight 
ratio of 1:10,000. This is equivalent to 25 ng DPPC/dose with an approximate radioactivity 
of between 100-200 kBq.  
 
2.2.3 Production of fluorescently labelled liposomes 
Fluorescently labelled liposomes were used in flow cytometric and fluorescence 
microscopy studies. The lipid 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) (Rho-DPPE) was incorporated into liposome bilayers 
using the same lipid-hydration method as discussed in section 2.2.1. Rho-DPPE was 
dissolved in a 9:1 mixture of chloroform:methanol to a final concentration of 2 mg/ml. 
Rho-DPPE was added to lipids in the rbf prior to removal of the solvents – a final Rho-DPPE 
concentration of 1 mol %  was used based on work by Zelphati (Zelphati et al., 1998).  
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2.3 Characterisation of Liposomes 
2.3.1 Vesicle size and zeta potential 
Liposome vesicle size and zeta potential (ZP) were measured using a Brookhaven ZetaPlus 
instrument. The Brookhaven ZetaPlus measures the diameter of vesicles using the 
dynamic light scattering technique (DLS). This involves detection of scattered light from 
particles suspended in an aqueous solution. Particle movement, governed by Brownian 
motion, results in time-dependent variations in the light scattered which is detected and 
transformed into a linear measurement by way of the Stokes-Einstein equation. DLS is 
dependent on numerous factors including the concentration of the substance (in this case 
liposomes) being measured, the ionic strength of the aqueous solution used to suspend 
the liposomes, and the temperature. In order to limit variability, all liposomes were 
measured in a 10-fold dilution of the same buffer used for their production. Liposomes 
which had been stored at 4 °C were bought to room temperature prior to measurements.  
 
In preliminary experiments it was decided that 100 μl of liposomes (1.25 mg/ml) and 
therefore equivalent to approximately 125 μg lipid was sufficient for accurate 
determination of the vesicle size and ZP. Therefore for all size and ZP studies, 100 μl of 
liposomes (1.25 mg/ml) were added to approximately 3 mls of hydration buffer (10-fold 
diluted) and mixed well. In addition to the overall polydispersity of the sample, three size 
measurements were recorded from each run. Therefore, unless stated otherwise, 
triplicate experiments resulted in a mean vesicle size derived from 9 values. Values which 
were clearly anomalies or outliners were not included. To measure the ZP a palladium 
probe (Brookhaven Instruments) was inserted into the sample (the same one used to 
measure vesicle size) and 10 measurements recorded per sample. Again, values which 
were clearly anomalies were not included. The mean result of triplicate experiments was 
therefore derived from a maximum of 30 values.  
 
2.3.2 Imaging of liposomes 
A 1 ml sample of liposomes (1.25 mg/ml) was placed in a small clear HPLC vial and stored 
under the appropriate conditions. Photos were taken of the samples at various time-
points to compare liposome formulation stability.  
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2.3.2.1 Transmission electron microscopy (TEM) 
TEM was conducted at The University of Birmingham with the help of Paul Stanley. 
Liposomes were produced as described in section 2.2.1. A small drop (~ 10 μl) of 
liposomes was placed onto a 3.05 mm copper grid containing numerous hexagonal pores. 
The sample was left for 30 seconds and then blotted to remove excess solution. A 10 μl 
sample of uranyl acetate (UA) stain was placed onto the grid and again blotted after 30 
seconds. The sample was viewed with a transmission electron microscope and photos 
taken. In addition to UA stain, ammonium molybdate (AM) also known as ammonium 
heptamolybdate ((NH4)6Mo7O24), and phosphotungstic acid (PTA; H3PW12O40) were also 
investigated as AM and PTA have both been described to work best at neutral pH values. 
In contrast UA works best at pH 4 and is known to precipitate at higher pH values. All three 
are negative stains that dispose heavy atoms on the surface of the samples – one of the 
consequences can be the flattening of larger liposomal structures. Comparative images of 
DDA:TDB liposomes stained with all three stains were taken.  
 
2.3.2.2 Fluorescence imaging of liposomes 
Fluorescently labelled liposomes were produced as described in section 2.2.3 with the 
inclusion of Rho-DPPE which allows liposomes to be viewed under the rhodamine filter on 
a fluorescence microscope. Occasionally liposomes were also viewed with the addition of 
fluorescein isothiocyanate (FITC) labelled ovalbumin (OVA). To view the samples a small 
drop (~ 10 μl) of liposomes was placed on a standard glass microscope slide and covered 
with a glass cover slip. Liposomes were viewed using phase contrast and fluorescence 
filters (Rhodamine for liposomes, FITC for protein).  
 
2.4 Methods in Protein Detection 
2.4.1 The BCA assay 
For simple, quick and accurate protein detection and quantification, the bicinchoninic acid 
(BCA) protein assay was used. The assay relies on reduction of Cu2+ to Cu1+ which is 
proportional to the amount of protein present. Analysis is based on a colour change from 
green to purple/blue which is detected at 562 nm. To measure the presence of protein 
accurately the protein concentration should be between 0.2 – 1 mg/ml which relates to 
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protein concentrations of 5 – 25 μg/25 μl (the suggested volume for use in a 96-well 
plate). To make the BCA reagent, a 50:1 ratio of components A and B are mixed; 200 μl of 
this working reagent is added to the protein-containing wells of a 96-well plate. The 
absorbance, read at 562 nm, can be translated into a protein concentration with the aid of 
a non-linear polynomial standard curve produced using a serially diluted 1 mg/ml protein 
stock (Pierce Biotechnology). 
 
Determination of protein adsorption to liposomes was undertaken indirectly by measuring 
the protein presence in the supernatant of centrifuged liposomes as opposed to that 
adsorbed directly to the liposome. This is due to the lipid content of the liposome 
suspension interfering with the absorbance readout. 
 
2.4.2 SDS-PAGE 
Gel electrophoresis was also used to semi-quantify protein adsorbed to liposomes and/or 
found unassociated. A standard gel electrophoresis protocol was followed using Tris-
glycine gels and staining either with coomassie blue or silver stain. The silver staining 
technique is known to be 10-50 fold more sensitive for protein detection than coomassie 
staining and was therefore used when the protein levels were considered especially low 
(Merril et al., 1981).  Silver staining was conducted with a Bio-Rad kit using the standard 
staining procedure outlined in the protocol. Briefly, once the electrophoresis run was 
complete, the gels were removed, fixed, oxidized, washed and silver reagent (silver 
nitrate) added, followed by a further wash and then development using a pre-mixed 
sodium carbonate/paraformaldehyde solution. A 5 % (v/v) acetic acid solution was used to 
stop development.  
 
2.4.3 Radiolabelling of proteins 
In order to detect protein in biodistribution studies, radiolabelling was implemented using 
125I. Iodination of protein was undertaken using Pierce iodination tubes containing Pierce 
iodination reagent (formally known as IODO-GEN® tubes) which contain an oxidizing 
reagent that converts Na125I into a reactive iodine molecule that can insert into the tyrosol 
group of tyrosine amino acids (Figure 2.1). The number of tyrosine amino acids in the 
protein to be labelled is therefore of importance, however for proteins which contain few 
tyrosine amino acids the Bolton-Hunter reagents can be used to introduce iodinatable 
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sites. The amount of 125I added to the iodination tube was dependent on the type of 
protein being labelled and the amount of protein required. For the labelling of OVA and 
Ag85B-ESAT-6, a pH 7.4 Tris buffer (10 mM) was used as the proteins were stable in these 
conditions. OVA and Ag85B-ESAT-6 contain 9 and 13 tyrosine amino acids respectively; this 
was sufficient for efficient radiolabelling. For the radiolabelling of lysozyme, Tris buffer (10 
mM) was also used however the pH was reduced to pH 4 with the use of HCl as 
preliminary studies showed this pH gave the best detection of unlabelled lysozyme using 
the BCA assay. The protein CTH1 was radiolabelled in a pH 4 phosphate citrate (PC) buffer 
(70 mM) as it was supplied and is stable in this buffer. For both in vitro stability studies and 
in vivo biodistribution studies each dose contained ~ 100 kBq of 125I. For in vivo studies 
mice received a dose of 2 μg Ag85B-ESAT-6 or 5 μg CTH1 or lysozyme. Therefore the 
protein:125I ratio varied, as did the radiolabelling efficiency for the different proteins. 
Furthermore, as the decay rate of 125I is 60 days the volume of 125I required was variable. 
Sample volumes for the production of 40 doses of protein (2 μg/dose) would therefore 
involve the addition of 100 μl protein (800 μg/ml) with 5.71 MBq 125I (40 doses at 100 kBq 
each, plus 30 % extra due to labelling inefficiency and is therefore counted as ‘free 
unbound’ 125I). For the radiolabelling of CTH1 and lysozome, additional 125I was added to 
the iodination tube as the labelling efficiency decreases with each decrease in pH unit 
(Pause et al., 1982). For total volumes (125I and protein) of over 200 μl, two iodination 
tubes were used to maximise iodination reagent:protein: 125I interaction. The mixture was 
left in the iodination tube for between 45 – 90 minutes with frequent swirling to ensure 
complete exposure of protein and 125I to the iodination reagent.  
 
In order to remove unbound 125I from the protein solution, a gel filtration column 
prepared with Sephadex™ G-75 was used. A glass 5 ml pipette was used to minimise 
protein/plastic interactions. Sephadex™ G-75, rehydrated with a 10-fold dilution of the 
same buffer used to dissolve the antigen in, was poured into the glass pipette leaving ~ 2 
cm space at the top of the column (cotton wool was used to block the bottom of the 
pipette). The total volume of the column was therefore ~ 8 cm3 and the elution speed was 
~ 0.25 ml/minute. Each minute a sample was collected which therefore resulted in the 
total column volume being eluted within 40 minutes. Frequent addition of the same buffer 
used to make the column was used to prevent the column running dry. Once 40 samples 
had been collected the column was disposed of and all the samples collected were 
counted on a γ-counter to quantify 125I presence. To determine the presence of protein, 25 
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μl of each sample was removed and added to the wells of a 96-well plate; 200 μl of BCA 
reagent was added to each well and the plate was incubated at 37 °C for 30 min followed 
by reading the absorbance at 562 nm (see section 2.4.1 for more detail of the BCA assay). 
Samples which correlated for the presence of protein and 125I were pooled; on average this 
accounted to four samples and therefore the resulting total volume of 125I:protein was ~ 1 
ml. This sample was diluted accordingly for in vitro stability or in vivo biodistribution 
studies.   
 
 
Figure 2.1 Diagram showing the incorporation of 125I into amino acid residues of proteins 
during the radiolabelling procedure. The reaction was undertaken in Pierce iodination 
tubes containing Iodination reagent. 
 
2.4.4 Fluorescence labelling of OVA protein 
The model protein OVA was used to investigate protein binding to DDA:TDB liposomes 
using fluorescence techniques. OVA was labelled with FITC in a PBS buffer as opposed to 
Tris buffer due to the incompatibilities between amine-containing compounds with FITC. A 
5:1 weight ratio of OVA:FITC was dissolved in PBS (10 mM, pH 7.4) to a final OVA 
concentration of 50 mg/ml. This was left overnight at 4°C in the dark with frequent 
swirling. A Sephadex™ G-75 gel filtration column was used to separate unbound FITC; the 
same method described in section 2.4.3 to remove unbound 125I was implemented. The 
protein was eluted with 1 mM PBS buffer and the final concentration of OVA adjusted to 
10 μg/ml. 
 
2.5 Methods in Cell Culture 
2.5.1 Culture and maintenance of continuous cell lines  
Murine and human monocyte/macrophage like cell lines were used to investigate the 
effect of liposomes on cellular properties. The murine RAW 264.7 gamma NO(-) and J774.1 
cell lines, both originally derived from the ATCC, were cultured in DMEM media 
supplemented with 10 % foetal bovine serum (FBS) and 1 % (penicillin-streptomycin-
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glutamine (PSG). Cells grew as an adherent monolayer and were passaged by scrapping. 
Although a preliminary experiment showed that cell viability was increased if EDTA/trypsin 
was used as an alternative to scrapping, over time the ability of the cells to adhere was 
reduced, therefore scrapeing was used to dislodge cells. The cells grew quickly and 
required approximately 2-3 passages/week when passaged at a 1:9 ratio of cells:media. 
Cells were used between passages 7-20 however during early 2010 it seems likely that the 
liquid N2 storage tank ran dry which forced us to throw out all cyropreserved vials. 
Consequently a new batch of J774.1 cells were obtained from a neighbouring lab and 
these cells were used between passage number 20-30. Low passage number was 
maintained by cyropreserving cells in 10 % dimethyl sulphoxide (DMSO) in FBS in a liquid 
N2 tank. The human monocyte cell line THP-1, donated by Andrew Devitt, Aston 
University, Birmingham, was maintained in RPMI media supplemented with 10 % FBS and 
1 % PSG. In certain studies this cell line was grown with the addition of vitamin D3 (VD3) to 
induce macrophage like properties. In such instances, VD3 was added to complete RPMI at 
a final concentration of 250 nM and cells typically differentiated within 2 days. All cell lines 
were maintained at 37 °C, 5 % CO2 and 95 % relative humidity. 
 
2.5.2 Determination of cell number  
During routine cell passage, the dilution factor was estimated from the level of confluence. 
Determination of cell number for experiments or freezing was achieved via tryphan blue 
exclusion whereby 20 μl of resuspended cells was removed and mixed with an equal 
volume of tryphan blue. With the aid of a hemocytometer, cells excluding tryphan blue 
were quantified and the number of cells/ml was calculated using the following equation: 
 
No of cells/ml = no. cells/sq x dilution factor x 104 
Where:  no. cells/sq is the average of 10 squares in the hemocytometer 
Dilution factor is 2 if equal volumes of resuspended cells and tryphan blue 
are used 
104 is the multiplication factor related to the volume of the 
hemocytometer grid 
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2.5.3 Measurement of cell characteristics 
2.5.3.1 Neutral red assay 
The neutral red (NR) assay was used as a simple method to determine cell viability. The 
method relies on the uptake of the viable stain ‘neutral red’ which becomes blocked in 
lysosomes of cells with an active metabolism. After washing of cell monolayers, the cells 
are lysed to release neutral red which can then by quantified using a spectrophotometer. 
In general, cells were seeded into a 96-well microplate at a density of 1-2 x 105 cells /ml 
with 100 μl cells/well and allowed to grow for 24-48 hrs or until ~ 70 % confluent. The NR 
assay was used to investigate cell viability as a consequence of liposome toxicity. 
Therefore, liposomes were added to cells at a range of concentrations (0.005 - 50μg 
lipid/ml) in media without the presence of FBS to prevent serum protein induced 
aggregation of liposomes. Liposomes were left on the cells for between 1 - 48 hrs followed 
by washing with cold FBS-free media and addition of 100 μl NR (100 μg/ml). After 1 hr cells 
were washed twice with cold PBS followed by addition of 100 μl ‘stop solution’ (1 % acetic 
acid:49 % H2O:50 % ethanol) to lyse cells. Plates were gently tapped/swirled to ensure all 
cells were lysed and NR evenly distributed throughout the well. The absorbance at 405 nm 
was read to determine the proportion of viable cells compared to negative (lysis of cells 
using Triton-X prior to NR addition) and/or positive controls (cells without liposomes).  
 
2.5.3.2 MTS assay 
The MTS assay is a commonly used version of the previous MTT assay (and similar XTT 
assay) which all measure cell viability/proliferation/cytotoxicity in a colorimetric manner. 
The method relies on the cells ability to reduce ‘MTS’ into a soluble formazan product 
which can be measured at 490 nm using a spectrophotometer. Cells were treated in the 
same method as described for the NR assay (section 2.5.3.1) with the exception that 
instead of adding 100 μl NR, 100 μl of MTS reagent (20 % v/v with media) was added. The 
cells were left at 37 °C for between 1 – 4 hrs followed by measurement of the formazan 
product at 490 nm. The percentage of viable cells was determined against negative (lysis 
of cells using Triton X-100 prior to MTS addition) and/or a positive controls (cells without 
liposomes).  
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The MTS assay was used in initial experiments however the results produced were similar 
to the NR assay – ultimately the NR assay was used preferentially as it is cheaper and 
therefore a larger proportion of variables could be screened with ease. However, it is 
important to note that whilst the MTS assay relies on cells being metabolically active (as 
MTS is taken up by mitochondria), the NR assay relies on NR uptake and entrapment in 
lysosomes and therefore does not require cells to be metabolically active. For the purpose 
of cell viability due to liposome induced toxicity, the NR assay was sufficient.  
 
2.5.3.3 LDH assay 
In a similar method to the MTS and NR assays, the LDH assay can be used to give an 
indication of cell viability due to the toxic effects of liposomes (or indeed other factors). 
Unlike the MTS or NR assays which measure the number of viable cells, the LDH assay 
measures the number of damaged or lysed cells by detecting the presence of the 
intracellular enzyme lactate dehydrogenase (LDH) in the surrounding culture media. The 
enzyme LDH catalyses one of the two reactions which leads to formazan production which 
is subsequently detected using a spectrophotometer at 490 nm. Formazan production is 
directly proportional to the number of lysed cells. The process of LDH detection involved 
the same cell/liposome preparation and incubations as applied to the MTS and NR assays. 
As the supernatant and not the cells were assayed, at the end of the cell and liposome 
incubation period, 50 μl of culture supernatant was removed and placed into a new 96-
well plate. To this, 50 μl of LDH substrate mix was added and the plates incubated at 37 °C 
for 30 min in the dark. The reaction was stopped by adding 50 μl of ‘Stop solution’ and the 
absorbance read at 490 nm. Numerous controls were included: media only (‘background’), 
cells without liposomes (spontaneous LDH release), lysed cells (maximum LDH release) 
and a kit supplied LDH positive control to ensure the enzymatic reaction functions 
correctly.  
 
2.5.3.4 NAG assay 
NAG, or β-N-acetylglucosaminidase, is an enzyme found in mammalian cells which 
catalyses the hydrolysis of 4-nitrophenyl N-acetyl-β-D-glycosaminde (NP-GlcNAc) resulting 
in p-nitrophenol. This reaction is important for glycolipid and glycoprotein degradation in 
lysosomes and can therefore be used as a method to investigate cellular activity. The assay 
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was conducted using a kit whereby the provided substrate NP-GlcNAc is hydrolysed by 
cellular NAG. As NAG is an intracellular enzyme, cell lysis to release NAG into the culture 
supernatant for assaying is crucial. However, it should be noted that the NAG assay can 
also give false positives when looking for cellular activation if, for example, the cell has 
been lysed due to the toxicity of the components added. Therefore, it is wise to carry out a 
simultaneous cell viability assay (MTS, NR or LDH) to verify that the cell numbers are the 
same for all conditions. 
 
The cells were treated with the relevant liposome formulations for the chosen time 
period. In some experiments cells were pre-treated with LPS to stimulate them. Media 
from all wells was removed and the cells lysed by adding 1 % Triton X-100. After 1 hr, 20 μl 
of cell supernatant was removed and added to a new 96-well plate. 80 μl of NAG substrate 
(Np-GlcNAc) was added to each well and the plate incubated for 30 min at 37 °C. ‘Stop 
solution’ (200 μl/well) was added and the absorbance at 405 nm was read using a 
spectrophotometer. Controls included unlysed cells (background NAG levels), substrate 
without cell lysate (non-specific NAG enzyme activity), colour control (maximum colour 
production) and an enzyme control using kit NAG enzyme and substrate (to confirm NAG 
substrate specificity).  
   
2.6 Biodistribution Studies in Mice 
Balb/c mice were used to study the movement of liposomes and antigen from the site of 
injection (SOI). Three to five mice were used for each experimental group: whilst 3 
mice/group were used for the initial experiment, and 5 mice/group in the second 
experiment, it was finally decided that 4 mice/group was sufficient to produce quality data 
even in the presence of an outliner. Mice were housed under conventional conditions (22 
°C, 55 % humidity, 12 h day/night cycle) in their experimental groups (therefore between 
3-5 mice/cage) and were given a standard diet ad-lib. All mice were purchased at 6-8 
weeks of age at the start of the experiment.  
 
2.6.1 Pontamine blue for the detection of immune tissues 
Four to seven days prior to injection of the vaccines, sterile filtered (0.2 μm) pontamine 
blue (0.5 % w/v in PBS) was injected subcutaneously (s.c) into the neck region as a marker 
for lymph nodes (Tilney, 1971). The volume injected (100 - 200 μl) depended on the 
62 
 
mouse weight/age but was always standardized within each experiment. In certain 
biodistribution experiments a tail-bleed (50 μl) was taken 3 days after injection of 
pontamine to identify cell types taking up pontamine blue. To collect blood, capillary tubes 
lightly coated in 1 % heparin (in PBS) were used to draw up blood from a small incision at 
the base of the tail. The blood from 20 mice was pooled in PBS (10 mM) and washed once 
(13,000 rpm, 5 min). OptiLyse®C lysing solution (1 ml) was added and left for 10 min 
followed by addition of 1 ml PBS (10 mM). The samples were mounted onto glass slides 
using a cytospin and mounted with glass cover slips using a DAPI-containing hard mount 
solution (Vector labs). Samples were viewed using a fluorescent microscope to identify 
pontamine blue containing cells (the fluorescent nature of pontamine blue is attributed to 
its six benzene rings). 
 
2.6.2 Preparation of radiolabelled vaccines 
Biodistribution studies were conducted with 3H-labelled liposomes and 125I-labelled 
protein antigen, produced as described in sections 2.2.2 and 2.4.3 respectively. Due to the 
dilution of antigen during the gel filtration step after iodination, the concentration of the 
liposomes had to be increased 2-fold so that upon mixing of equal volumes of protein and 
liposome, the final concentration remained 1.25 mg lipid/ml equivalent to 250 μg 
lipid/dose. Furthermore, the final concentration of the liposomes and antigen had to be 
further concentrated as whilst this dosage volume (200 μl) is suitable for subcutaneous, 
intraperitoneal (i.p) or intravenous (i.v) injections, the recommended volume for 
intramuscular (i.m) injection is 50 μl. Therefore, liposomes were actually rehydrated in a 
volume of buffer 8-fold less than usual, followed by addition of an equal volume of antigen 
at a concentration 2-fold higher than required. Table 2.2 summarizes these volumes with 
respect to DDA:TDB liposomes. Furthermore, as Tris buffer used to rehydrate lipid films is 
not isotonic, 20 % (w/v) trehalose was included in the Tris buffer so that upon dilution 
with an equal volume of radiolabelled protein, the final trehalose concentration was 10 % 
(w/v). Approximately 1 hr prior to injection, liposome and antigen were mixed; each dose 
contained 250 μg lipid, 50 μg TDB and 2 or 5 μg protein antigen. Vaccines were given by 
either the i.m route into the quadriceps (dose volume 50 μl) or via the s.c route into the 
flank (dose volume 200 μl).  
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Table 2.2 Quantity of liposome components required to make ‘DDA:TDB’ liposomes for a 
range of experiments 
Application DDA 
(μg) 
TDB (μg) Rehydration  
buffer (μl) 
Volume of antigen 
required (μl) 
Physicochemical analysis 1250 250 1000[1]  
BD study (s.c)  250 50 100 100 
BD study (i.m) 250 50 25 25 
BD study (i.m) 
‘Big liposomes’ 
250 50 10[2] 25 
BD, biodistribution; s.c, subcutaneous; i.m, intramuscular 
[1] Assuming no antigen will be added.  
[2] With a further 15 μl buffer added once liposomes have formed.  
 
 
2.6.3 Processing of tissues 
Mice were terminated at the relevant time-points by cervical dislocation and various 
tissues collected (Table 2.3). The exception to this was for experiments in which the blood 
was also collected; in this case blood was collected by cardiac puncture with mice 
asphyxiated by CO2, followed by cervical dislocation to confirm death. All tissues were 
processed in the same manner, the major steps being tissue solubilisation, quantification 
of 125I, bleaching followed by quantification of 3H. Each tissue sample was weighed into a 
γ-vial and Solvable™ (1.5 ml) added to each sample before quantifying 125I presence using 
a Cobra™ CPM Auto-Gamma® counter (Packard Instruments Company inc., IL, USA). To 
verify that the presence of undigested tissue and whole organs did not affect the count 
rate, all samples from original experiments were counted for 125I prior and post tissue 
digestion with no difference in the results noted (results not shown). Samples were heated 
at 40 °C until tissues were fully solubilised, following which they were allowed to cool and 
then transferred into 20 ml scintillation vials. Both glass and plastic scintillation vials were 
used although within each experiment the vial type was kept constant. Hydrogen peroxide 
(200 μl) was added to each sample and once fully bleached (sometimes additional heating 
of samples was required to ensure complete digestion), Ultima Gold™ scintillation fluid (10 
ml) was added to each sample and 3H presence quantified using a standard 3H detection 
protocol.  
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Table 2.3 Approximate weights of various tissues collected during biodistribution studies 
Tissue Approximate weight collected (mg) 
Blood 100 
Heart* 150 
Lung 100 
Liver 100 - 200 
Kidney *(one of two) 150 
Spleen* 100 
Small Intestine 100 
Brain 100 - 200 
Site of injection (quadriceps) 300 - 400 
Site of injection (flank) 200 - 300 
Lymph node* (local draining) 1 - 2 
Not all tissues were collected in every study. * indicates whole organ 
 
2.6.4 Quantification of the proportion of vaccine components in 
tissues 
For the determination of liposome (3H) and antigen (125I) in the different tissues, the data 
was either presented as radioactivity (counts per minute; CPM) or a proportion of the 
dose (% dose). In both cases, the results were presented as whole tissue or mg tissue. To 
calculate the % dose, triplicate samples of the original dose were processed 
simultaneously to the tissue processing. These doses represented a fraction of the whole 
dose and relevant dilution factors were considered after obtaining the CPM values. For all 
samples, the CPM values derived from the Cobra™ CPM Auto-Gamma® counter (relating 
to 125I presence) did not need additional processing as 3H cannot be detected by the 
gamma counter without the presence of a scintillant; solely the removal of background 
values (average of three Solvable™ samples) was undertaken. For the determination of 3H 
however the 125I overspill had to be considered as 125I is detectable on a scintillation 
counter. To overcome this problem a method was developed whereby the 125I could be 
factored out by the use of a standard curve. Triplicate samples of 125I starting at an activity 
equivalent to the dose administered in vivo (~ 100 kBq) were diluted 2-fold until 
background levels (~ 20 cpms) were reached. These samples were counted using a γ-
counter and then transferred and processed as the tissue samples would be (see section 
2.6.3). The samples were then counted on a scintillation counter using the same 3H 
detection protocol as used for the tissue samples. A plot of the cpm values derived from 
the gamma counter (x-axis) against the cpm values derived from the scintillation counter 
(y-axis) was made and the line of best fit and equation derived for samples below 50,000 
cpm (~ 2 % of the dose or less) and those above 50,000 cpm (~ 2 % of the dose or more). 
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These two equations were used to calculate the effective interference that the 125I would 
have on the 3H values determined by scintillation counting. We found that the efficiency of 
125I counting using our scintillation counters was approximately half of that seen by the γ-
counter; however for each separate biodistribution study conducted, a new 125I standard 
curve was produced as the counting efficacy of the machine can change and is also 
dependent on the amount of 125I in the sample. To investigate whether this relationship 
was linear, known volumes of 3H were added to the serially diluted 125I samples and 
counted on the scintillation counter. The results showed a linear relationship indicating 
that there is no quenching effect between the two radioisotopes and that the above 
equation method to remove interfering 125I counts is valid.  
 
2.7 Immunisation Studies in Mice 
2.7.1 Experimental set-up 
Two separate immunisation studies were conducted, the first in partnership with lab 
colleagues (RK, Randip Kaur; JH, Jubair Hussain; MH, Malou Henriksen) and the second 
conducted alone by MH. The number of mice per experimental group and allocated per 
researcher was not constant between experiments – Table 2.4 outlines the experimental 
design.  
 
Table 2.4 Outline of the liposome formulations used in the two immunisation studies 
 Immunisation study 
Formulation 1 2 
1 DDA:TDB:OVA (6) DDA:TDB:H1, Small (5) 
2 OVA (6) DDA:TDB:H1, Medium (5) 
3 OVA with ICF (3) DDA:TDB:H1, Large (5) 
4 PBS (3) DDA:TDB:H1, Extra large (5) 
5  H1 with ICF (4) 
6  PBS (4) 
Numbers of mice per group are shown in brackets. H1, Ag85B-ESAT-6 
 
2.7.2 Vaccine formulations and preparation 
Liposomes were produced as described in section 2.2.1 with the addition of 10 % trehalose 
to the rehydrating Tris buffer to provide isotonicity. Furthermore, the volume of Tris used 
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for rehydration was adjusted so that upon addition of antigen (OVA or Ag85B-ESAT-6) the 
final dose (50 μl) contained 250 μg DDA, 50 μg TDB and 10 μg OVA or 2 μg Ag85B-ESAT 6.  
 
For the OVA immunisation experiment, injection of OVA alone was used to determine the 
adjuvantal effect of DDA:TDB liposomes. In this case OVA was dissolved in PBS (10 mM, pH 
7.4) to a final concentration of 200 μg/ml so that each dose (50 μl) contained 10 μg OVA.  
 
For the Ag85B-ESAT-6 immunisation experiment, the aim of the experiment was to 
determine the effect of vesicle size on resulting immunogenicity. Ag85B-ESAT-6 adsorbing 
DDA:TDB liposomes were made to four different sizes. All formulations were made using 
the lipid-film hydration method (see section 2.2.1) with the following described 
alterations. To produce small liposomes the rehydrated liposome mixture was sonicated at 
4 microns for 2 x 30 seconds. Medium sized liposomes were not altered in any way. Large 
liposomes were produced by rehydration of the lipid film in a volume equal to one fifth of 
the required volume. Once cooled, the remaining four fifths of the required rehydration 
volume was added. To produce the largest liposomes, PBS buffer (10 mM, pH 7.4) rather 
than Tris buffer was used as the rehydrating medium. As PBS is isotonic, no trehalose was 
added to the buffer unlike the small, medium and large liposomes which were all 
rehydrated in Tris buffer containing 10 % trehalose.  
 
Both studies included a positive (antigen with ICF) and negative (PBS buffer alone) control. 
For the production of the antigen:ICF positive control, equal volumes of antigen (OVA or 
Ag85B-ESAT-6) and ICF were vortexed well until a homogenous solution resulted. Each 
dose (50 μl) contained 10 μg OVA or 2 μg Ag85B-ESAT-6 in combination with 25 μl ICF. The 
negative naïve control group was PBS alone for both experiments. Mice were injected i.m 
(50 μl) into the left or right quadriceps with formulations prepared on the day of injection.  
 
2.7.3 Antibody analysis 
Antibodies were detected in the serum of tail-bled mice. Blood was collected using 
capillary tubes dipped in 1 % heparin (PBS, 10 mM) and placed immediately into 
eppendorfs containing 450 μl PBS (10 mM). All tubes were centrifuged (13,000 x g, 5 
minutes) and the supernatant from each tube was placed in a new eppendorf and frozen (- 
20 °C) until use. Serum was consequently 20-fold diluted in PBS if the volume ratio of red 
blood cells:sera is assumed to be 1:1.  
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To detect antibodies in serum, standard enzyme-linked immunosorbent assays (ELISA) 
were used. ELISA pates were coated overnight at 4 °C with 50 μl OVA in PBS (2 μg/well) or 
Ag85B-ESAT-6 (5 μg/ml) for the relative studies (Agger et al., 2008b). Plates were washed 
three times to remove unbound antigen; the wash buffer used throughout was ‘PBST’ (40 
g NaCl, 1 g KCl, 1 g KH2PO4, 7.2 g Na2HPO4(2H2O), 0.4 ml Tween 20, 5 L ddH2O). Marvel milk 
powder (100 μl; 1 % w/v) was added per well to block non-specific binding (Agger et al., 
2008b). After 1 hr incubation at 37 °C, the plates were washed three times with PBST and 
were now ready for addition of serially diluted serum. Figure 2.2 shows an example plate 
setup for the OVA immunisation study: 190 μl of PBS (10 mM, pH 7.4) was added to each 
well in row A whilst 100 μl PBS was added to each well in rows B-H. Serum (10 μl) was 
added to the appropriate wells of row A and mixed well – a 50 μl sample was removed and 
added to the wells in row B. Again, this was thoroughly mixed and the serial dilutions 
continued until lastly 50 μl of diluted serum was removed from the wells of row A and H so 
that the total volume of serially diluted serum in all wells was 100 μl. Each sample was 
investigated in duplicate. Plates were incubated at 37 °C for 2 hrs followed by three 
washes with PBST and addition of 50 μl of isotype specific immunoglobulin (IgG, 1:500; 
IgG1, IgG2a, IgG2b, 1/4000 dilution). After 1 hr at 37 °C all plates were washed again three 
times and 50 μl of substrate added per well. The substrate comprised 5 x 10 mg tablets of 
2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) dissolved in 83.3 ml citrate buffer 
(0.92 g citric acid, 1.956 g Na2HPO4, 100 ml ddH2O) and 7.5 μl H2O2. After 20 min 
incubation at 37 °C, the absorbance at 405 nm of all wells was measured (Bio-Rad, model 
680). The results were expressed as the log10 value of the reciprocal of the end point 
dilution which gave an optical density (O.D) of 0.2 or above.  
 
  1 2 3 4 5 6 7 8 9 10 11 12 
  1.1 1.2 1.3 1.4 1.5 1.6 1.1 1.2 1.3 1.4 1.5 1.6 
A 1/400             
B 1/1,200             
C 1/3,600             
D 1/10,800             
E 1/32,400             
F 1/97,200             
G 1/291,600             
H 1/874,800             
 
Figure 2.2 Outline of the ELISA plate set-up used for the OVA immunisation study to study 
the adjuvant ability of DDA:TDB liposomes in OVA immunisation. 
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2.7.4 Splenocyte proliferation 
To test cells for their ability to respond to antigen in vitro, splenocytes were restimulated 
with various concentrations of antigen and their proliferation, determined by 3H-
thymidine uptake, measured. On day 49 mice were terminated by cervical dislocation and 
their spleens harvested and placed in a 7 ml bijoux containing ~ 5 ml ice cold PBS. Each 
spleen was treated individually and kept on ice until processing. Spleens were mashed 
through a cell strainer into a 50 ml centrifuge tube using the 5 ml PBS and a further 10 ml 
cold cRPMI (RPMI containing 10 % FBS and 1 % PSG). Each tube was left for ~ 5 min to 
allow cell debris to settle. The supernatant (~ 13 ml) was transferred into a 15 ml falcon 
tube and centrifuged at 1200 rpm, 15 °C for 10 min, after which the supernatant was 
discarded and the pellet resuspended in 10 ml cold cRPMI. The wash was repeated and 
the pellet resuspended in 5 ml cold cRPMI and a cell count performed as described in 
section 2.5.2. The cell number was adjusted to between 0.2-1 x 107 cells/ml.  
 
According to the immunisation experiment, serial dilutions of OVA (0.5, 5 and 50 μg/ml) or 
Ag85B-ESAT-6 (0.05, 0.5 and 5 μg/ml) in cRPMI were made and 100 μl added per well of a 
96-well culture plate (Holten-Andersen et al., 2004). Wells containing medium only or 5 
μg/ml of concanavalin A (ConA) were included in all experiments as negative and positive 
controls respectively. Splenocytes (100 μl, 0.2-1 x 107 cells/ml) were added to each well 
making a final well volume of 200 μl. Cultures were incubated at 37 °C, 5 % CO2, 95 % 
humidity for 72 hrs following which 18.5 kBq (0.5 μCi) 3H-thymidine (40 μl in cRPMI/well) 
was added (Eyles et al., 2003). After a further 24 hrs incubation under the same 
conditions, cells were harvested using a cell harvester (Titertek). For harvesting, media and 
cells from each well was aspirated onto a quartz filter mat. Each mat was placed into a 
plastic scintillation vial and 5 ml Ultima Gold™ scintillation fluid added/sample. All samples 
were counted using a standard 3H scintillation counting protocol. 
 
2.7.5 Cytokine analysis from in vitro restimulated splenocytes 
Splenocytes were prepared in the same way as described in section 2.7.3. According to the 
immunisation experiment, dilutions of OVA (5 and 50 μg/ml) or Ag85B-ESAT-6 (0.05, 0.5 
and 5 μg/ml) in cRPMI were made and 100 μl was added per well of a 96-well culture 
plate. Wells containing medium only or 5 μg/ml of ConA were included in all experiments 
as negative and positive controls respectively. Six to ten wells for each condition were 
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used so that sufficient supernatant could be obtained. Splenocytes (100 μl, 0.2-1 x 107 
cells/ml) were added to each well and the plates incubated at 37 °C, 5 % CO2, 95 % 
humidity for 48 hrs, following which the supernatants were removed, pooled according to 
group and frozen at -70 °C until use. Supernatants were assayed for the presence of IFN-γ, 
IL-2, IL-5, IL-6 and IL-10, using standard duo-set capture ELISA. Whilst the protocol was the 
same for each ELISA, there were variations in the concentrations of ELISA components. 
The general setup involved coating ELISA 96-well microplates overnight at rtp with 100 μl 
of the appropriate capture antigen (IL-2 and IL-5, 1 μg/ml; IL-6, 2 μg/ml; IL-10 and IFN-γ, 4 
μg/ml).  The following morning plates were washed using PBST (for recipe see section 
2.7.3) followed by a block step with 300 μl of 1 % BSA in PBS containing 0.05 % NaN3. After 
approximately 1 hr at rtp, the plates were washed again using PBST and the samples and 
standards added (100 μl/well). The cytokine standards were 2-fold serial dilutions of the 
supplied cytokine diluted in 0.2 μm sterile filtered reagent diluent (0.1 % BSA, 0.05 % 
Tween 20 in Tris buffered saline (20 mM Tris, 150 mM NaCl), pH 7.2 – 7.4). Each standard 
was diluted 6 times and included a 0 pg/ml control. Whilst most samples were added neat 
without any dilution, where necessary reagent diluents was used to dilute samples and 
dilution factors applied correspondingly. After 2 hrs incubation at rtp, the plates were 
washed again in PBST and 100 μl of the appropriate detection antibody added. New 
microplate slips were added to each plate and following a further 2 hrs incubation at rtp 
the plates were washed again with PBST. Streptavidin-HRP conjugate, diluted in reagent 
diluents, was added to each well (100 μl) and plates incubated in the dark at rtp for 20 
min. Following a further wash with PBST, a substrate solution produced of 1:1 ratio of 
component A (H2O2) and component B (tetramethylbenzidine (TMB) agent (1 mg tablet), 
with 1 tablet dissolved in 1 ml DMSO and 9 ml phosphate citrate buffer (0.05 M, pH 5)) 
was added to each well (100 μl) and again left in the dark for 20 min. The reaction was 
stopped by addition of 50 μl/well ‘STOP’ solution (2N H2SO4) and the absorbance (O.D) at 
450 nm and 560 nm of each well read using a microplate reader (BioRad, model 680).  
 
All standards and samples were assayed in duplicate and the O.D at 560nm removed from 
the 450nm value to correct for imperfections in the ELISA plates. The average values of 
each standard and sample were determined and the average 0 pg/ml cytokine standard 
value was subtracted from all other standards and samples. Using GraphPad Prism, a four-
parameter sigmoidal standard curve was created for each set of cytokine standards and 
the cytokine concentrations in the unknown samples calculated accordingly.  
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2.8 Statistics 
For all experiments the mean ± standard deviation (S.D) was calculated, unless stated 
otherwise. Statistical analysis of data was tested by one- or two- way analysis of variance 
(ANOVA). When significant differences were indicated, differences between means were 
determined by Bonferroni’s multiple comparison tests. All statistical analyses were 
performed in GraphPad Prism version 4 or 5 (GraphPad Software Inc., La Jolla, CA). 
 
2.9 Collaborative Works; brief methods 
2.9.1 Trinity College Dublin, Ireland 
To investigate the ability of liposomes to stimulate production of IL-1α and Il-1β from DCs, 
bone marrow-derived dendritic cells (BMDCs) from C3H/HeN mice were plated at 6.25 × 
105 cells/ml and incubated for 6 hours in the presence of LPS (5 ng/ml). Cells were then 
stimulated with DDA, DDA:TDB or DSPC:TDB liposomes which were made at Aston 
University using the protocol described in section 2.2.1 to a final concentration of 5 mg 
lipid/ml. Liposomes were added to the cells at concentrations starting with a 10-fold 
dilution (500 μg/ml) and thereafter 4-fold dilutions until a dilution of 1/40,960 was 
reached. Supernatants were removed after a further 24 hours and analysed for IL-1α and 
IL-1β by ELISA.  The results are presented as the mean of triplicate samples ± S.E. 
 
2.9.2 Statens Serum Institute, Denmark 
The collaboration with Statens Serum Institute (SSI) involved the shared aim of basically 
improving cationic liposomes formulations designed as adjuvants for immunisation against 
tuberculosis (TB). The TB antigen Ag85B-ESAT-6 used for work both at Aston University 
and SSI was supplied by SSI. In addition to the immunisation studies which took place at 
SSI, a TB challenge experiment also took place. In all cases, liposomes were made at Aston 
University using the method described in section 2.2.1. Liposomes were made so that each 
dose would contain 250 μg lipid +/- 50 μg TDB. Ag85B-ESAT-6 (2 μg/dose) was added prior 
to immunisation at SSI. Analytical methods including antibody and cytokine detection, T-
cell polyfunctionality, T-cell cycling in vivo, dendritic cell uptake studies and TB challenge 
studies are all described in the respective papers (Christensen et al., 2010b; Henriksen-
Lacey et al., 2009; Henriksen-Lacey et al., 2010b, c). This work was supported by projects 
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TBVAC (contract n. LSHP-CT-2003-503367) and NewTBVAC (contract no. HEALTH-F3-2009-
241745).  
 
2.9.3 University Hospital of Zurich, Switzerland  
The importance of the route of injection and antigen delivery system was investigated in a 
collaboration involving Leiden/Amsterdam Centre for Drug Research (Netherlands), ETH 
Zurich (Switzerland), Aston University and The University Hospital of Zurich, the later being 
the location of the experiment. The experimental details are fully described in the relevant 
paper (Mohanan et al., 2010).   
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3.1 Aims 
This chapter addresses the initial studies conducted on liposomes based on 
dimethyldioctadecylammonium bromide (DDA). The physicochemical effects of additional 
stabilising and immunomodulatory molecules, in addition to the choice of rehydrating 
buffer and its molarity, on the DDA based formulations are presented. The stability of 
these formulations is addressed and both model and antigenic proteins are investigated in 
combination with the different DDA based liposomes in immunisation studies. 
Furthermore the biodistribution of the vaccine constructs and the importance of injection 
route are presented. 
 
3.2 Introduction  
Nearly 50 years have passed since the lipid DDA was originally described as having 
immunogenic properties (Gall, 1966), however it is still clear that our understanding of its 
adjuvantal abilities are inconclusive. The adjuvant action of liposomes composed of DDA 
has been primarily attributed to its ability to protect and deliver antigen to APCs and to 
form what is termed as an ‘antigen depot’ whereby antigen is retained at the injection site 
for a prolonged period of time. Antigen protection is of great importance as the 
increasingly common antigenic recombinant peptides and proteins produced are small and 
non-immunogenic and consequently enzymatic breakdown or more simply clearance by 
the circulatory system results in rapid clearance, normally via the kidneys, of these 
important molecules. Liposomes are good antigen-protectors as they convert ‘soluble’ 
antigenic molecules into a particulate form, rendering them effectively larger and more 
immunogenic. This trait of adjuvants - to make soluble antigen into a particulate substance 
- is not a sole property of liposomes but is in fact a common property shared by all 
adjuvants including emulsions and aluminium salts among others. However the ability of 
various adjuvants to retain antigen in a particulate form varies significantly and can be due 
to numerous factors such as the administration route or simply adjuvant breakdown in 
vivo. In terms of the antigen depot-effect, this is a property which also appears to be 
shared across numerous adjuvants, in particular aluminium salts. However, aluminium salt 
adjuvants tend to produce granulomas due to tissue damage and uric acid production 
(Goto et al., 1997). It is also likely that the viscous nature of liposomes may also lead to an 
antigen (and liposome) depot-effect in injected tissues.  
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3.2.1 Improving DDA-based liposome stability 
Liposomes composed of DDA have been described as having immunostimulatory 
properties in numerous TB studies (Andersen, 1994; Bosio and Orme, 1998; Brandt et al., 
2000; Davidsen et al., 2005; Holten-Andersen et al., 2004; Lindblad et al., 1997), however, 
their poor stability and only weakly immunogenic responses led to investigations in which 
additional stabilising molecules and/or immunomodulators were incorporated. 
Cholesterol is an abundant component of mammalian cell membranes and has been 
extensively studied as an artificial membrane stabiliser using phospholipid liposomal 
systems (Gregoriadis and Davis, 1979; McMullen and McElhaney, 1996; Sulkowski et al., 
2005). The incorporation of cholesterol into liposomal membranes has been shown to lead 
to improved lipid packing consequently reducing or even eliminating the main phase 
transition temperature (Christensen et al., 2009; Ohtake et al., 2005). The resulting lower 
gel to liquid phase transition temperature leads to an increased bilayer fluidity and 
liposomes show improved stability both in vitro and in vivo (Gregoriadis and Davis, 1979). 
In fact many of the earlier studies using liposomes as drug delivery systems incorporated 
cholesterol to not only improve liposome stability but also to increase the half-life of 
intravenously administered formulations; the inclusion of cholesterol into the liposome 
membrane limits plasma protein association with the liposome surface and consequently 
reduces the tendency of liposomes to be rapidly uptaken by the mononuclear phagocyte 
system (MPS) (Gregoriadis, 1985, 1995b; Semple et al., 1996). Whilst cholesterol is not 
inherently immunogenic, numerous studies have shown that incorporation of cholesterol 
into liposomes leads to more favourable liposome properties such as increased 
transfection rates (Xu and Anchordoquy, 2008) and improved immunogenicity (Bakouche 
and Gerlier, 1986). However this is not a rule of thumb for all liposome formulations as 
cholesterol inclusion in other liposome formulations has been shown to lead to reduced 
immunogenicity (Christensen et al., 2009; Nakano et al., 2002). Therefore whilst liposome 
stability can be improved by using cholesterol, this is not always the optimum method due 
to the forfeited loss of immunogenicity.  
 
3.2.2 Methods to augment the immunostimulatory actions of DDA-
based liposomes  
In an attempt to improve the immunogenicity of DDA liposomes, the incorporation of 
various bacterial derived substances has been investigated. Perhaps the most common is 
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monophosphoryl lipid A (MPL), a less toxic version of lipid A which is the anchor moiety of 
Gram-negative bacteria lipopolysaccharide (LPS) (Alving and Rao, 2008). Addition of MPL 
to DDA liposomes has been shown to significantly improve the immunogenicity of the 
formulation with strong cell-mediated immune responses observed in TB studies (Brandt 
et al., 2000; Holten-Andersen et al., 2004; Langermans et al., 2005; Olsen et al., 2001). 
Two mycobacterial derived substances which have been studied in TB models include N-
acetylmuramyl-L-alanyl-D-isoglutamine (muramyl dipeptide; MDP), administered in 
solution (Pettis et al., 2000) and liposomal form (Holten-Andersen et al., 2004), and 
trehalose 6,6’-dimycolate (TDM). TDM has been used in a wide range of disease models as 
it is a strong inducer of humoral and cell-mediated immunity. Only recently has a cellular 
receptor for TDM (and its synthetic analogue) been discovered (Ishikawa et al., 2009) 
although the receptor itself was first identified over a decade ago (Matsumoto et al., 1999) 
and has been known as a receptor for certain fungal species (Wells et al., 2008; Yamasaki 
et al., 2009). The receptor, known as Mincle or CLEC4, is postulated to directly bind the 
TDM glucose head groups possibly in a 2:1 Mincle:TDM ratio, although this has yet to be 
fully tested (Ishikawa et al., 2009). The discovery of the Mincle receptor is important as a 
specific target is now identifiable rather than the previously considered scavenger 
receptor MARCO and also TLR 2 to which TDM was linked (Bowdish et al., 2009). 
Furthermore, in addition to the receptor itself, the downstream signalling pathway has 
been identified as the Syk-Card9-Bcl10-Malt1 pathway; using selective knock-out studies 
TDM and its synthetic form trehalose 6,6’-dibehenate (TDB) have been shown to signal via 
this pathway resulting in the induction of the innate immune response with a Th1/Th17 
bias (Werninghaus et al., 2009).  
TDM is a large molecule (C186H366O17 ± 10CH2; Mw 2970 ± 140) (Noll et al., 1956) and is 
known to interfere with lipid organisation in liposomal membranes (Crowe et al., 1994; 
Spargo et al., 1991). Furthermore the similarity between TDM and its natural pathogen 
makes it relatively toxic in vivo and it is therefore unsuitable for use in vaccines (Hunter et 
al., 2006; Kato, 1973). The synthetic analogue TDB is composed of the same glucose 
disaccharide head groups whilst the mycolate chains are reduced in number and their 
length shortened (Matsunaga and Moody, 2009) leading to a significantly decreased 
toxicity whilst retaining immunogenic properties. TDB is considerably smaller than its 
natural analogue (Mw 987) and can be readily incorporated into DDA liposomes at 
concentrations of at least 20 mol % without any significant changes to properties such as 
liposome size or IFN-γ production in immunisation studies (Davidsen et al., 2005). The 
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optimum amount of TDB incorporation into DDA liposomes is observed at 11 mol %  and in 
addition to producing liposomes expressing long term stability at 4 °C (Linderstrøm et al., 
2009), this concentration has been shown to give the highest antibody titres when 
compared to other TDB concentrations (Davidsen et al., 2005). TDB has also been shown 
to be successfully incorporated into DDA lipid bilayers up to a 1:1 TDB:DDA w/w ratio 
(equivalent to 39 mol %  TDB) and although the membrane fluidity of the liposomal 
systems decreases, the main gel to liquid phase transition temperature does not fall below 
41 °C (Christensen et al., 2008) which is important for in vivo applications if more rigid 
liposomes are required. The stabilising effect of TDB in DDA bilayers is attributed to the 
interaction of TDB glucose head-groups with surrounding water molecules of the aqueous 
hydrating solution (Christensen et al., 2008; Davidsen et al., 2005). It is therefore 
conceivable that changes to the hydrating solution, such as pH, molarity or buffer 
composition will have an effect on the physicochemical characteristics of the liposomal 
system. Whilst these properties have not been studied in great detail with DDA based 
liposomes, similar work using other cationic liposomes in which various concentrations of 
NaCl were added to the hydrating buffer showed significant alterations in both the 
physicochemical properties of the liposomes and in their ability to immunise mice in a 
tumour vaccine model (Yan and Huang, 2009). Improvements in immunogenicity were 
noted upon addition of small amounts of NaCl (30 mM) and the authors hypothesised that 
this improvement was due to altered physicochemical attributes such as an increase in 
vesicle size and zeta potential and facilitated antigen release in vivo.  
 
3.2.3 Choice of route of administration for immunisation studies 
Human vaccines are most commonly administered via the parental route with all protein 
based vaccines being given via intramuscular (i.m) injection whilst inactivated 
microorganisms are given predominantly via the subcutaneous (s.c) route. Although both 
the i.m and s.c routes of injection are preferential with regards to ease of administration, 
neither route is favoured amongst immunologists seeking to target immunologically 
privileged sites. For this, intradermal (i.d) administration is probably most favourable as 
the dermal layers of the skin comprise many Langerhans cells which are able to 
endocytose and present antigen (Kissenpfennig et al., 2005; Steinman and Banchereau, 
2007). The i.d route is also becoming more popular due to its use in novel administration 
techniques such as transdermal skin patches and microneedles (Cevc and Vierl, 2010). 
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Consequently when delivery routes described in experimental studies published in more 
traditional vaccine journals are compared with those in journals focussing on delivery 
systems, the i.d route is preferential in the latter whilst i.m and s.c routes of 
administration are favoured in the former (Johansen et al., 2010). Figure 3.1 shows the 
tissue physiology encountered after i.m, i.d and s.c. injection. 
 
Figure 3.1 Diagram showing simplified tissue physiology encountered after injection via 
intramuscular (i.m), intradermal (i.d) or subcutaneous (s.c) administration routes. Taken 
from (Chester, 1998). 
 
3.3 General Methods 
Liposomes composed of DDA, with or without TDB or cholesterol, were produced and 
their physicochemical characteristics identified. These DDA-based liposomes were used to 
investigate how model proteins ovalbumin (OVA) and bovine serum albumin (BSA) affect 
the aforementioned liposomes. The role of DDA-based liposomes in initiating an antigen 
depot-effect was investigated in biodistribution studies using dual-radiolabelled 
components; the effect of TDB and cholesterol are both documented. Furthermore, the 
role of ‘administration route’ in altering the depot-effect was analysed after injection via 
the i.m and s.c routes of injection. 
To investigate whether vaccine delivery via different routes of administration had an effect 
on the ensuing immune responses, DDA and DDA:TDB liposomal vaccines delivered via i.m, 
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s.c, i.d or intralymphatic (i.ln) routes of injection were investigated in a collaborative study 
headed by Pål Johansen (University Hospital of Zurich, Switzerland). The principle aim of 
this study, also in partnership with Bruno Gander (ETH, Switzerland) and Wim Jiskoot 
(Leiden/Amsterdam Centre for Drug Research, Netherlands), was to investigate how non-
adjuvanted and adjuvanted vesicular delivery systems delivered by various routes of 
injection effect the immune response of OVA immunised mice. In total three different 
delivery systems and four different routes of injection were studied with each delivery 
system being made in a different laboratory (Table 3.1 and 3.2). The i.ln injection route 
was to act primarily as a positive control as this has, unsurprisingly, been shown to 
improve the immune response to protein and peptide vaccines (Johansen et al., 2005; 
Martinez-Gomez et al., 2009; Senti et al., 2009).  
 
Table 3.1 Outline of the various routes of injection used in collaborative studies with Pål 
Johansen, University Hospital of Zurich, Switzerland 
 
Table 3.2 Formulations produced for collaborative work with Pål Johansen, University 
Hospital of Zurich, Switzerland 
DDA, dimethyldioctadecylammonium bromide; TDB, trehalose 6,6’-dibehenate; TMC, N-
trimethyl chitosan; LPS, lipopolysaccharide; PLGA, poly(lactide-co-glycolide). 
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The ability of DDA based liposomes to immunise mice and cause appropriate antibody and 
cytokine production was also investigated at Aston University, again using the model 
antigen OVA. The principle aim of this experiment was to investigate inter-researcher 
variation and to allow each researcher (MH, Malou Henriksen; RK, Randip Kaur; JH, Jubair 
Hussain) to gain experience of the experimental set-up in addition to gathering statistically 
significant data. Each step (formulation production, collection of blood, injections, spleen 
harvesting etc) of the study was conducted individually so to investigate inter-researcher 
variance. OVA was injected alone (non-adjuvanted), with Incomplete Freund’s Adjuvant 
(ICF) (positive control) or with DDA:TDB liposomes (adjuvanted vaccine formulation).  
 
Importantly, the choice of antigen (OVA), batch of antigen, adjuvant formulation 
(DDA:TDB liposomes), adjuvant dose (250 μg DDA, 50 μg TDB) and mouse strain (Balb/c) 
used in the immunisation experiment conducted at Aston University and at University 
Hospital of Zurich were the same and therefore allowed direct comparison between the 
results. The only variations between the two immunisation experiments involved the OVA 
dose, which was 10 μg/dose for studies conducted at Aston University and 20 μg /dose for 
those conducted at University Hospital of Zurich, and the researcher conducting the 
injections and analysis.  
 
3.4 Results and Discussion  
3.4.1 Physicochemical characterisation of DDA-based liposomes 
Initial work focussed on the characterisation of the liposomal formulations and 
investigating how changes such as buffer molarity or addition of protein antigens have an 
effect on the physicochemical characteristics of the liposomes. The simplest liposome 
construct was composed of DDA alone, at a concentration of 1.25 mg lipid per ml of 
rehydrating buffer. Liposomes composed of DDA and rehydrated in Tris buffer (10 mM) 
were typically 403 ± 24 nm in diameter and expressed a polydispersity of 0.226 (Table 3.3). 
Polydispersity can be used as a measure of heterogenicity and differs from the standard 
deviation (SD) or standard error of the mean (SEM) as it assesses the whole time period 
which the sample is being measured for, whilst the SD or SEM is based on the individual 
values recorded by the machine. To clarify, if a liposome sample is assessed for 1 minute 
with 3 values recorded, the SD or SEM with be calculated from these 3 values. The PD 
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however will take into account the sample variance detected for the 1 minute period. PD 
can range from 0 (100 % homogenicity) to 1.0 (100 % heterogenicity). As no attempt was 
made during the liposome formulation to physically define the vesicle size range, the 
observed heterogenicity seen with DDA liposomes was to be expected and is considered 
quite low.  
 
Table 3.3 Physicochemical characteristics of DDA and DDA:TDB liposomes 
 DDA liposome (1.25 
mg/ml), Tris buffer (10 
mM) 
DDA:TDB liposome (1.25:0.25 
mg/ml), Tris buffer (10 mM) 
Vesicle Size (nm) 403 ± 24 417 ± 33 
Polydispersity  0.226 0.275 
Zeta Potential (mV) 51 ± 12 45 ± 7 
Results denote the mean ± SD of at least 3 experiments 
 
Liposomes composed of solely DDA show instability over time (Davidsen et al., 2005), as 
measured by an increase in vesicle size due to particle aggregates forming. Although DDA 
liposomes are immunogenic, the addition of the synthetic bacterial cell wall glycolipid TDB 
has been shown to improve their immunogenicity and stability (Davidsen et al., 2005). 
Previous studies which investigated the effect of various molar ratios of DDA:TDB have 
shown that addition of 11 mol % TDB to DDA liposomes gave optimal immunogenicity and 
stability for the liposome formulation (Davidsen et al., 2005). Through the use of DSC, TDB 
was shown to incorporate into DDA bilayers with the carbohydrate head group in the 
hydrophilic partition of the bilayer (Davidsen et al., 2005). Liposomes composed of DDA 
and TDB (at the 11 mol % ratio, equivalent to a weight ratio of 1.25:0.25 mg DDA:TDB) had 
a vesicle size of approximately 417 ± 33 nm and a polydispersity of 0.275, neither of which 
were significantly different from DDA liposomes alone (Table 3.3). Importantly, the 
addition of 11 mol % TDB to DDA liposomes did not alter their zeta potential suggesting 
that the quantity of TDB added does not ‘dilute out’ the strong cationic charge attributed 
to the DDA head-group; DDA and DDA:TDB liposomes expressed zeta potentials of 51 ± 12 
mV and 45 ± 7 mV respectively (Table 3.3). Vesicles produced from DDA and TDB were 
multilamellar, as shown using trace amounts of rhodamine labelled DPPE to identify the 
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bilayers (Figure 3.2). By conducting ‘z-slices’ through liposome samples mounted on a glass 
slide it was possible to see the ‘onion-skin’ appearance of DDA:TDB liposomes. The use of 
fluorescence and transmission election microscopy (TEM) highlights the heterogeneity of 
the vesicles produced, and the occasional non-spherical nature of the vesicles (Figure 3.3). 
 
A
FED
CB
 
Figure 3.2 Z-stack series of DDA:TDB liposomes incorporating 1 mol % of Rho-DPPE lipid to 
act as a tracer stain of the bilayers. A->F, top to bottom of z-stack.  
 
500nm2μm 1μm
 
Figure 3.3 Transmission election microscope images of DDA:TDB liposomes.  
 
The liposomes described above were all produced using Tris buffer (10 mM) to hydrate 
lipid films. One of the disadvantages of using Tris buffer is its non-isotonic nature; 
consequently an isotonic supplement must be added for any in vivo studies. A common 
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laboratory buffer which does not have this requirement is PBS; therefore we also 
investigated the effect of rehydrating the lipid-films with PBS buffer as opposed to Tris 
buffer. As noted in Figure 3.4, using PBS buffer of the same molarity as Tris buffer (10 mM) 
resulted in the production of significantly larger liposomes (~ 3000 nm). However, by 
reducing the molarity of PBS the vesicle size could also be reduced which suggests this 
change in size is a salt induced effect. No significant differences in the zeta potential were 
observed. TEM images also confirm the presence of larger DDA:TDB liposomes when 
produced using PBS buffer to hydrate lipid-films (Figure 3.5).  
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Figure 3.4 Vesicle size (bars) and zeta potential (points) of DDA:TDB liposomes rehydrated 
with varying molarities of PBS buffer. Samples were measured using a Brookhaven 
ZetaPlus and represent the mean ± SD of three separate readings.  
 
 
Figure 3.5 TEM image of DDA:TDB liposomes produced with PBS buffer (10 mM). 
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An important property for pharmaceutical preparations is stability. With this is mind, 
physicochemical properties of DDA:TDB liposomes were measured over time at room 
temperature (~ 20 °C) and also at 4 °C, thereby mimicking a cold-chain environment. 
Liposomes were produced using the standard lipid-film hydration method and a 1 ml 
aliquot placed in a glass vial so that visually any changes in the suspension could be 
observed. In addition, at certain time-points a sample of the liposomes was removed from 
a separate aliquot and their vesicle size, polydispersity and zeta potential measured. From 
Figure 3.6 it is clear that PBS buffer has a significant effect on the initial size of DDA:TDB 
liposomes and their stability over time. DDA:TDB liposomes produced with PBS buffer 
exhibit more variation in their mean vesicle diameter and zeta potential (Figure 3.6, C, D) 
whilst Tris buffer formed liposomes show no significant changes in the vesicle size over 
time. The physical instability of DDA:TDB liposomes formed with PBS buffer is seen visually 
in Figure 3.7 in which photos of 1 ml samples were taken at the same time-points. PBS 
buffer formed liposomes show clear phase separation just 1 day post formation whilst Tris 
buffer formed samples remain homogenous even after 56 days at room temperature.  
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Figure 3.6 Variation on vesicle size (A,C) and zeta potential (B, D) of DDA:TDB liposomes 
made with a Tris (A,B) or PBS (C,D) buffer, both at 10 mM. Data is presented from samples 
stored at 4 °C (○) and room temperature (■). Samples were measured using a Brookhaven 
ZetaPlus and represent the mean ± SD of three separate readings.  
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Figure 3.7 DDA:TDB liposome samples, made in either Tris or PBS buffer (both 10 mM) 
were stored for 56 days at 4 °C or 20 °C.  
 
Salt-induced aggregation of charged vesicles has been reported previously but by simply 
reducing the molarity of the saline buffer, aggregation of vesicles can be prevented 
((Kawakami et al., 2000; Ogris et al., 1998) and  Figure 3.4). The presence of neutralising 
counterions in saline buffers has been suggested as the cause of aggregation, due to 
reduced repulsion between adjacent vesicles (Yan and Huang, 2009). Whilst the formation 
of aggregates such as those seen in Figure 3.7 is undesirable for pharmaceutical 
preparations requiring a long shelf-life, studies have shown that lipoplexes developed with 
these larger salt-induced aggregates induce 10 - 100 fold higher levels of transfection in 
vitro (Ogris et al., 1998). Furthermore, results derived from in vivo studies described 
improved transfection in lung (Kawakami et al., 2000) and improved immune responses 
for therapeutic cancer vaccines (Yan and Huang, 2009).  
 
3.4.2 Addition of protein to DDA-based liposomes 
DDA-based liposomes have a cationic surface charge (Table 3.3). Therefore, upon addition 
of molecules such as peptides or protein which have an isoelectric point (pI) of < 7 units 
(consequently expressing an overall anionic charge at neutral pH values), electrostatic-
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mediated adsorption of the molecule to the liposome surface can occur. Two commonly 
used model proteins are ovalbumin (OVA) and bovine serum albumin (BSA), primarily used 
due to their availability, inexpensiveness and the large amount of data relating to them. 
OVA and BSA have a pI of 4.5 and 4.6 units respectively making them negatively charged at 
pH 7.4. The size of OVA and BSA proteins vary slightly with OVA containing 386 amino 
acids with an overall size of 45 kDa whilst BSA is composed of 607 amino acids and an 
overall size of 68 kDa. The effect of addition of different concentrations of OVA and BSA to 
DDA:TDB liposomes produced in Tris buffer was investigated primarily to see at what 
concentration liposomes become saturated with protein and the effect this has on the 
physicochemical properties. OVA and BSA were added to liposomes to produce a final 
concentration of 1, 5 of 10 mg protein per ml liposomes; liposomes were measured for 
their vesicle size, zeta potential and protein adsorption efficacy.   
DDA:TDB liposomes made in Tris buffer originally expressed a mean vesicle diameter of ~ 
600 nm and zeta potential of ~ 50 mV, however, upon addition of OVA or BSA there was 
an increase in vesicle size and decrease in zeta potential (Figure 3.8, A,B). Interestingly 
upon addition of OVA or BSA (1 mg/ml) there was an increase in vesicle size to ~ 3000 nm 
and a reduction to near neutral zeta potential. On further addition of either OVA or BSA, 
vesicle size decreased to ~ 2000 nm whilst the zeta potential continued to decrease to 
around -25 mV. Further increases in concentration of either protein resulted in no 
significant difference in vesicle size or zeta potential. These results suggest that addition of 
either protein results in aggregation of the liposomes into larger constructs which have 
their cationic charge neutralised by the anionic proteins. However the extent of 
aggregation is dependent on the liposome/protein ratio, or indeed liposome/nucleic acid 
ratio (McNeil et al., 2010; Ogris et al., 1998). This saturation effect is supported by the 
measurement of protein adsorption to the liposomes. The BCA assay was used to measure 
non-adsorbed protein in the supernatant of pelleted liposomes and not that associated 
with the liposome directly due to lipids interfering with the absorbance readout. Addition 
of either OVA or BSA to a final concentration of 1 mg/ml led to very high levels of 
adsorption (~ 0.8 to 0.9 mg/ml; Figure 3.8, C). Further addition of either protein did not 
greatly increase the proportion of protein adsorbed to the liposomes (e.g. ~ 30 % of 5 
mg/ml was determined to be adsorbed to the liposomes which is equivalent to 1.5 mg/ml, 
and addition of 10 mg/ml OVA or BSA resulted in ~ 15 % adsorption equivalent to ~ 1.5 
mg/ml; Fig 3.8 C), suggesting a saturation point had been reached.  
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Similar high levels of OVA adsorption to DDA:TDB liposomes, made in Tris buffer, were 
also detected using radiolabelled OVA validating the above BCA method. In this case the 
concentration of OVA added to liposomes was less as the formulations were intended for 
in vivo immunisation studies conducted at University Hospital of Zurich. The final OVA 
concentration was 100 μg/ml liposomes and of this, 88.8 ± 0.33 % of OVA was found 
adsorbed to the liposomes (Figure 3.8). Measurement of OVA association after 18 hrs at 
37 °C showed high retention with 74.79 ± 1.39 % of OVA still adsorbed to DDA:TDB 
liposomes (results not shown). In a further immunisation study conducted here at Aston 
University, the effect of OVA (final concentration 50 μg/ml) on DDA:TDB liposome made in 
Tris buffer was investigated by measuring the vesicle size and zeta potential of liposomes. 
Upon addition of OVA to a final concentration of 50 μg/ml, no significant changes in 
vesicle size or zeta potential are noted, presumably due to the low protein concentrations 
employed (Figure 3.8, A, B).  
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Figure 3.8 The effect of addition of OVA or BSA to DDA:TDB liposomes made with Tris 
buffer. Proteins were added to liposomes at a final concentration of 0.05, 0.1, 1, 5 or 10 
mg protein/ml liposomes. Vesicle size (A) and zeta potential (B) were measured using a 
Brookhaven ZetaPlus machine. Protein adsorption was determined using the BCA assay ( 
or radiolabelling, #) and is expressed as a % of protein added. Where shown, significance 
between data is against results of 0 mg/ml protein and was calculated using 2-way ANOVA 
from the mean values of 4 separate studies (n.s, not significant; *, p<0.05; **, p<0.01, ***, 
p<0.001). N/D, not determined. 
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Due to the wide OVA concentration range that can be produced, OVA is an ideal protein to 
study protein-induced changes on liposomal systems. However, OVA is not a disease 
model antigen and whilst it is commonly used in immunisation studies, vaccination with 
OVA as an antigen does not protect against disease. We therefore moved towards the use 
of the subunit protein Ag85B-ESAT-6, also known as H1, developed as an antigen for 
immunisation against tuberculosis (Olsen et al., 2001). Ag85B-ESAT-6 is approximately 44 
kDa and has a pI of 4.9 units making it similar in size and pI to OVA. The pI of Ag85B-ESAT-
6 favours its association via electrostatic interactions with cationic charged particles such 
as DDA:TDB liposomes. For in vivo studies, each liposome dose (250 μg lipid) contained 2 
μg Ag85B-ESAT-6. This is equivalent to an antigen concentration of 10 μg/ml for liposomes 
made to the usual 1.25 mg lipid/ml concentration. Ag85B-ESAT-6 was supplied from 
Statens Serum Institute at a concentration of 0.8 mg/ml and therefore was generally used 
at low concentrations (bearing in mind the relevant dilution factors upon addition to 
liposomes). Hence, due to the concentration constraints of Ag85B-ESAT-6, much of the 
initial characterisation work described previously was conducted with OVA with which 
higher concentrations could be obtained.  
Figure 3.9 shows the effect of adding Ag85B-ESAT-6 (final concentration 10 μg/ml) to both 
DDA and DDA:TDB liposomes. No significant changes in size were observed upon addition 
of the TDB glycolipid or the Ag85B-ESAT-6 antigen due to the low concentrations of both 
components used. TDB was incorporated into DDA liposomes to a final concentration of 
11 mol %, based on previous results documenting improved physicochemical and 
immunological results compared to lower (6 mol %) or higher (20 mol %) TDB 
concentrations (Davidsen et al., 2005).  
 As mentioned previously, the use of Ag85B-ESAT-6 as opposed to OVA was due to the 
requirement of an antigenic protein for immunisation studies. It was therefore of interest 
to observe the effect of exposure of the liposomal system to an in vivo environment. 
Liposomes adsorbing Ag85B-ESAT-6 were consequently exposed to a 50 % v/v solution of 
foetal calf serum (FCS) with Tris buffer at 37 °C. As seen in Figure 3.9 immediate liposome 
aggregation is observed and the surface charge of liposomes decreases to approximately - 
17 mV due to the adsorption of anionic serum proteins, also noted with other cationic 
liposomal systems (Oku et al., 1996; Zelphati et al., 1998). Continued exposure to FCS for a 
period of 96 hrs did not change the observed aggregation or decrease in zeta potential: by 
96 hrs vesicle sizes of ~ 2 μm and a zeta potential of -22 mV were observed for both DDA 
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and DDA:TDB liposomes (results not shown). Ag85B-ESAT-6 adsorbed to DDA and 
DDA:TDB liposomes to a very high degree and was well retained in conditions simulating 
the in vivo environment (Figure 3.10). Over the 96 hr measurement period no more than 
13 % of the original amount of Ag85B-ESAT-6 added to the liposomes was found to be 
released from the liposomes; constraints with sterility of the FCS by this time meant that 
the experiment could not be continued. However these results show the strong adsorption 
abilities of DDA based liposomes and when added at concentrations of < ~ 50 μg/ml, no 
protein induced physicochemical changes to the DDA-based liposomes are observed.  
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Figure 3.9 The effect on the vesicle size (bars) and zeta potential (points) of DDA or 
DDA:TDB liposomes after addition of Ag85B-ESAT-6 (H1) and subsequent placement in 50 
% FCS at 37 °C for 1 hr. Results denote mean ± SD of three separate experiments in which 
the pellet obtained after 2 washes was measured. 
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Figure 3.10 Ag85B-ESAT-6 antigen retention profile to DDA and DDA:TDB liposomes when 
stored at 37 °C in 50 % FCS. Results denote mean ± SD of three separate experiments.  
 
3.4.3 Membrane stability of DDA-based liposomes 
DDA liposomes are unstable structures but the addition of the immunomodulatory 
molecule TDB is able to stabilise the vesicles and inhibit aggregation (Davidsen et al., 
2005). Although liposome bilayers can be considered as a fluid system with movement 
between lipid monomers, loss of lipid components into the surrounding aqueous media 
does not occur because of the hydrophobic nature of the hydrocarbon chains and the 
critical micellar concentration (CMC) of the lipid. A simple method to test membrane 
stability is the incorporation of a trace amount of radiolabelled lipid whose presence 
either in the liposome or ‘leaked’ into surrounding media can be measured. To conduct 
this study, 3H-labelled DPPC was employed – 3H-DPPC was also used to detect liposome 
presence in vivo in biodistribution studies (this will be discussed in section 3.4.6). As only 
tracer amounts were used, no physicochemical changes in the system were noted (Table 
3.4). Dialysis was used to study the retention of 3H-DPPC in the liposome membrane; 
aliquots of dialysis media were removed at various time-points and the amount of 3H 
present measured. Figure 3.11 shows the time scale of 3H-DPPC release from the DDA:TDB 
liposomal membrane. Over the 96 hour period ~ 7 % of the original 3H-DPPC dose was 
recovered supporting the hypothesis that lipid membranes remain intact under in vivo 
conditions.  
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Table 3.4 Physicochemical characteristics of DDA:TDB liposomes with DPPC lipid 
 DDA:TDB liposome (1.25:0.25 
mg/ml) 
DDA:TDB liposome (1.25:0.25 
mg/ml), incorporating  0.17 nM 
DPPC 
Vesicle Size (nm) 578 ± 61  589 ± 72  
Polydispersity  0.256 0.301 
Zeta Potential (mV)  54 ± 13  48 ± 9 
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Figure 3.11 Membrane integrity of DDA:TDB liposomes was studied using a trace amount 
of 3H-DPPC. Results express the % of the original 3H-DPPC dose added to liposomes that is 
detected in the dialysis buffer over a 96 hr time period. The samples were stored at 37 °C 
in 50 % FCS. Results denote mean ± SD of three separate experiments. 
 
3.4.4 Attempts to improve salt-induced aggregation with the 
stabilising component cholesterol  
A further commonly used method to stabilise liposomes is the addition of cholesterol. 
Cholesterol is a natural component of mammalian cell membranes and provides rigidity 
due its large structure acting as a space filling component. Cholesterol was included in 
DDA:TDB liposomes at a molar ratio of 8:4:1 DDA:CHOL:TDB and both Tris and PBS buffers 
were used for the formation of the liposomes so that the stabilising effects of cholesterol 
could be investigated in the otherwise highly unstable PBS buffer formed liposomes 
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(Figure 3.6, C). As seen in Figure 3.12, the addition of cholesterol to DDA:TDB liposomes 
was not able to stabilise PBS buffer formed liposomes as phase-separation is noted 
regardless of the temperature at which liposomes are stored. Cholesterol containing Tris-
buffer formed liposomes were slightly larger than their non-cholesterol containing 
counterparts, however, their zeta potential did not differ significantly (Table 3.5). The 
stability of these cholesterol-containing formulations over time at 4 °C and at room 
temperature was investigated and whilst Tris buffer formed liposomes showed stability 
over the 56 day period, the size of PBS buffer formed liposomes varied significantly (Figure 
3.13, bars). Whilst cholesterol has been shown to improve bilayer stability by limiting 
plasma protein association (Gregoriadis and Davis, 1979; Semple et al., 1996), it does not 
appear to be able to improve bilayer stability of liposomes which show aggregation in 
buffers with a high salt content such as PBS.  
4°C 25°C
DDA:CHOL:TDB
TRIS
PBS
Day 0 Day 0Day 56 Day 56
 
Figure 3.12 PBS buffer induced DDA:TDB liposome instability ensues regardless of whether 
cholesterol is or is not included in the formulation.  
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Table 3.5 Physicochemical characteristics of DDA and DDA:TDB liposomes.  
 Vesicle Size 
(nm) 
Zeta Potential 
(mV) 
Ag85B-ESAT-6 
adsorption (%) 
DDA:TDB – Tris buffer 586 ± 78 33 ± 5 97.5 ± 0.8 
DDA:CHOL:TDB - Tris buffer  737 ± 53 42 ± 3 97.2 ± 0.2 
DDA:TDB – PBS buffer 2916 ± 446 55 ± 9 n.d 
DDA:CHOL:TDB – PBS buffer 2573 ± 632 56 ± 10 n.d 
n.d; not determined 
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Figure 3.13 DDA:CHOL:TDB liposome vesicle size (bars) and zeta potential (points) was 
measured over a 56 day period to investigate the stability of the formulations. 
DDA:CHOL:TDB liposomes were produced using Tris (A) and PBS (B) buffers, both 10 mM. 
Results represent mean ± SD of three individual samples stored at 4 °C (▲) or room 
temperature (∆) as depicted. 
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3.4.5 In vitro toxicity testing of DDA-based liposomes 
Cationic liposomes are well known for their toxicity in comparison to neutral or anionic 
liposomes (Filion and Phillips, 1997). This is partly due to affinity to cell surfaces 
encouraging liposomal uptake and lysis upon excessive endocytosis. A simple method to 
test their toxicity is to apply various concentrations of liposomes to cell monolayers and 
then measure the cell viability after a certain period of time. The monocyte/macrophage 
cell line RAW264 was used to study the lipid-mediated toxic effects of liposomes. Initially 
the MTS assay was used, however, large variance was noted and therefore the neutral red 
(NR) assay was used instead in conjunction with the LDH assay. The NR and LDH assays 
complement each other because the NR assay measures internalised NR dye in viable cells 
whilst the LDH assay measures leaked LDH enzyme that is present in the extracellular 
media due to lipid-associated cell membrane damage. The lipid-mediated toxic effects of 
DDA based liposomes were measured over a range of lipid concentrations applied for a 
period of 24 hrs. As shown in Figure 3.14, the highest lipid concentration that did not 
result in a significant decrease in cell numbers was 5 μg/ml which is in agreement with 
findings by Korsholm et al. in which lipid mediated toxicity on murine bone-marrow 
dendritic cells was evaluated (Korsholm et al., 2006). At the highest concentration (50 
μg/ml) DDA:TDB liposomes were significantly (p<0.001) more toxic than DDA:CHOL:TDB 
liposomes (Fig. 3.14 A,B).  
The results obtained from the NR and LDH assays are in strong agreement with each other 
and show that between the lipid concentrations 0.005–5 μg/ml the liposomes do not 
mediate toxic effects characterised by decreases in cell viability. Of note is that the LDH 
specific lysis results were calculated from the positive control in which cells were lysed 
with Triton® X-100. This is the recommended lysing solution by Promega and therefore 
this assumes that Triton® X-100 does indeed fully lyse cells. Whilst the toxicity of cationic 
liposomes has been attributed to factors such as reversal of the cell surface charge 
(Campanhã et al., 1999; Carmona-Ribeiro et al., 2006), the toxicity noted here is most 
probably due to excessive phagocytosis by the RAW264 cells initiated by electrostatic 
interactions between the anionic cell surface and the cationic liposomes (Filion and 
Phillips, 1997). Filion et al. also noted increased toxicity upon incorporation of fuseogenic 
lipids and decreased toxicity when liposomes were applied to cells with decreased 
phagocytic abilities (Filion and Phillips, 1997).   
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Figure 3.14 Cell viability measured using the neutral red (A) and LDH (B) assays to 
determine the highest lipid concentration that could be applied to RAW264 cells without 
significant loss of cell numbers. Results indicate the mean ± SD of three separate 
experiments in which four wells of a 96-well microplate were assayed per condition. A; cell 
viability was calculated as a % of cells without any liposomes therefore considered 100 % 
viable. B; Specific cell lysis is calculated as a % of maximum cell lysis as obtained by Triton® 
X-100. Lipid concentrations refer to the final DDA concentration/ml. Two way ANOVA was 
used to determine significance levels (**, p<0.01; ***, p< 0.001).  
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The MTS assay was originally used to measure cell viability and whilst it did give the same 
mean cell viability as the NR assay (MTS, 74.8 ± 24.8 %; NR, 72.7 ± 14.7 %), the well to well 
and inter-experiment variance was significantly greater. There are two principle reasons 
why a larger variance was seen upon implementation of the MTS assay as opposed to the 
NR assay. Firstly the MTS reagent was viscous and therefore small differences in the 
volume of MTS reagent applied per well may have lead to inaccuracies. Secondly the MTS 
assay relies on active mitochondrial metabolism for the successful reduction of the MTS 
reagent to a coloured product. In comparison the NR assay relies on lysosome activity (as 
the NR dye must be uptaken and blocked in lysosomes) and intact cell membranes. 
Therefore it would be expected that the MTS assay could be more prone to variation due 
to factors such as cell passage, the stage of their cell cycle and their ‘healthiness’. Taken 
together, for the purposes of determining liposome-mediated toxicity in future 
experiments, the NR assay was implemented and not the MTS assay. Furthermore, the NR 
assay was chosen preferentially over the LDH assay because of its ease of use and 
inexpensiveness compared to the LDH assay.  
 
3.4.6 Biodistribution studies: the liposomal depot-effect  
DDA-based liposomes have previously been described as causing a depot-effect at the site 
of injection (SOI). However, no studies have quantified the retention of either the 
liposomal or antigenic component. Using a dual-radiolabelling technique, the 
biodistribution of liposomes and antigen were studied in mice. Tissues, including the 
spleen, liver, lung and importantly the lymph nodes which drain tissue antigen from the 
SOI, were removed and tested for the relative proportions of DDA-based liposomes and 
simultaneously injected Ag85B-ESAT-6 antigen (Figure 3.15). Regardless of the time-point 
post injection (p.i), the proportion of liposome detected in the various tissues was higher 
than the proportion of antigen detected (Fig. 3.15 A vs B). Also of note is the trend of 
increasing liposome presence in most tissues over the 14 day period whilst antigen 
presence generally decreases over time. In general, the level of DDA:TDB liposomes or 
Ag85B-ESAT-6 was low (< 0.5 % of the injected liposome dose) for all tissues except the 
site of injection (SOI) and therefore only the muscle from the SOI and the local draining 
lymph nodes were investigated further. 
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Figure 3.15 Detection of DDA:TDB liposomes (A) and adsorbed Ag85B-ESAT-6 antigen (B) 
in various tissues. Muscle from the site of injection has been omitted for clarity as the 
proportion of antigen and liposome dose are much higher. Instead, muscle from the non-
injected leg is shown. Results represent mean ± SD of three mice. PLN, popliteal lymph 
node; BLN, brachial lymph node; p.i, post injection.  
 
The role of the immunomodulator TDB and the stabilising component cholesterol in 
eliciting a liposome or antigen depot-effect was investigated. DDA, DDA:TDB, and 
DDA:CHOL:TDB liposomes adsorbing Ag85B-ESAT-6 were administered to Balb/c mice via 
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the i.m route of injection, and tissues removed on days 1, 4 and 14 p.i to analyse the 
proportion of liposome and antigen present. Using radiolabelled antigen, the level of 
Ag85B-ESAT-6 adsorption to DDA:CHOL:TDB liposomes was investigated and was shown to 
be as high (97.2 ± 0.2 %) as that seen for DDA and DDA:TDB liposomes with less than 10 % 
loss over 96 hrs when stored in 50 % FCS at 37 °C (results not shown). Figure 3.16 shows 
the presence of liposome (A) and Ag85B-ESAT-6 antigen (B) at the SOI after i.m injection of 
antigen adsorbing formulations. DDA, DDA:TDB and DDA:CHOL:TDB liposomes were all 
highly retained at the SOI with between 40 - 50 % of the original dose being recovered 2 
weeks p.i (Figure 3.16, A). All three formulations showed a trend of decreasing liposome 
presence at the SOI with time although a significant decrease compared to day 1 p.i was 
only noted for DDA liposomes by day 14 p.i (p<0.01). This may be due to the stabilising 
effects of TDB and/or cholesterol which are known to improve liposome bilayer stability 
(Davidsen et al., 2005; Gregoriadis and Davis, 1979).  
Ag85B-ESAT-6 injected without a liposomal carrier was cleared quickly with < 6 % of the 
injected dose detected on day 1 p.i and less than 0.5 % by day 14 p.i. In contrast, the 
retention of Ag85B-ESAT-6 at the SOI when injected with a liposomal carrier was very high 
on day 1 p.i with between 75 - 77 % of the original dose being retained at the SOI (Figure 
3.16, B). Similar levels of Ag85B-ESAT-6 were detected on 4 p.i regardless of whether 
antigen was injected with DDA, DDA:TDB or DDA:CHOL:TDB liposomes. However, by day 
14 p.i a significant decrease in Ag85B-ESAT-6 at the SOI was only noted after delivery with 
DDA liposomes. This suggests an important role for simultaneous liposome retention at 
the SOI for an increased antigen depot-effect (Figure 3.16, A and B). Importantly, antigen 
could still be detected at the SOI 2 weeks p.i with between 1 - 7 % of the original dose 
being recovered, regardless of the liposome used for delivery. The importance of the 
antigen depot-effect remains unclear, however it is accepted that antigen retained at sites 
with increased exposure to immune cells will lead to increased uptake and subsequent 
presentation on APCs (Obst et al., 2007).  
With regards to movement of vaccine components to the local draining popliteal lymph 
node (PLN), DDA:TDB presence was significantly higher (p<0.01) at day 4 p.i and by day 14 
p.i liposome presence was approximately 5-fold higher than on day 1 p.i (p<0.001) (Figure 
3.17). Furthermore, the addition of the immunomodulatory molecule TDB resulted in an 
increased draining of DDA-based liposomes to the PLN (p<0.05 by day 14 p.i). The 
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presence of Ag85B-ESAT-6 in the PLN was low at all time-points and difficult to detect 
accurately (Figure 3.15, B). 
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Figure 3.16 Presence of liposome (A) and antigen (B) at the site of injection following 
intramuscular injection of Ag85B-ESAT-6 antigen adsorbing to DDA-based liposomes. 
Tissue was collected on days 1, 4 and 14 p.i and assayed for the presence of 3H and 125I 
relating to liposome and antigen respectively. Results represent mean ± SD of three mice. 
Significance is against results from day 14 of the same formulation and was determined 
using 2-way ANOVA (*, p<0.05).  
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Figure 3.17 Liposome recovery from the draining popliteal lymph node (PLN) shown as a % 
of the original dose divided by the mass (mg) of PLN. Results show mean ± SD of three 
mice. Significant differences were measured using 2-way ANOVA (*, p<0.05; **, p<0.01; 
***, p<0.001) and unless bracketed, significance is against day 14 p.i of the same 
formulation.  
 
I.m injection leads to a strong retention of antigen and especially liposomes in the muscle 
(Figure 3.16). The quadriceps muscle is the largest muscle that can be injected into and 
whilst the injection volume (50 μl) is kept as low as is possible (with respect to liposome 
formulation), it is possible and likely that the muscle cannot retain such a volume. 
Furthermore the tissue physiology of muscle does not allow for massive dispersion of 
injected materials when compared to intravenous or intraperitoneal injection for example. 
Another commonly used route of injection is the subcutaneous (s.c) route due to the ease 
of administering substances with a larger volume. For this reason the s.c. route was also 
studied to see whether an antigen depot-effect could also be initiated upon injection with 
DDA:TDB liposomes. Figure 3.18 outlines the pharmacokinetics of DDA:TDB and associated 
Ag85B-ESAT-6 at the SOI (A) and in the brachial lymph node (BLN; B) which is the local 
draining lymph node to the injection site. Unfortunately the entire dose was not collected 
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from the SOI on day 1 p.i and therefore no data is presented. However by day 4 and 14 p.i 
the entire tissue was successfully collected and the liposome presence shows a similar 
trend to DDA:TDB liposomes following i.m injection. Also presented is the movement of 
freely administered Ag85B-ESAT-6 antigen, without the use of a liposome carrier. 
Compared to Ag85B-ESAT-6 administration with DDA:TDB liposomes, freely administered 
antigen drains rapidly and the proportion of antigen remaining in the subcutaneous tissue 
is minute (Fig. 3.18, A). In agreement with i.m injection, liposome presence in the local 
draining lymph nodes increases steadily over time and shows the same increase in the 
levels of significance over the 14 day period (Fig. 3.18, B).  
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Figure 3.18 A; Presence of freely administered Ag85B-ESAT-6 antigen and Ag85B-ESAT-6 
adsorbing to DDA:TDB liposomes at the site of injection after subcutaneous injection into 
the flank. B; DDA:TDB liposome presence in the local draining brachial lymph nodes – 
Ag85B-ESAT-6 antigen presence is not shown due to the low values obtained. Results 
represent mean ± SD of three mice. Significant differences were measured using 2way 
ANOVA (**, p<0.01; ***, p<0.001). N/C; not collected due to difficulties isolating the 
entire injected dose from the subcutaneous tissue. H1, Ag85B-ESAT-6. Experiment 
conducted in collaboration with Vincent W Bramwell. 
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3.4.7 Pontamine blue dye and its use as a leukocyte marker 
Pontamine blue is an azo dye that has been described as being uptaken by macrophages in 
vivo therefore allowing for the identification of lymphoid tissue such as lymph nodes 
(Tilney, 1971). Although pontamine blue was primarily employed as a lymph node 
identification marker, it also served as a marker for identification of infiltrating 
macrophages to the SOI. Studies in vitro using the monocyte/macrophage cell line J774 
confirmed the ability of the cells to take up the dye (Figure 3.19). Furthermore, pooled 
blood from mice injected with pontamine blue (0.5 % w/v) 3 - 5 days prior to vaccine 
injection also showed the presence of pontamine blue within cells (Figure 3.20). Cytospins 
of red-blood cell lysed blood were mounted with a hard-mount containing DAPI to stain 
nuclei. Although the specific cells taking up pontamine blue were not identified, based on 
the nuclei morphology there appears to be pontamine blue uptake by neutrophils (open 
arrows) and monocyte-like cells (closed arrows) (Figure 3.20, B).  
Figure 3.21 shows the pontamine blue staining seen at the SOI 14 days after i.m injection. 
The intensity of blue staining was strongest for TDB containing DDA liposomes and 
weakest after injection of Ag85B-ESAT-6 antigen alone. Interesting the blue staining was 
more intense for DDA liposomes containing TDB as opposed to solely DDA, although the 
proportion of liposomes found at the SOI were not significantly different for either 
formulation (Fig. 3.16, A). Inclusion of cholesterol in the DDA:TDB liposomes did not have 
any effect on the intensity of pontamine blue staining noted at the injection site (Figure 
3.22). Importantly, DDA liposomes incorporating cholesterol also contained the strong 
immunomodulator TDB which is proposed to play a more significant role on macrophage 
influx. Therefore the similar blue staining seen between DDA:TDB and DDA:CHOL:TDB 
formulations was to be expected.  
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Figure 3.19 Pontamine blue (0.05 %) added to J774 cells is uptaken and can be viewed 
under FITC, DAPI or Rhodamine filters.  
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Figure 3.20 Cytospins of pooled blood from mice subcutaneously injected with pontamine 
blue ~ 4 days prior to collection. Red blood cells were lysed using OptiLyse and cell 
suspensions mounted on glass slides with DAPI-containing hard mount solution. Images 
were taken using rhodamine (A) and DAPI (B) filters and phase contrast (A-C). Composite 
images using phase contrast with rhodamine (A), DAPI (B) or rhodamine and DAPI together 
(C) were produced. Open arrows show neutrophil-like cells whilst closed arrows show cells 
with less granular nuclei such as seen in monocytes.  
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Figure 3.21 Pontamine blue staining at the site of injection 14 days after i.m injection site 
with free Ag85B-ESAT-6 (A), DDA liposomes adsorbing Ag85B-ESAT-6 (B) or DDA:TDB 
liposomes adsorbing Ag85B-ESAT-6 (C). 
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Figure 3.22 Cholesterol inclusion in DDA:TDB liposomes has no effect of the intensity of 
blue staining seen at the site of injection. Pictures are representative of 4 mice/group and 
show the quadriceps muscle from the vaccine injected leg.  
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3.4.8 Immunisation studies using OVA as a model antigen 
DDA:TDB liposomes have been shown to elicit strong cell-mediated immunity 
characterised by high levels of IFN-γ, Il-2 and IgG2a production. Due to their successful 
track-record, DDA:TDB liposomes were chosen as the ideal formulation to investigate 
inter-researcher variability and the effect of various routes of administration on the 
observed immune responses. OVA antigen was used as a model antigen for both studies as 
it is well characterised and allows for a direct comparison between the two studies. 
Regarding the experiment to investigate inter-researcher variability based at Aston 
University, all three researchers had experience formulating DDA:TDB liposomes and 
whilst only a limited number of mice were allocated per researcher (1 or 2 per 
experimental group, see Chapter 2, Table 2.4), the aim was that final results could be 
collated to provide statistically relevant data. The second study involved the collaboration 
with Pål Johansen, University Hospital of Zurich, looked at the effect of the administration 
route in addition to addressing whether omission of the immunomodulator TDB from DDA 
liposomes affected immunogenicity.  
 
The results derived from the immunisation study conducted at Aston University to 
investigate inter-person variability were very mixed. Whilst a successful antibody response 
with little inter-person variation was observed, the results relating to re-stimulated 
splenocyte proliferation and their cytokine production were disappointing. Figure 3.23 
shows total IgG (A) and IgG1 (B) antibody production in response to immunisation with 
OVA alone, adsorbed to DDA:TDB liposomes or mixed with Incomplete Freund’s Adjuvant 
(ICF). All mice injected with DDA:TDB:OVA liposomes mounted a strong IgG response 
which peaked 35 days after the initial immunisation. By contrast, ICF:OVA injected mice 
required longer for all mice to mount a similarly strong IgG response. Injection of OVA 
alone did also cause increases in the IgG titre however these were lower at each time-
point compared to adjuvanted formulations. With regards to the IgG1 response, 
immunisation of OVA with DDA:TDB liposomes, but not with ICF or alone, induced above 
background levels of IgG1 in all 6 mice after just one immunisation (Figure 3.23, B). By 
contrast, OVA immunisation with ICF required one booster injection whilst OVA 
administered alone required two booster injections. Neither group however reached 
similar levels of IgG1 production as seen after immunisation with DDA:TDB liposomes. 
Naïve mice did not mount any IgG response. In addition to testing mouse sera for IgG1, the 
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IgG2a response was measured but no IgG2 production was noted (results not shown). 
Increasing the concentration of IgG2 antibody and decreasing the serum dilutions had no 
effect. These results were unexpected as DDA:TDB liposomes have previously been shown 
to elicit IgG2 antibody production when given both in conjunction with the TB antigen 
Ag85B-ESAT-6 (Davidsen et al., 2005; Kirby et al., 2008a; Kirby et al., 2008b) and with OVA 
(Agger et al., 2008b) (although OVA leads to IgG2a responses ~ 10-fold lower than Ag85B-
ESAT-6). This disparity between the documented production of IgG2 antibodies in mice 
immunised with DDA:TDB liposomes compared to the nonexistent IgG2 responses noted 
here could have been due to a number of factors including the antigen dose, the use of 
OVA antigen as opposed to the strongly antigenic Ag85B-ESAT-6 antigen and the choice of 
mouse strain (Balb/c versus the more traditionally used C57Bl/6). These variables were 
addressed in a subsequent immunisation study in which C57Bl/6 mice were immunised 
with Ag85B-ESAT-6 antigen (Chapter 6).  
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Figure 3.23 Antibody responses to immunisation with OVA alone, with DDA:TDB liposomes 
or with ICF. Total IgG (A) and IgG1 (B) are shown as the log10 of reciprocal endpoint 3-fold 
dilutions (starting at 1:400) required to reach an OD of 0.2 derived from the mean ± SD of 
6 mice (DDA:TDB:OVA and OVA groups) or 3 mice (ICF:OVA and naïve groups). Each mouse 
(Balb/c) received 3 injections on days 1, 14 and 28 (shown with arrows).  
 
DDA and DDA:TDB liposomes were also sent to Pål Johansen, University Hospital of Zurich, 
where the effect of the route of injection was investigated, in addition to a comparison 
between different vesicular systems as adjuvants for OVA immunisation. OVA (20 μg/dose) 
and Balb/c mice were again used thereby providing a comparative study to the OVA-
immunisation study conducted at Aston University. Figure 3.24 shows the IgG1 and IgG2a 
responses to DDA and DDA:TDB liposomes. In accordance with the results obtained at 
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Aston University, DDA-based liposomes did not need a booster injection to elicit IgG1 
responses, regardless of the route of injection used or whether TDB was included in the 
formulation (Figure 3.24 A, B). Initially there were significantly higher levels of IgG1 after 
administration of DDA or DDA:TDB liposomes via the i.ln route as opposed to the i.d, i.m 
or s.c routes. These differences diminished however upon administration of a booster 
injection on day 39, after which IgG1 titres were greatly improved and reached peak titres 
of above 200,000 regardless of the immunisation route.  
 
Figure 3.24 The effect of route of administration on the antibody response against DDA (A, 
C) and DDA:TDB (B, D) liposomes adsorbing OVA. Liposomes were injected into Balb/c 
mice on days 0 and 39 (depicted by arrows) via the intralymphatic (i.ln), intradermal (i.d), 
intramuscular (i.m) or subcutaneous (s.c) routes of administration. Serum was collected at 
relevant time-points and analysed for the presence of IgG1 (A, B) and IgG2a (C, D) 
antibodies. Antibody titres are expressed as the inverse of the highest dilution reaching an 
absorbance equal or higher than that of a negative serum plus two standard deviations, 
and the titres were expressed as means ± SD (n = 4). Previously published (Mohanan et al., 
2010). 
 
IgG2a responses were noted but these were more dependent on the booster injection 
given on day 39. Whilst DDA liposomes did not induce any significant levels of IgG2a prior 
to the day 39 booster, regardless of the injection route, after this booster injection the 
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IgG2a titres detected after i.ln or i.d immunisation reached ~ 100,000. Only very small 
increases in the IgG2a titres were noted after i.m and s.c booster injections of DDA 
liposomes (Figure 3.24, C). Inclusion of TDB in the DDA liposome formulation gave a very 
different result with i.ln, i.d and i.m injection all reaching peak titres of ~ 10,000 – 100,000 
by the end of the study. Only DDA:TDB injection via the s.c route did not cause significant 
production of IgG2a.  
 
From these results it appears that both the i.ln and i.d routes of injection offer the fastest 
and strongest immune response characterised by both IgG1 and IgG2a production. 
Omission of TDB from DDA liposomes does not appear to have a major effect on the IgG1 
or IgG2a responses noted, with the exception of IgG2a levels after i.m injection. As to why 
DDA:TDB liposomes caused IgG2a production in this experiment whilst no IgG2a was seen 
in the experiment conducted at Aston University is unclear. In both experiments the 
vaccines were formulated by the same person using the same raw materials, with the only 
differences in the immunisation protocol being the antigen dose and the immunisation 
timescale (3 doses with 2-week intervals verses 2 doses with a 39-day interval). 
Furthermore, the concentration of OVA antigen used for IgG2a detection (via indirect 
ELISA) was 10-fold higher for the Aston University immunisation experiment, suggesting 
that the problem was not related to the IgG2a detection protocol. To test this, the sera 
from DDA:TDB:OVA immunised mice was tested using antibody isotype testing strips 
(AbDSerotec, Oxford, UK) which offer a fast and reliable method to detect antibodies 
(IgG1, IgG2a, IgG2b, IgG3, IgM and IgA) in mouse serum. The results show that little if any 
IgG2a was present in the sera of DDA:TDB:OVA immunised (and naïve) mice (Figure 3.25) 
and therefore confirms the previous suggestion that the lack of detection of IgG2a by 
ELISA was actually due to no IgG2a production by the mice. 
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Figure 3.25 Isotyping test strips in which sera from DDA:TDB:OVA immunised mice at a 
1/10,000 and 1/500 dilution was tested for the presence of IgG2a. Sera from unimmunised 
mice (1/500 dilution) is also shown for comparison. A blue line shows the presence of the 
corresponding antibody whilst a blue line next to the ‘ + + ‘ marker confirms the strip 
efficacy. Whilst IgG1 antibody is present in all samples shown, only low levels of IgG2a can 
be detected.  
 
In addition to assessing the antibody responses, spleens from mice were restimulated in 
vitro with OVA to investigate splenocyte proliferation and cytokine responses.  The results 
obtained from the Aston immunisation study were highly dependent on the researcher 
conducting the splenocyte preparation. Figure 3.26 shows the proliferative responses of 
splenocytes from mice injected with OVA alone, OVA combined with ICF or DDA:TDB 
liposomes and finally naïve PBS injected mice. All splenocyte cultures were restimulated 
with ConA as a positive control, however, as is seen in Figure 3.26, A, not all splenocyte 
cultures responded to the positive control. Looking specifically at splenocytes processed 
by MH (Figure 3.26, B), all immunised mice responded well to ConA and showed an OVA 
concentration dependent increase in proliferation. DDA:TDB:OVA immunised mice showed 
the highest levels of proliferation of splenocytes with thymidine uptake being between 10 
- 100 fold higher that that noted of OVA injected alone or with ICF. These results show that 
OVA immunisation with DDA:TDB liposomes leads to higher levels of splenocyte 
proliferation than seen with OVA alone or with the commonly used ICF adjuvant. It is 
important to note however that these results are only indicative of 1 or 2 mice as the 
results obtained from RK and JH processed mice did not respond well to ConA (Figure 3.26, 
A) or to OVA (results not shown). This inter-researcher variation was however only noted 
with assays relating to splenocytes – no variation in IgG antibody presence in the sera was 
noted (Figure 3.27). 
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Figure 3.26 Splenocyte proliferation, as measured by tritiated thymidine uptake, in 
response to OVA antigen restimulation or exposure to ConA. A; Splenocytes derived from 
mice immunised with DDA:TDB:OVA liposomes, OVA alone, ICF:OVA or PBS were exposed 
to the positive control stimulant ConA (1 μg/ml) and the level of proliferation measured 
using tritiated thymidine uptake expressed in counts per minute (CPM). Splenocytes from 
6 (DDA:TBD:OVA and OVA) or 3 mice (ICF:OVA and naïve) were investigated in triplicate – 
results show thymidine uptake of  individual wells with the results of each researcher (RK, 
JH or MH) represented. B;  Splenocytes derived from mice immunised with DDA:TDB:OVA 
liposomes, OVA alone, ICF:OVA or PBS (naïve) were exposed to the positive control 
stimulant ConA (1 μg/ml) or OVA at concentrations of 0.05, 0.5 or 5 μg/ml. Results are the 
mean ± SD of triplicate wells of mice injected and processed by MH only.  
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Figure 3.27 Total IgG OD readings for serially diluted serum from DDA:TDB:OVA injected 
mice (n=6). Blood was collected on days 12, 24, 35 and 48 (A, B, C and D respectively) post 
injection of DDA:TDB liposomes adsorbing OVA. Each investigator (■/□ RK, Randip Kaur; 
▲/∆ JH, Jubair Hussain; ●/○ MH, Malou Henriksen) made and injected the liposomes and 
collected serum from their respective mice (1-6). 
 
In addition to looking at splenocyte proliferation, the supernatants of restimulated 
splenocytes were collected and assayed for the presence of various cytokines (again, only 
MH processed splenocytes were investigated). The data obtained from [MH processed] 
splenocytes was rather unexpected as whilst ConA simulated splenocytes produced 
relatively high levels of all cytokines measured, cytokine production in response to OVA 
was low (Figure 3.28). All DDA:TDB:OVA and ICF:OVA immunised mice were capable of 
producing cytokines in response to ConA to levels of ≥ 300 pg/ml (Figure 3.28, A). OVA 
immunised mice were not highly responsive to ConA as less than ~ 300 pg/ml of all 
cytokines was detected. With regards to the responses of DDA:TDB:OVA immunised mice 
to OVA specifically, the results were unexpected; levels of IL-2 and IFN-γ were low/non-
existent with many non-responsive cultures even though both these cytokines, 
representative of Th1 immune responses, have previously been shown to be produced in 
high amounts after DDA:TDB immunisation (Kirby et al., 2008a; Vangala et al., 2007). With 
regards to IFN-γ in particular, the results are highly surprising as DDA:TDB liposomes have 
an established history of being capable of inducing high levels of IFN-γ in splenocyte and 
blood cultures (Agger et al., 2008b; Christensen et al., 2010a; Davidsen et al., 2005; 
Holten-Andersen et al., 2004; Kirby et al., 2008a; Linderstrøm et al., 2009; Vangala et al., 
2007). However, it is important to note that none of these immunisation studies used OVA 
as an antigen, instead preferring disease antigens such as Ag85B-ESAT-6 or hepatitis A 
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antigen. Importantly, IFN-γ production in TB vaccine studies can be directly correlated with 
vaccine efficacy (Agger and Andersen, 2001) and therefore it is an important cytokine to 
measure in such studies. Levels of IL-10 were also low however IL-5 and IL-6 production 
appeared to show an OVA restimulation concentration dependent effect with splenocytes 
derived from DDA:TDB:OVA immunised mice producing the highest levels of IL-5 (~ 150 
pg/ml for both). IL-5 is a typical Th2 cytokine and is expressed to variable levels in 
DDA:TDB vaccine studies. However, in the majority of cases the levels are low and 
occasionally not significantly higher that background naïve mice (Kirby et al., 2008a; 
Vangala et al., 2007). IL-6 is also thought of as a Th2 cytokine and has a role in directing 
CD4+ T cell differentiation into Th2 cells via upregulation of IL-4 production and 
suppression of IFN-γ signalling and production (Diehl and Rincón, 2002; Dienz and Rincon, 
2009; Rincón et al., 1997). In an interesting twist, although IL-6 shifts the Th1/Th2 balance 
towards the Th2 immune response, IL-6 has also been shown to promote differentiation of 
Th17 cells with production of IL-17 (Dienz and Rincon, 2009). This is especially interesting 
with regards to DDA:TDB vaccination as DDA:TDB liposomes have recently been shown to 
induce high amounts of IL-17 after vaccination with Ag85B-ESAT-6 (Henriksen-Lacey et al., 
2010c; Kamath et al., 2009). Therefore IL-6 may act in counterproductive ways in this 
current vaccination model.  
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Figure 3.28 Cytokine production from ConA (A) or OVA (B) restimulated splenocytes 
derived from [MH] immunised mice. A; Splenocytes derived from mice immunised with 
OVA alone, DDA:TDB:OVA or ICF:OVA were restimulated in vitro with ConA (1 μg/ml) as a 
positive control for cytokine production. Results are representative of the mean of 
duplicate wells of splenocytes derived from one mouse. B; Cytokine production from 
splenocytes derived from MH processed DDA:TDB:OVA immunised mice and restimulated 
in vitro with 0, 0.5 or 5 μg/ml OVA.  Results denote mean ± SD of duplicate wells of 2 mice.  
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Whilst IL-4 was not investigated in the study conducted at Aston University, IL-4 (and IFN-
γ) production from restimulated splenocytes derived from DDA and DDA:TDB injected 
mice were investigated with our collaborative partners at University Hospital of Zurich. IL-
4 production was low for all injection routes and did not vary significantly after the 
incorporation of TDB (Figure 3.29). Similar findings were found for IFN-γ secretion with the 
exception of the i.ln injection route with produced high levels (~ 400 pg/ml) of IFN-γ which 
increased ~ 1.5 fold upon incorporation of TDB into the liposomal vaccines (Figure 3.30). 
The successful production of IFN-γ after the i.ln injection route correlates with the strong 
lasting IgG1 and IgG2a response seen in the same study. However it should be noted that 
i.ln injection was originally included in this study as a positive control as direct application 
of antigen (OVA) and adjuvant to the lymphoid organ is obviously the easiest and most 
efficient way to expose APCs to antigen, as well as priming lymphocytes (Johansen et al., 
2010). Therefore, whilst it is not really possible to compare responses between i.ln 
injection and other routes, it is possible to compare how the addition of TDB to the 
liposomal formulation affects the immune response.   
 
 
Figure 3.29 IL-4 production from restimulated splenocytes obtained from mice injected 
with DDA:OVA liposomes (clear bars) or DDA:TDB:OVA liposomes (black bars). The effect 
of different injection routes was studied (i.ln, intralymphatic; i.d, intradermal; i.m, 
intramuscular; s.c, subcutaneous) after injection on day 1 and 39; splenocytes were 
harvested on day 100 and exposed to OVA (10 μg/ml) for 72 hrs prior to harvesting 
supernatants and detection of IL-4 by ELISA. Previously published (Mohanan et al., 2010). 
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Figure 3.30 The route of administration has an effect on IFN-γ production from 
restimulated splenocytes derived from mice immunised with DDA (A) or DDA:TDB (B) 
liposomes adsorbing OVA antigen. Mice were given one booster injection on day 39 and 
spleens removed on day 100 and restimulated with OVA (10 μg/ml). Culture supernatants 
were harvested after 72 hrs and analysed by ELISA for IFN-γ. Routes of administration 
included intralymphatic (i.ln), intradermal (i.d), intramuscular (i.m) and subcutaneous (s.c). 
Previously published (Mohanan et al., 2010). 
 
 3.5 Discussion and Conclusion 
These initial findings confirm many of the previously documented physicochemical 
characteristics of DDA-based liposomes. DDA liposomes, with or without the addition of 
the immunomodulator TDB (11 mol %) are between 400 - 500 nm in size and express a 
highly cationic surface charge of ~ 40 mV. Whilst addition of TDB can enhance DDA 
liposomes stability, cholesterol can also be incorporated into the lipophilic bilayer 
although this does not counteract the unstable nature of DDA:TDB liposomes hydrated 
with PBS buffer. The nature of PBS-induced instabilities is due to the high saline content – 
reducing the molarity of PBS buffer is able to reduce vesicle aggregation.  
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Proteins such as OVA, BSA and Ag85B-ESAT-6, all of which express a pI of below 7 units can 
be effectively adsorbed to the surface of DDA-based liposomes. Whilst low doses (~ 10 
μg/ml) of protein do not cause any significant physicochemical changes to DDA-based 
liposomes, increasing the protein dose has a significant effect resulting in aggregation of 
vesicles and a decrease in the zeta potential. The ability of DDA-based liposomes to adsorb 
Ag85B-ESAT-6 allows the resulting liposomal formulation to be used in vivo as an effective 
antigen delivery system. Upon administration via either the i.m or s.c routes of injection a 
strong retention of antigen at the injection site is noted and unlike injection of Ag85B-
ESAT-6 alone, antigen can still be strongly detected 14 days p.i.  
Liposomes composed of DDA with or without TDB can be used as adjuvants for 
immunisation of the model protein OVA. Whilst there is no doubt that IgG1 antibodies can 
be successfully induced after a single injection of DDA or DDA:TDB liposomes, the 
induction of IgG2 antibodies was more variable; in one study there was no production of 
IgG2 whilst in another its production required a booster injection. Furthermore, the 
characteristically Th1 cytokine IFN-γ, often linked to IgG2 production, was notably absent 
in both immunisation studies. Liposome administration via i.d, s.c or i.m routes of injection 
had no effect in the induction of IFN-γ.  
Whilst the results obtained from the physicochemical characterisation of DDA-based 
liposomes provide some interesting findings, especially with respect to PBS induced 
characteristics, the finding that DDA:TDB liposomes are unable to induce the Th1 arm of 
the immune response when used as an adjuvant for OVA are surprising. There are many 
documented studies of DDA-based liposomes inducing strong levels of IFN-γ, IL-2 and 
IgG2, all of which are described as being characteristic of the Th1 response. However, the 
combination of OVA antigen and the Balb/c mouse strain is rarely used in the DDA-based 
liposome immunisation model. It is possible that this mouse strain is unable to mount a 
strong Th1 immune response against OVA when adjuvanted with DDA-based liposomes. 
For this reason, and presented in Chapter 6, the more commonly used C57Bl/6 mouse 
strain in combination with Ag85B-ESAT-6 antigen was used to investigated the immunising 
abilities of DDA:TDB liposomes.  
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Chapter 4: The Importance of Protein Antigen 
Adsorption to Charged Liposomes with regards to the 
Efficiency of Liposomes as Vaccine Adjuvants 
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and Perrie Y. Liposomal cationic charge and antigen adsorption are important properties 
for the efficient deposition of antigen at the injection site and ability of the vaccine to 
induce a CMI response. 2010, Journal of Controlled Release 145, 102-108.  
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4.1 Aims 
The aim of the work reported in this chapter was to investigate the importance of 
liposome-antigen interactions, defined by electrostatic association, for the successful 
production of an adjuvant and antigen depot-effect at the site of injection. Cationic and 
neutral liposomes with various antigens were studied and their physicochemical 
characteristics noted. Biodistribution and immunogenicity studies of certain formulations 
were undertaken and collaborations involving dendritic cell activation studies were 
pursued.  
 
4.2 Introduction 
Cell bilayers express an overall anionic surface charge due to the presence of anionic lipids 
phosphatidylserine (PS) and phosphatidylinositol (PI), in combination with the zwitterionic 
lipids phosphatidylcholine (PC) and sphingomyelin (SM) (Ohvo-Rekilä et al., 2002). Upon in 
vivo administration of cationic liposomes, electrostatic attractions between the cell 
surface and liposomes can occur, unrelated to the presence of receptor-ligand 
interactions. Whilst this is one of the properties which makes cationic liposomes efficient 
transfection agents (Gao and Huang, 1991; Kawakami et al., 2004; Li et al., 2010; McNeil 
and Perrie, 2006; Ramezani et al., 2009; Simberg et al., 2004), there are also reports that 
anionic cell surface glycosaminoglycans can actually inhibit cationic liposome mediated 
gene uptake (Ruponen et al., 2004). Prior to the use of liposomes as transfection agents, 
liposomes were used primarily as drug delivery systems, however, problems with drug 
leakage, liposome instability and rapid clearance via the mononuclear phagocyte system 
(MPS) were significant problems (Gregoriadis, 1985, 1995b). Cholesterol incorporation, as 
well as the creation of ‘stealth’ liposomes by adding poly (ethylene glycol) (PEG) to the 
liposome surface, has been used to overcome these issues thereby minimising the binding 
of plasma proteins to the liposome surface (Gregoriadis, 1985; Gregoriadis and Davis, 
1979).  
 
Although plasma proteins make up less than 4.4 % of the total blood volume (the 
remaining being water, ~ 49.5 %, erythrocytes, ~ 45 % and (in)organic substances, ~ 1.1 %) 
(Sigma-Aldrich Co., 2010), they play a major role in charge-mediated liposome-
aggregation.  As noted in Chapter 3, the exposure of cationic liposomes to conditions 
which simulate the in vivo environment (i.e. ~ 50 % serum at 37 °C) results in rapid 
119 
 
aggregation of the cationic vesicles due to electrostatic interactions between serum 
proteins and positively charged liposomes (Chapter 3, Figure 3.9). Therefore it was 
questioned whether electrostatic interactions between cationic liposomes and cells or 
serum proteins mediate vesicle aggregation and may be the reason why such high levels of 
liposome deposition at the injection site, regardless of the injection route, are noted 
(Chapter 3, Figures 3.16 and 3.18). To investigate this, a comparison was made between 
cationic and neutral/anionic liposomes, the later being less likely to associate 
electrostatically with cells or with plasma proteins at the site of injection. The lipid 
distearolyphosphatidylcholine (DSPC) was used in place of DDA to form liposomes with 
TDB. DSPC has a zwitterionic phosphate head group and consequently forms 
neutral/slightly anionic liposomes. DDA:TDB and DSPC:TDB liposomes were investigated 
for their ability to associate with, and promote a depot-effect of, the TB antigen Ag85B-
ESAT-6. Furthermore the immune response towards Ag85B-ESAT-6 delivered with 
DDA:TDB or DSPC:TDB liposomes was analysed.  
 
Ag85B-ESAT-6 is itself immunogenic and has shown promising results in numerous in vivo 
studies when combined with a delivery system (Agger et al., 2008a; Agger et al., 2006; 
Andersen et al., 2009; Bhowruth et al., 2009; Davidsen et al., 2005; Kamath et al., 2009; 
Kamath et al., 2008a; Kamath et al., 2008b; Korsholm et al., 2010; Linderstrøm et al., 2009; 
Rosenkrands et al., 2005). Unlike the BCG vaccine which is considered the current TB 
vaccine gold standard, Ag85B-ESAT-6 comprises the ‘ESAT-6’ epitope which has been 
deleted in BCG due to years of sub-passage and attenuation (Agger and Andersen, 2002). 
Fusion of Ag85B (strong antigen) with ESAT-6 (weak antigen) to form Ag85B-ESAT-6 leads 
to a synergistic increase in immune responses and importantly, when combined with 
cationic liposomes, levels of protection equal to vaccination with BCG are conferred 
(Brandt et al., 2000; Olsen et al., 2001). Synergistic effects when BCG and Ag85B-ESAT-6 
are combined have also been observed (Dietrich et al., 2007).  
 
The importance of antigen association to liposomes was studied with emphasis on the 
liposome-mediated antigen depot-effect (described in Chapter 3). To achieve this, protein 
antigens of varying isoelectric points (pI) were selected based on the overall charge 
expressed when at neutral pH values. OVA and Ag85B-ESAT-6 both have pI values of ~ 4.5 
units and therefore at neutral pH they express an overall anionic surface charge. Both 
antigens are able to strongly associate with cationic liposomes due to the opposing electric 
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charge. In contrast, it was hypothesised that an antigen with a pI of >7.4, and therefore of 
cationic charge above neutral pH values, would not be able to associate electrostatically 
with cationic liposomes.  
 
To this aim, two proteins were tested: 
 lysozyme was investigated as a model antigen as it has a high pI (11  units). 
Lysozyme is a 16 kDa protein and whilst not commonly used in vaccine studies, 
lysozyme is a useful protein to study the effect of non-electrostatically adsorbed 
protein to DDA based cationic liposomes.  
 a 2-part subunit Chlamydia antigen termed CTH1 was also investigated as it is 
immunogenic and expresses an overall pI of 9 units. Itwas therefore postulated to 
not adsorb to cationic liposomes.  
 
A final component in the investigation between the effects of neutral DSPC:TDB and  
cationic DDA-based liposomes involved a collaboration with Trinity College Dublin (The 
University of Dublin, Ireland) to look at the ability of these formulations to cause IL-1α and 
IL-1β production in dendritic cells (DCs).  
 
4.3 Results and Discussion 
4.3.1 Physicochemical characteristics including characterisation of 
protein association 
Liposomes composed of DDA and TDB at a 5:1 weight ratio expressed similar 
physicochemical characteristics as described in Chapter 3. DSPC:TDB liposomes were made 
at 5:1 weight ratios and 8:1 molar ratios (therefore mimicking the DDA:TDB formulation) 
without any change in the physicochemical characteristics noted: DSPC:TDB liposomes had 
an average vesicle size 1488 nm and polydispersity of 0.381 (Table 4.1). DSPC:TDB 
liposomes were approximately 3-fold larger than their counterpart DDA:TDB liposomes 
(Table 4.1). This size variation was confirmed by TEM imaging and by inclusion of trace 
quantities of rhodamine labelled DPPC and fluorescence imaging (Figure 4.1). DSPC lipid 
has a zwitterionic head group and therefore liposomes produced of DSPC with TDB 
express a neutral/slightly anionic surface charge. Therefore, substitution of DDA with DSPC 
results in a decrease in surface charge from approximately +50 mV to -5 mV (Table 4.1).  
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Table 4.1 Physicochemical characteristics of DDA:TDB and DSPC:TDB liposomes 
 DDA:TDB Liposomes DSPC:TDB Liposomes 
Vesicle diameter (nm) 450 ± 63 1488 ± 239 
Polydispersity  0.282 ± 0.037 0.381 ± 0.024 
Zeta potential (mV) 46 ± 7 - 4.1 ± 9 
 
 
1μm1μm
A B C
 
Figure 4.1 TEM (A, B) and fluorescence (C) images of DSPC:TDB liposomes showing their 
supra-micron size and multilamellar nature.  
 
The effect of protein on the physicochemical characteristics of DDA:TDB and DSPC:TDB 
liposomes was investigated initially using the model protein OVA as high concentrations of 
protein could be added to the liposomes. OVA was dissolved in a Tris buffer (10 mM, pH 
7.4) and added to DSPC:TDB and DDA:TDB liposomes to a final OVA concentration of 1, 5 
or 10 mg/ml. Figure 4.2 shows the effect of OVA at these concentrations on the vesicle 
size and surface charge of the liposomes. Unlike the immediate and significant aggregation 
of DDA based vesicles upon protein addition, DSPC:TDB liposomes do not aggregate or 
change significantly in their physicochemical characteristics. OVA expresses an anionic 
charge under the pH neutral conditions used and therefore addition of OVA to the neutral 
DSPC:TDB liposome construct does not favour strong levels of electrostatic interaction and 
adsorption between the protein and liposomes (Figure 4.3). However, addition of 5 or 10 
mg/ml to DSPC:TDB liposomes did lead to some association (~ 13 % of that added, 
therefore equivalent to between 0.65 – 1.3 mg/ml), suggesting that the DSPC:TDB 
liposome surface may become saturated at higher protein concentrations.   
 
By contrast to the low OVA association to DSPC:TDB liposomes upon addition of 1 mg/ml, 
strong adsorption of OVA to DDA:TDB liposomes was noted and is in correlation with 
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previous results investigating proteins with a pI of between 4 - 5 units (Chapter 3, Figures 
3.8 and 3.10).  
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Figure 4.2 The effect of addition of OVA to DDA:TDB and DSPC:TDB liposomes made with 
Tris buffer. OVA was added to liposomes to a final concentration of 1, 5 or 10 mg/ml 
liposomes. Vesicle size (A) and zeta potential (B) were measured using a Brookhaven 
ZetaPlus machine. Results denote mean ± SD of 4 separate studies. Where shown, 
significance between data is against results of 0 mg/ml protein (**p<0.01, ***p<0.001). 
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Figure 4.3 Quantification of OVA adsorption to DDA:TDB and DSPC:TDB liposomes when 
added to a final concentration of 1, 5 or 10 mg/ml. Protein adsorption was determined 
using the BCA assay and is expressed as a % of that added. Results denote mean ± SD of 4 
separate studies. n.s, not significant; ***p<0.001.  
 
Whilst OVA is a model protein to characterise the effects of a wide range of protein 
concentrations on charged liposomes, we also wished to examine model antigenic 
proteins as well as those with high pI values. To this aim three different proteins were 
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added to DSPC:TDB and/or DDA:TDB liposomes to a final concentration of 10 μg (Ag85B-
ESAT-6) or 25 μg (lysozyme or CTH1) per ml liposomes. The higher doses of lysozyme and 
CTH1 were chosen as immunisation with CTH1 had previously been documented at 5 μg 
and not 2 μg/dose (Andersen et al., 2009), and as lysozyme was expected to exhibit more 
similarity to CTH1 than to Ag85B-ESAT-6, it too was characterised at this higher dosage.  
 
Figure 4.4 shows the adsorptive abilities and effect of Ag85B-ESAT-6, lysozyme and CTH1 
on DDA:TDB and DSPC:TDB liposomes. Whilst the addition of Ag85B-ESAT-6 (10 μg/ml) or 
lysozyme (25 μg/ml) to DDA:TDB or DSPC:TDB liposomes had no effect on the vesicle size 
or polydispersity of the formulations, addition of CTH1 (25 μg/ml) altered the vesicle size 
of these formulations significantly (DDA:TDB, p<0.001; DSPC:TDB, p<0.01; Figure 4.4 A, C). 
With regards to the protein induced changes in zeta potential, CTH1 is the only protein 
that significantly (p<0.001) altered the zeta potential of DDA:TDB liposomes (Figure 4.4, B). 
This effect was not seen with DSPC:TDB liposomes (Figure 4.4, D).  
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Figure 4.4: Variation in physicochemical properties of DDA:TDB (A,B) and DSPC:TDB (C,D) 
liposomes upon addition of the antigens Ag85B-ESAT-6 (10 μg/ml), lysozyme or CTH1 
(both 25 μg/ml). The antigens were added to the liposomes post-hydration of the lipid 
film. Characteristics such as vesicle size (A,C; bars), polydispersity (A,C; points), zeta 
potential (B,D; points) and antigen adsorption to the liposomes (B,D; bars) were 
determined. Results represent mean ± SD of at least 3 samples.  
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With regard to protein adsorption, and as observed previously in Chapter 3, Ag85B-ESAT-6 
bound strongly to cationic DDA:TDB liposomes (98 ± 1 %) and, as postulated due to the 
similarly charged nature of both components, Ag85B-ESAT-6 only weakly associated to 
DSPC:TDB liposomes (27 ± 1 %). As expected, the high pI value of lysozyme (11.6 units) did 
not lead to strong adsorption to cationic DDA:TDB liposomes due to electrostatic 
repulsion; only 29 % was found associated which was confirmed by SDS-PAGE (Figures 4.4 
and 4.5).  Low association of lysozyme to DSPC:TDB liposomes (12 %; Figure 4.4, D) was 
also noted and qualitatively confirmed by SDS-PAGE (Figure 4.5). However unexpectedly, 
CTH1 was shown to bind to both DDA:TDB and DSPC:TDB liposomes to relatively strong 
levels of 66 ± 8 % and 54 ± 9 % respectively (Fig 4.4 B,D and Fig 4.5). This relatively strong 
adsorption, combined with the effect CTH1 had on liposome size, lead to further 
investigations.  
 
 
M     CC P     S      P      S
P       S       P        S      CL M
 
Figure 4.5 SDS-PAGE gel confirming the low/medium-binding efficiencies of lysosome and 
CTH1 respectively to DDA:TDB and DSPC:TDB liposomes. Proteins were added to 
liposomes for 1 hr to allow adsorption (if any) to occur, after which formulations were 
centrifuged (13 krpm, 30 mins) to separate unbound (supernatant, S) and bound (pellet, P) 
lysozyme and CTH1 from the liposome formulations. CTH1 and lysozyme antigen control 
lanes (Cc and CL respectively) and molecular markers (M) are also shown.   
 
CTH1 is an unstable protein and is therefore supplied in a phosphate-citrate buffer (70 
mM) of low pH (pH 4) with glycerol (10 %) and cysteine (10 mM) added as stabilising 
agents (Dennis Christensen, personal communication). Initially the effect of the glycerol 
and cysteine components on the various liposome formulations were investigated. 
125 
 
However, their addition to DDA:TDB liposomes did not affect the physicochemical 
characteristics of DDA:TDB liposomes (Figure 4.6, A).  
 
DDA:TDB w/cysteine w/glycerol
0
500
1000
1500
ZP
Size
0
20
40
60
80
V
e
s
ic
le
 S
iz
e
 (
n
m
)
Z
e
ta
 P
o
te
n
tia
l (m
V
)
0 2 20 70
0
1000
2000
3000
4000
5000
6000
ZP
Size
0
10
20
30
40
50
60
Phosphate-citrate buffer molarity (mM)
V
e
s
ic
le
 S
iz
e
  
(n
m
)
Z
e
ta
 P
o
te
n
tia
l (m
V
)
A
B
 
 
Figure 4.6 Determination of the aggregation mediating component of CTH1 on DDA:TDB 
liposomes. The effect of stabilising components cysteine and glycerol (A) and the molarity 
of the phosphate citrate buffer (B) were all investigated by measuring the vesicle size (left 
axis, bars) and zeta potential (right axis, points) of DDA:TDB liposomes. Results are the 
mean ± SD of 3 experiments.  
 
 
As buffer choice and molarity had previously been shown to have an effect on liposome 
characteristics (Chapter 3, section 3.3.1), the effect of the phosphate-citrate buffer on the 
DDA:TDB liposomes was consequently studied (Fig 4.6B). Various molarities of phosphate-
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citrate buffer (pH 4) were added to DDA:TDB liposomes post formation (liposomes were 
still hydrated in Tris buffer). The liposomes were mixed with the buffer and left for 10 min 
followed by size and zeta potential analysis. A trend of increasing vesicle size and 
decreasing in zeta potential was observed upon increasing the molarity of the phosphate-
citrate buffer (Figure 4.6, B). The addition of 70 mM phosphate-citrate buffer (the same 
molarity as CTH1 is dissolved in) resulted in immediate aggregation of the DDA:TDB 
liposomes, the sizes of which were out of the range of the Brookhaven ZetaPlus 
instrument (although a value is recorded, vesicle size is measured by Brownian motion 
which is therefore affected if the size of particles is so large that sedimentation may 
occur). Therefore it was determined that the CTH1 mediated changes in vesicle size and 
zeta potential observed upon addition of 25 μg/ml CTH1 to DDA:TDB and DSPC:TDB 
liposomes was due to the phosphate citrate buffer and not the CTH1 protein itself. 
 
4.3.2 Liposome characteristics in simulated in vivo conditions 
In Chapter 3 the stability of DDA:TDB liposomes over a 56-day period was described 
(Chapter 3, Figure 3.6). These liposomes showed good stability with regards to consistent 
vesicle size and zeta potential measurements. Furthermore their stability over a shorter 
time period, but in conditions designed to simulate the in vivo environment, was assessed 
and whilst liposome aggregation was noted (Chapter 3, Figure 3.9), DDA:TDB liposomes 
retained Ag85B-ESAT-6 antigen well (Chapter 3, Figure 3.10). To investigate if DSPC 
liposomes were subject to similar aggregation, the effect of FCS on DDA:TDB and 
DSPC:TDB liposomes in combination with and without the three different antigens was 
also investigated (Figure 4.7).  
 
Similar to the results described in Chapter 3, the exposure of DDA:TDB liposomes to FCS 
results in a significant and immediate aggregation of vesicles and drop in the zeta potential 
of ~ 35 mV regardless of the protein antigen added to the liposomes (Figure 4.7, A, B). 
Incubation of DSPC:TDB liposomes under the same conditions had no significant effect on 
either the vesicle size or zeta potential of the liposomes. These FCS induced effects were 
further investigated over a longer period of time using Ag85B-ESAT-6 antigen; only 
cationic DDA:TDB liposomes were affected by the FCS whilst DSPC:TDB liposomes 
remained  ~ 1500 nm in size and ~ -30 mV in surface charge throughout the study (Figure 
4.8, A, B). Furthermore, no changes in Ag85B-ESAT-6 adsorption were noted over time 
with 26 ± 9 % of the original amount of Ag85B-ESAT-6 added to DSPC:TDB liposomes 
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recovered after 96 hrs (Figure 4.8, C). The FCS induced changes in physicochemical 
properties of cationic DDA:TDB liposomes have been noted previously (McNeil and Perrie, 
2006) and are due to interactions between charged plasma proteins and the positively 
charged surface of the liposomes. As DSPC:TDB liposomes are weakly anionic/neutral, they 
consequently do not interact with plasma proteins in the same way and no significant 
plasma protein binding to the DSPC:TDB liposomes which could cause vesicle aggregation 
is observed, neither is any Ag85B-ESAT-6 displaced.  
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Figure 4.7 The effect of FCS on the vesicle size (A) and zeta potential (B) of DDA:TDB and 
DSPC:TDB liposomes without or associated with various proteins antigens. Ag85B-ESAT-6, 
CTH1 and lysozyme proteins were added to liposomes at dose concentrations and left to 
adsorb for 1 hr prior to dilution with 50 % FCS/Tris buffer, thereby simulating the in vivo 
milieu. The formulations were incubated at 37 °C for 1 hr, followed by centrifugation to 
obtain a pellet. The pellet was washed twice prior to measurement of the vesicle size and 
zeta potential. Results denote mean ± SD of triplicate experiments. 
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Figure 4.8 Physicochemical characteristics of DDA:TDB and DSPC:TDB liposomes 
associated with Ag85B-ESAT-6 after placement in a 50 % FCS solution at 37 °C for a 96 hr 
period. Vesicle size (A) and zeta potential (B) were measured with a Brookhaven ZetaPlus 
instrument whilst Ag85B-ESAT-6 association to liposomes (C) was measured using 125I-
radiolabelled Ag85B-ESAT-6. Results denote mean ± SD of triplicate experiments.  
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4.3.3 In vitro studies of cationic and neutral liposomes 
4.3.3.1 Studies using monocyte/macrophage cell lines 
Whilst cationic liposomes are commonly associated with toxicity in vitro (Felgner et al., 
1987; Filion and Phillips, 1997, 1998; Kuo et al., 2005; Lappalainen et al., 1994; Senior et 
al., 1991), studies have shown that it is not necessarily the same in vivo (Hilgers and 
Snippe, 1992; Larsen et al., 2004), nor is it a standard rule of thumb for all cationic 
formulations (Filion and Phillips, 1997). DDA-based liposomes were shown to be toxic to 
monocyte/macrophage cultures at concentrations of ≥ 50 μg/ml (Chapter 3, Figure 3.14, 
and (Korsholm et al., 2006)). It was therefore investigated whether DSPC:TDB liposomes 
exhibiting a neutral/anionic surface charge were also toxic to monocyte/macrophage cell 
cultures at similar concentrations.  
 
The NR and LDH assays were used to measure cell viability and liposome mediated cell 
toxicity respectively. Unlike DDA based liposomes, DSPC:TDB liposomes were not toxic at 
any of the concentrations tested (Table 4.2). DDA:TDB and DSPC:TDB liposomes were also 
added to another macrophage cell line,  J774 cells, and phase contrast microscopy used to 
visualise any liposome-mediated changes in cell physiology. As is seen in Figure 4.9, 
application of DDA:TDB but not DSPC:TDB liposomes to J774 cells for a 24 hr period led to 
changes in cell morphology such as cytoplasmic vacuolisation. Vacuolisation is a feature of 
necrosis, in this case due to cationic-liposome mediated cytotoxicity, and has been 
observed previously  upon exposure of adherent cervical cancer cells to DDA-based 
liposomes (> 10 μM) (Lappalainen et al., 1994). The cationic liposome-mediated 
cytotoxicity noted is in contrast to the results presented in Chapter 3 documenting the 
highest non-toxic concentration of DDA:TDB liposomes to be 5 μg/ml (Figure 3.14).In 
addition to factors such as differences in cell culture volume (the toxicity assays using 100 
μl wells whilst microscopic analysis used 6-well plates), the importance of using multiple 
assays in parallel to determine cell viability was confirmed, as has been noted by 
Lappalainen et al. (Lappalainen et al., 1994). 
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Table 4.2 DSPC:TDB liposome mediated cytotoxic effects on RAW264 cells measured via 
cell viability (a, NR assay) and specific cell lysis (b, LDH assay) assays.  
Lipid concentration (μg/ml) Cell viability (%)a Cell lysis (%)b 
0.005 
0.05 
0.5 
5 
50 
84 ± 14 
80 ± 20 
87 ± 17 
86 ± 21 
87 ± 23 
1.4 ± 2.4 
-0.4 ± 0.6 
-1.6 ± 3.0 
1.9 ± 2.7 
1.8 ± 3.0 
Results indicate the mean ± SD of three separate experiments in which four wells of a 96-
well microplate were assayed per sample. Cell viability was calculated from the % of viable 
cells without exposure to liposomes and therefore considered 100 % viable. Specific cell 
lysis is calculated as a % of maximum cell lysis as obtained by Triton® X-100. Lipid 
concentrations refer to the final DSPC concentration/ml. 
 
 
 
   
 
Figure 4.9 Phase contrast images of J774 macrophages without (A) or with DDA:TDB (B) or 
DSPC:TDB (C) liposomes applied at a final concentration of 5 μg/ml for 24 hrs. Arrows 
indicate the presence of large internal vacuoles after exposure to DDA:TDB liposomes. 
 
In an attempt to quantify liposome uptake by phagocytes, the human continuous cell line 
THP-1 treated with vitamin D3 (VD3) was used. THP-1 cells are a monocytic cell line which 
differentiate into ‘alternative’ macrophages of a reparative phenotype when stimulated 
with VD3 for approximately 2 days. The cells are adherent which allows cell monolayers to 
be effectively washed; when treated with EDTA the cells come into suspension easily. 
Fluorescently labelled cationic DDA:TDB and neutral DSPC:TDB liposomes were applied to 
THP-1 cells for up to 4 hrs, following which monolayers were washed to remove liposomes 
not associated with the cells. As well as applying liposomes to the cells at 37 °C, cells and 
liposomes were investigated at 4 °C thereby inhibiting endocytosis. The proportion of the 
total cell population containing or associated with fluorescent liposomes was quantified 
using flow cytometry.  
 
Figure 4.10 shows the time-dependent uptake of DDA:TDB liposomes after application to 
THP-1 cells at both 37 °C and 4 °C. No surface stripping of cells to remove adsorbed 
A           B        C 
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liposomes was undertaken and therefore the proportion of liposome +ve cells noted after 
incubation at 4 °C shows a relatively high proportion of liposomes adsorbing to the cells. In 
contrast, the application of neutral DSPC:TDB liposomes to cells at either 37 °C or 4 °C 
resulted in levels of liposome association similar to background fluorescence of the cells (~ 
5 %).   
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Figure 4.10 Liposome association with THP-1 vitamin D3 stimulated monocytes after 
incubation at 4 °C or 37 °C for up to 4 hours (240 minutes). **p<0.01 against DDA:TDB 
liposomes applied at 37 °C.  
 
4.3.3.2 Investigation of cytokine production from dendritic cells 
In vitro studies were also conducted to measure the ability of cationic DDA:TDB and 
anionic/neutral DSPC:TDB liposomes to cause IL-1α and IL-1β production in primary bone-
marrow derived DCs (studies undertaken in collaboration with E. McNeela and Dr E. 
Lavelle, Trinity College Dublin). The IL-1 cytokine family are a group of pro-inflammatory 
cytokines with widespread actions on the immune system but particularly linked to 
inflammatory diseases (Dinarello, 1996, 2005; Roux-Lombard, 1998; Sutton et al., 2006). 
Unlike many other cytokines, IL-1β (like IL-18) production is rather complex as it is 
produced in an inactive precursor form following activation of Toll-like receptors (TLRs) 
and activation of the NF-κB pathway (Chapter 1, Figure 1.5). For activation of IL-1β the 
‘pro’ domain must be cleaved and this requires inflammasomes which are themselves 
composed of an inactive caspase component. Only upon efflux of potassium ions and 
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binding of ATP to P2X7 receptors does the enzyme dependent activation of caspase 1 
occur which can consequently cleave the ‘pro’ domain from IL-1β (Dinarello, 1996, 2005).  
 
In agreement with previous results obtained from this group where emulsion systems 
were investigated, application of liposomes without pre-stimulation with LPS did not 
induce any IL-1α/β production (results not shown). DCs were consequently pre-treated 
with LPS (5 ng/ml) for 6 hrs followed by application of DDA, DDA:TDB and DSPC:TDB 
liposomes and measurement of IL-1α and IL-1β in the supernatant after 24 hrs. Cationic 
DDA and DDA:TDB liposomes were variable in their ability to stimulate IL-1α production by 
DCs and only after application of the highest concentrations was IL-1α detected (Figure 
4.11, A). By contrast, neutral DSPC:TDB liposomes were able to stimulate IL-1α production 
in a liposome-dose dependent manner (Figure 4.11, A).  
 
IL-1β production was significantly enhanced if DCs were exposed to cationic DDA or 
DDA:TDB liposomes as opposed to neutral DSPC:TDB liposomes (Figure 4.11, B), and for all 
liposome formulations a lipid-dose dependent effect was noted. It is interesting to note 
that the concentrations used were very high compared to the concentrations applied to 
RAW264 and J774 macrophages; a starting concentration of 500 μg lipid/ml was applied to 
DCs (1/10 dilution) and only at the 1/640 dilution (equivalent to ~ 8 μg lipid/ml, similar to 
the highest concentration not found to be toxic to macrophages (Chapter 3, Figure 3.14)) 
were levels in IL-1α/β non-significant increased compared to LPS-treated cells alone. This 
suggests that either DCs were more resilient compared to macrophages against the 
cytotoxic effects of the liposomes, or the liposomes caused cell lysis leading to leakage of 
IL-1α/β into the supernatant.  
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Figure 4.11 IL-1α (A) and IL-1β (B) production from BMDCs stimulated with DDA, DDA:TDB 
or DSPC:TDB liposomes. Liposomes (5 mg/ml) were applied to DCs starting at a 1/10 
dilution and serially diluted thereafter; the supernatant was assayed for the presence of 
IL-1α and IL-1β after a 24 hr period. All BMDCs were stimulated in the presence of LPS (5 
ng/ml). Experiments were conducted at Trinity College Dublin, Ireland. Results denote 
mean ± SD of triplicate wells. ***, p<0.001. 
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4.3.4 Biodistribution studies: the effect of surface charge and 
protein adsorption 
To determine the effect of liposomes charge on the biodistribution and clearance of 
liposomes and antigen, a biodistribution study was conducted using the developed dual-
radiolabelling protocol (Chapter 3). Both the effect of liposome charge and antigen 
adsorption on the depot-effect were investigated. 
4.3.4.1 Vaccine retention at the SOI 
DDA:TDB liposomes showed a similar retention profile at the SOI regardless of whether 
they were prepared with Ag85B-ESAT-6 or CTH1 antigens (Figure 4.12, A). Between 74 – 
84 % of the injected liposome dose was found at the SOI 1 day p.i and this decreased to 
approximately 30 % of the dose by day 14 p.i irrespective of the antigen used. In contrast, 
neutral DSPC:TDB liposomes exhibited a faster drainage profile with significantly less 
(p<0.001) liposomes present on days 4 and 14 p.i (Figure 4.12, A). With regards to the 
movement of antigen from the SOI, two distinct profiles were noted (Figure 4.12, B). 
Antigen which showed a poor binding ability to liposomes, such as lysozyme with DDA:TDB 
and Ag85B-ESAT-6 with DSPC:TDB, drained rapidly from the SOI with as little as 7 % of the 
injected dose detectable 1 day p.i. In contrast, antigen which showed medium/strong 
adsorption abilities to liposomes, such as noted with CTH1 and Ag85B-ESAT-6 antigen 
adsorbing to DDA:TDB liposomes, were well retained at the SOI with ~ 55 % of the injected 
dose present 1 day p.i. On day 4 p.i there were still significant differences noted between 
the drainage profiles; between 10 – 20 % of injected Ag85B-ESAT-6 and CTH1 was still 
present whilst the non-adsorbed lysozyme and Ag85B-ESAT-6 administered with DSPC:TDB 
liposomes was present in very low quantities (~ 3 %). Taken together these results show a 
clear need for antigen association with liposomes in order for the antigen to be retained at 
the injection site. Furthermore, prolonged liposome presence at the SOI requires a 
cationic surface charge which, aside from their role as antigen delivery systems, may be a 
particularly favourable property for liposomal systems exhibiting immunostimulatory 
abilities such as the ability to upregulate co-stimulatory molecules or stimulate chemokine 
production (Vangasseri et al., 2006; Yan et al., 2007). The antigen depot-effect has also 
been established as an important mechanism of adjuvant action as it allows lengthened 
antigen exposure to APCs in an environment rich in cellular and molecular immune 
components (Mosca et al., 2008; Obst et al., 2007).  
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Figure 4.12 Presence of liposome (A) and antigen (B) at the site of injection (SOI) after 
administration of dual-radiolabelled vaccine formulations. DDA:TDB and DSPC:TDB 
liposomes were mixed with various antigens (Ag85B-ESAT-6 (H1), CTH1 or lysozyme (LYZ)) 
and injected via the i.m route. Results denote the mean ± SD of 3 or 4 mice. Significance 
(***p<0.001) is against DDA:TDB:H1 liposomes at the same time-point. 
 
4.3.4.2 Movement of vaccine components to the local lymph nodes  
In addition to investigating the presence of both liposome and antigenic components at 
the SOI, the local draining lymph nodes (PLN) were removed for vaccine quantification.  
The results show that faster draining of liposomes to the PLN was linked to liposome 
charge; DSPC:TDB liposomes drained faster and consequently reached a peak presence on 
day 4 p.i (Figure 4.13, A). In contrast, cationic DDA:TDB liposomes which exhibited a 
stronger retention at the SOI drained slower to the PLN. The slower drainage pattern was 
also dependent on the antigen with which the liposomes were administered; whilst 
DDA:TDB liposomes adsorbing CTH1 and Ag85B-ESAT-6 (albeit to varying amounts) 
showed a slow time-dependent increase in liposome presence, the administration of 
lysozyme with DDA:TDB liposomes (which shows a poor antigen association profile) 
drained faster and to higher levels. With regards to antigen detection in the PLN, as was 
seen in Chapter 3, the recovery of antigen in the PLN was low and difficult to quantify 
(Figure 4.12, B). For all DDA:TDB liposome formulations there were no remarkable 
differences in the antigen present in the PLN. However, after administration of DSPC:TDB 
liposomes with Ag85B-ESAT-6 there were elevated levels of Ag85B-ESAT-6 noted on days 
1, 4 and 14 p.i. This observation suggests that Ag85B-ESAT-6 passively drains through the 
PLN when administered with liposomes to which it does not adsorb, such as DSPC:TDB 
liposomes. In contrast, the same antigen or indeed CTH1 or lysozyme administered with 
DDA:TDB liposomes does not passively drain through the PLN. However, this raises an 
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important question: why does lysozyme which does not associate with DDA:TDB 
liposomes also not show heightened presence in the PLN? One possibility is differences 
within the antigen itself, as lysozyme is a relatively small protein compared to Ag85B-
ESAT-6 (16 kDa vs 44 kDa) and exhibits a high pI of 11 units in contrast to Ag85B-ESAT-6 
which has a pI of ~ 4.6 units. It has been suggested that proteins exhibiting extreme pI 
values may form electrostatic interactions with endothelial cells or components of the 
extracellular matrix (Melkko et al., 2002). However, this would therefore suggest that 
lysozyme would be retained at the SOI, although not due to the usual liposome-mediated 
antigen depot-effect. As lysozyme is not detected at the SOI or in the PLN to particularly 
high amounts it can only be assumed that lysozyme is removed and degraded, such as 
occurs naturally with enzymatic degradation of endogenous proteins.   
 
1 4 14
0.0000
0.0025
0.0050
0.0075
0.0100
0.0125
***
***
***
**
**
Days post injection
%
 l
ip
o
s
o
m
e
 d
o
s
e
/m
g
 t
is
s
u
e
fr
o
m
 t
h
e
 P
L
N
1 4 14
0.0000
0.0025
0.0050
0.0075
0.0100
0.0125
0.0150
0.0175
DDA:TDB:H1
DDA:TDB:CTH1
DDA:TDB:LYZ
DSPC:TDB:H1
***
Days post injection
%
 a
n
ti
g
e
n
 d
o
s
e
/m
g
 t
is
s
u
e
fr
o
m
 t
h
e
 P
L
N
A B
Figure 4.13 Pharmacokinetic profile of liposomes (A) and antigen (B) draining to the local 
lymph node. DDA:TDB and DSPC:TDB liposomes were mixed with various antigens (Ag85B-
ESAT-6 (H1), CTH1 or lysozyme (LYZ)) and injected via the i.m route. Results denote the 
mean ± SD of 3 or 4 mice. *p<0.05, **p<0.01, ***p<0.001. 
 
4.3.4.3 Use of pontamine blue as a marker for innate immune 
responses 
The slower drainage of DDA:TDB liposomes from the SOI when compared to DSPC:TDB 
liposomes would suggest that the immune response to the former formulation would be 
heightened due to potential sustained tissue damage and the presence of inflammatory 
mediators due to the toxic nature of cationic liposomes (Filion and Phillips, 1997). Immune 
cells infiltrate to such areas and actively undergo endocytosis which is important for 
subsequent antigen presentation. In order to determine the level of immune cell influx to 
the SOI, pontamine blue dye was administered between 4 - 7 days prior to the termination 
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date. Pontamine blue is known to be readily uptaken by monocytes and therefore offers a 
simple yet novel method to identify innate immune cell influx in response to vaccine 
injection.  
 
Figure 4.14 shows tissue from the SOI (quadriceps) collected on days 1, 4 and 14 p.i of 
DDA:TDB or DSPC:TDB liposomes associated with Ag85B-ESAT-6 antigen. Ag85B-ESAT-6 
adsorbing to DDA:TDB liposomes resulted in a strong blue staining at the SOI which 
increased over time. This is indicative of monocyte influx and is in correlation with data 
presented in Figures 3.21 and 3.22, Chapter 3. The same strong blue staining was not 
noted upon administration of DSPC:TDB:Ag85B-ESAT-6 liposomes (Figure 4.14). Although 
these results are not quantitative, they suggest that cationic liposomes are able to 
improve phagocyte influx to the site of injection. This is especially important if APC influx is 
also increased as a result of a liposomal depot-effect, furthermore still if the liposome is 
able to cause an antigen depot-effect which may therefore promote simultaneous 
liposome and antigen uptake by APCs.  
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Figure 4.14 Pontamine blue staining at the site of injection (quadriceps muscle) 1, 4 and 14 
days post injection (p.i) of DDA:TDB and DSPC:TDB liposomes associated with Ag85B-ESAT-
6 (H1). 
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4.3.5 Ability of liposomes to immunise mice and induce T cell 
proliferation 
In collaboration with Statens Serum Institute (SSI), experiments were conducted to 
determine the immunising abilities of DDA:TDB and DSPC:TDB liposomes using 
formulations prepared  at Aston University.  
4.3.5.1 T cell proliferation measured using antigen-specific transgenic 
mice 
The ability of DDA:TDB and DSPC:TDB liposomes to induce division of T cells expressing a T 
cell receptor (TCR) for the antigen Ag85B was investigated, thereby determining the 
antigen presenting abilities of the liposome formulations rather than any cellular 
activational abilities they may possess. The method used involved fluorescently labelling 
splenocytes derived from Ag85B241-255 TCR transgenic mice with 5,6-carboxyfluorescein 
diacetate succinimidyl ester (CFSE), which were then injected into ‘normal’ C57Bl/6 mice 
which had been immunised with DDA:TDB or DPSC:TDB liposomes in association with 
Ag85B-ESAT-6. By measuring the level of CFSE intensity in recipient mice the ability of 
liposomes to present antigen and induce T cell division could be determined. This assay 
therefore simulates secondary exposure to antigen and gives an indication as to the 
intensity of immune response that would be mounted following pathogen infection.  
 
Figure 4.15 shows the % divided cells (A, B) and divisional index (C, D) of cells derived from 
the lymph nodes of recipient mice either 3 or 14 days after immunisation with the vaccine 
formulations. All mice exposed to Ag85B-ESAT-6 showed significantly higher levels of T cell 
division compared to un-immunised control mice (Figure 4.15). Whilst immunisation with 
Ag85B-ESAT-6 associated DSPC:TDB liposomes did induce division of Ag85B-specific T cells, 
this was not significantly higher than seen in mice immunised with Ag85B-ESAT-6 alone. By 
contrast, DDA:TDB liposomes adsorbing Ag85B-ESAT-6 did result in significantly higher 
(p<0.05) levels of T cell division compared to mice immunised with Ag85B-ESAT-6 alone. 
The increased level of T cell division was deemed significant at both day 3 and 14 p.i, 
suggestive of long term antigen presentation or stimulation by DDA:TDB liposomes 
adsorbing Ag85B-ESAT-6.  
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Figure 4.15 Percentage dividing of- (A, B) and division index for- (C, D) the initial amount of 
Ag85B241-255 specific T cells 4 days after transfer into mice immunized three days (A, C) or 
14 days (B, D) previously with Ag85B-ESAT-6 alone (white) or in combination with 
DSPC:TDB (dashed) or DDA:TDB (grey) liposomes. Taken from (Henriksen-Lacey et al., 
2010c). 
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4.3.5.2 Cytokine production and stage of T cell differentiation  
Whilst the results seen in Figure 4.15 show the strong ability of DDA:TDB liposomes to 
deliver Ag85B-ESAT-6 to APCs for its subsequent presentation to Ag85B specific T cells, the 
results do not convey the efficiency of DDA:TDB liposomes to induce primary immune 
responses to antigen. Consequently an immunisation study was conducted whereby 
C57Bl/6 mice received Ag85B-ESAT-6 alone or in combination with DSPC:TDB or DDA:TDB 
liposomes. The immune response of mice was measured 3 weeks after the last of 3 
immunisations, each given 2 weeks apart. In addition to assessing the cytokine responses 
of restimulated splenocytes (Figure 4.16, A, B, C), the proportion of CD44High T cells 
producing IFN- , IL-2 and/or TNF-  was determined, thereby giving 8 possible cytokine 
combinations (Figure 4.16, D).  
 
Figure 4.16 Cytokine production (A, B, C) from restimulated splenocytes derived from mice 
immunised with Ag85B-ESAT-6 alone or in combination with DSPC:TDB or DDA:TDB 
liposomes. Detection of cytokines produced from CD44High CD4+ T cells (D) was used to 
determine the stage of T cell differentiation using the model derived by Seder et al. (Seder 
et al., 2008). Taken from (Henriksen-Lacey et al., 2010c) with minor formatting 
modifications. 
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The cytokines secreted emphasise the strong Th1 mediating effect of DDA:TDB liposomes 
as high levels of IFN-γ (> 20,000 pg/ml) combined with low levels of IL-5 (< 400 pg/ml) 
were detected from restimulated splenocytes derived from DDA:TDB liposome immunised 
mice (Figure 4.16, A, B). DSPC:TDB liposomes induced an opposite response characterised 
by low levels of IFN-γ (not significantly different from Ag85B-ESAT-6 immunisation alone) 
but with more IL-5. DDA:TDB liposomes were also efficient stimulators of Th17 mediated T 
cell responses, characterised by the production of IL-17 with levels significantly higher 
than Ag85B-ESAT-6 immunisation alone or in combination with DSPC:TDB liposomes 
(Figure 4.16, C). Finally, multiparameter flow cytometry to investigate the stage of T cell 
differentiation based on cytokine production indicated that DDA:TDB liposomes were 
efficient stimulators of IFN-γ+TNF-α+IL-2+ multifunctional T cells (~ 31 %) and TNF-α+IL-2+ 
central memory T cells (~ 36 %), whereas DSPC:TDB liposomes primarily induced TNF-α+IL-
2+ (~ 34 %) and TNF-α+ (~ 38 %) central memory T cells (Figure 4.16, D). Based on the 
progression of T cells from naïve undifferentiated cells towards an IFN-γ producing 
effector memory cell (Figure 1.4, Chapter 1) (Seder et al., 2008), these results suggest that 
whilst DDA:TDB liposomes are capable of driving the immune response towards a highly 
differentiated central memory Th1 cell, DSPC:TDB liposomes lead to only weakly 
differentiated central memory T cells suggestive of poor abilities to induce long-lived T cell 
memory responses.   
 
4.4 Discussion and Conclusion 
The aim of this chapter was to address the importance of liposome surface charge and 
liposome association with antigens expressing different pI values and consequently 
varying abilities to associate with charged vesicles. Understanding such liposome-antigen 
interactions is of special relevance to subunit protein vaccine design as antigen association 
with the delivery vehicle (in this case liposomes) may define the immunogenicity of the 
vaccine.  
 
In Chapter 3 the movement of Ag85B-ESAT-6 from the SOI was investigated; whilst antigen 
retention at the SOI was far superior after administration with cationic DDA-based 
liposomes, antigen did drain faster from the SOI than liposomes, suggesting that cationic 
liposomes become trapped in the tissue. As cationic liposomes interact with serum 
proteins in an electrostatic manner, the role of charge-elicited liposomal deposition upon 
in vivo administration was investigated. Would neutral liposomes also become ‘trapped’, 
142 
 
and if not, could the drainage profile of antigens which showed poor adsorption to 
cationic liposomes also be altered upon injection?   
 
The results obtained suggest that liposome cationic charge is indeed a prerequisite for 
long term liposome retention at the SOI; liposomes composed of DSPC and therefore 
expressing a neutral/slightly anionic surface charge drained significantly faster from the 
injected muscle. In addition it was noted that cationic liposome drainage from the SOI was 
not related to the antigen with which it was administered as both immunogenic (CTH1 and 
Ag85B-ESAT-6) and non-immunogenic (lysozyme) antigens injected with cationic DDA:TDB 
liposomes showed no significant differences in liposome drainage from the SOI. 
Simultaneously administered antigen did however effect the kinetics of cationic liposome 
movement to the local draining lymph nodes where initial APC:T cell interactions occur. 
Among the antigens investigated, three different levels of association with DDA:TDB 
liposomes were noted. In correlation with Chapter 3 and previous studies (Davidsen et al., 
2005), strong adsorption between Ag85B-ESAT-6 and cationic DDA:TDB liposomes was 
observed. Medium levels of adsorption between CTH1 and DDA:TDB were noted, probably 
due to the bipolar nature of CTH1 as well as instabilities between the antigen and 
liposome solutions. Weak association between lysozyme and cationic DDA:TDB liposomes 
was measured due to the high pI value of lysozyme making electrostatic adsorption 
unfavourable. Whilst medium/strong levels of antigen adsorption to cationic DDA:TDB 
liposomes were required for a long term antigen-depot at the SOI, low levels of 
antigen:liposome association as observed with lysozyme and DDA:TDB liposomes led to 
rapid removal of antigen.  
 
Neither CTH1 nor lysozyme was investigated in immunisation studies to determine the 
importance of antigen-liposome association on the ensuing immune responses. However, 
the role of liposome charge was measured using DDA:TDB (cationic) and DSPC:TDB 
(neutral) liposomes administered with Ag85B-ESAT-6. The results show a requirement of 
cationic liposomal charge for the induction of cell mediated immunity characterised by 
IFN-γ and IL-17 production. Levels of either cytokine were not significantly different to 
immunisation with Ag85B-ESAT-6 alone when neutral DSPC:TDB liposomes were used as 
the adjuvant. Furthermore, cationic DDA:TDB liposomes were able to induce 
multifunctional T cells whilst neutral DSPC:TDB liposomes were not. These findings were 
measured using multiparameter flow cytometry and give an indication to the abilities of 
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DDA:TDB liposomes to induce long-term immune responses characterised by memory T 
cells. Furthermore, DDA:TDB liposomes but not DSPC:TDB liposomes were strong inducers 
of Ag85B-specific T cell proliferation which was significantly higher than control mice at 
both early and late time-points.  
 
With regards to the use of DCs as opposed to macrophages, DCs are well known to be the 
‘professional’ antigen presenting cells (APCs) whilst macrophages are known as the 
‘professional’ phagocytic cell. Two of the many excellent in-depth reviews regarding DCs 
and their antigen presenting abilities include those by Gogolák and colleagues and work 
from Ralph Steinman’s group (Gogolák et al., 2003; Mellman and Steinman, 2001). There is 
an enormous quantity of research with regards to the specific targeting of vaccine 
adjuvants to DCs with the aim to improve antigen uptake and presentation on MHC 
molecules (for a selection see (Boscardin et al., 2006; Broekhoven et al., 2004; Cruz et al., 
2010; Sharp et al., 2009; Waeckerle-Men and Groettrup, 2005).  
 
Numerous in vitro studies have shown liposome-mediated activation of DCs (Vangasseri et 
al., 2006; Yan et al., 2007), however, the results obtained are also very dependent on the 
composition of the cationic liposomes. For example, DDA liposomes do not result in up-
regulation of CD40 or CD86 co-stimulatory molecules on DCs (Korsholm et al., 2006), 
however, when combined with TDB, DDA:TDB liposomes can lead to up-regulation of the 
same co-stimulatory molecules (CD40 and CD86) suggesting that this attribute is mediated 
by TDB and not the cationic lipid component (Christensen et al., 2010b; Kamath et al., 
2009).  
 
The finding that DDA:TDB liposomes but not DSPC:TDB liposomes induced IL-1β 
production is of interest for numerous reasons. Firstly IL-1βs production is directly linked 
to activation of TLRs which include receptors for bacterial substances such as Gram +ve 
peptidoglycans and lipopeptides (TLRs1/2 and TLRs2/6), flagellin (TLR5), MPL and LPS 
(TLR4), and numerous synthetic and natural nucleic acids including poly I:C (TLR3), ssRNA 
(TLR3, 7 and 8), R848 (TLR7 and 8) and CpG motifs (TLR9) (Chapter 1, Figure 1.7). In 
general, all these TLR-ligand combinations result in the downstream activation of NFκB 
leading to pro-inflammatory cytokine production and cell proliferation, and also activation 
of MAP kinases leading to chemokine production and co-stimulatory molecule 
upregulation. Therefore IL-1β production from cells to which immunomodulatory 
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liposomes have been applied is directly linked to TLR-liposome interactions and indeed in 
DDA-based liposomes comprising the TLR4 agonist monophosphoryl lipid A (MPL), IL-1β 
gene expression was shown to be upregulated after immunisation (Korsholm et al., 2010). 
Secondly, Il-1β has been shown to promote differentiation of Th17 cells (Sharp et al., 
2009) which themselves have an important role in recruitment of IFN-γ producing 
protective effector cells to the lung after Mycobacterium tuberculosis challenge studies 
(Khader et al., 2007). Importantly, IL-17 production (from Th17 cells) has recently been 
shown in numerous immunisation studies involving DDA:TDB liposomes adsorbing Ag85B-
ESAT-6 (Christensen et al., 2010b; Henriksen-Lacey et al., 2010c; Kamath et al., 2009; 
Werninghaus et al., 2009). 
 
In this chapter we have shown how DDA:TDB liposomes but not DSPC:TDB liposomes are 
able to offer a long term antigen depot-effect which results in desirable immune 
responses. Furthermore, long term exposure to antigen requires a certain degree of 
cationic liposome-antigen association in order to an antigen-depot effect to ensue.  
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5.1 Aims 
This chapter relates to liposomal adjuvants composed of cationic lipids with documented 
immunostimulatory actions and comparative membrane fluidity. The physicochemical 
properties of four cationic liposomes are discussed and their stability assessed in 
conditions relevant to in vivo work as well as shelf-life storage. Cationic liposomes 
adsorbing tuberculosis antigen Ag85B-ESAT-6 are investigated for their ability to form an 
antigen depot-effect in dual-radiolabelling biodistribution studies. Furthermore, their 
ability to induce immune responses is reported as well as collaborative work investigating 
the ability of liposomes to induce upregulation of co-stimulatory molecules.  
5.2 Introduction 
In the previous chapters the ability of liposomes to act as an antigen delivery vehicle, in 
addition to improving immune responses in immunisation studies has been addressed. 
These results demonstrated the exemplary nature of liposomes composed of 
dimethyldioctadecylammonium bromide (DDA) in combination with trehalose 6’6-
dibehenate (TDB). Termed DDA:TDB liposomes, they are capable of inducing a long term 
antigen depot-effect, stimulating both the Th1 and Th2 arms of the immune system and 
have good physicochemical characteristics favouring long term stability (Chapter 3). 
Substitution of the cationic component DDA with a neutral/slightly anionic lipid led to a 
poor antigen depot-effect and significantly lower immune responses (Chapter 4). 
Furthermore, a certain level of antigen adsorption to DDA:TDB liposomes was required for 
a long-term antigen depot-effect and based on the serum protein induced aggregation 
noted upon exposure of DDA:TDB liposomes to a simulated in vivo environment, it appears 
that the cationic charge of the liposome plays a key role (Chapter 4). Recently there has 
been a wealth of interest into the use of cationic structures as adjuvants for subunit 
protein vaccines. These include immune stimulating complexes exhibiting a cationic charge 
(PLUSCOMS) (Lendemans et al., 2007; McBurney et al., 2008), cationic peptides such as 
KLKL5KLK which is a component of IC-31® adjuvant (Intercell, Austria) (Schellack et al., 
2006), cationic bilayer fragments (Lincopan et al., 2009) and most relevantly here, cationic 
liposomes.  
Cationic liposomes have already been extensively investigated as  nucleic acid delivery 
systems due to their ability to complex to, condense and intracellularly deliver anionic 
nucleic acids such as DNA, mRNA and siRNAs. The first marketed liposome capable of 
transfecting cells with nucleic material was Lipofectin® (Felgner et al., 1987) which 
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comprises the cationic lipid 1,2-dioleoyl-distearoyl-3-trimethylammoniumpropane 
(DOTAP). DOTAP is an unsaturated quaternary ammonium lipid which can form liposomes 
on its own or with the addition of helper lipids (Simberg et al., 2004). Recently DOTAP 
liposomes have gained much interest over the last 5 years due to their ability to induce 
upregulation of co-stimulatory molecules on the surface of dendritic cells (DCs) 
(Vangasseri et al., 2006). DCs are professional antigen presenting cells (APCs), however, T 
cell activation can be improved by the upregulation of molecules such as CD80 and CD86. 
Importantly upregulation, or more precisely their initial production, must be initiated on 
APCs such as macrophages and B cells as these cells do not constitutively express co-
stimulatory molecules which are a requirement for the successful activation of T cells.  
Yan and colleagues recently investigated the role of reactive oxygen species (ROS) in the 
initiation of these activational responses (Yan et al., 2008). They showed that through 
production of ROS, DOTAP liposomes are able to stimulate the intracellular signalling 
pathways p38 and ERK which lead to cytokine and chemokine transcription respectively. 
Furthermore, co-stimulatory molecules CD80 and CD86 are all upregulated upon DOTAP-
induced ROS expression (Yan et al., 2008). Among the soluble factors induced by DOTAP 
liposomes are the chemokines CCL2, CCL3 and CCL4 which are all important 
monocyte/macrophage inflammatory and chemoattractant substances (Yan et al., 2007). 
Although liposomes composed solely of DOTAP have not been shown to induce cytokine 
production in these studies, previous work using liposomes composed of DOTAP, 
cholesterol, protamine sulphate and plasmid DNA resulted in a Th1 biased cytokine 
response characterised by IFN-γ, IL-12 and TNF-α production (Whitmore et al., 1999). This 
is supported by the antagonistic effect DOTAP liposomes have on induction of the Th2 arm 
of the immune response; both down-regulation of IL-1 signalling and a lack of IL-10 
production have been noted (Yan et al., 2007). It therefore appears that DOTAP liposomes 
are able to initiate a series of intracellular cascades that favour Th1 immune responses 
characterised by DC activation and recruitment of innate immune cells.  
Another cationic lipid which has been implemented to have lipid-specific 
immunostimulatory actions is N-(N’,N’-dimethylaminoethane)-carbamoyl] cholesterol (DC-
Chol), initially described as being a strong mediator of balanced Th1/Th2 responses 
(Brunel et al., 1999). Brunel and colleagues described the production of cytokines IL-2, IL-5 
and IFN-γ, in addition to IgG1 and IgG2 antibody production, in in vivo immunisation 
studies using hepatitis B subunit antigen. In further work using inactivated trivalent split 
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influenza antigens, the adjuvant effect of DC-Chol liposomes was confirmed and was 
shown to be dependent on antigen association with the liposomes (Guy et al., 2001). DC-
Chol adjuvanted influenza vaccines induced mixed IgG1/IgG2 production with strong 
hemagglutination inhibition (HI) responses after subcutaneous (s.c) and intranasal (i.n) 
vaccination (Guy et al., 2001). Studies to elucidate the mechanisms by which DC-Chol 
liposomes act as adjuvants have suggested a role for the chemokine CCL2, secreted by 
epithelial cells and involved in Langerhans cell recruitment (Cremel et al., 2006), 
complement activation (Plank et al., 1996) and the ability of DC-Chol liposomes to 
associate with antigen and initiate a depot-effect (Guy et al., 2001).    
These reports of cationic liposome-mediated immune responses suggest that not only do 
cationic liposomes initiate their adjuvant abilities by increasing antigen protection and 
delivery, but also that possible cellular receptors for such lipids (or liposomes) exist. One 
of the problems in determining whether this is indeed the case is that many of the 
documented studies use liposomes which are not directly comparable (i.e. due to the use 
of helper lipids, variable antigens, different administration routes etc). As liposomes 
composed of DDA:TDB have been shown to induce strong immune responses and an 
antigen-depot effect, we consequently decided to investigate whether the same was true 
for liposomes composed of DOTAP or DC-Chol. In order to conduct a direct comparison, 
liposomes composed of the lipids DDA, DOTAP or DC-Chol in combination with TDB were 
produced, mixed with the tuberculosis antigen Ag85B-ESAT-6 and administered by the i.m 
route.  
Whilst this selection of liposomes addresses the role of cationic lipid in producing an 
antigen-depot effect and subsequent immune response, one factor which remains variable 
is the fluidity of the resulting liposomes. Liposome fluidity is mediated by the main phase 
transition temperature (TM) of the lipids, in addition to whether additional components 
are included in the liposome bilayer. Therefore whilst DDA liposomes express a TM of 47 
°C, addition of TDB (11 mol %) lowers the TM to 42 °C due to its ability to change the lipid 
packing efficiency (Davidsen et al., 2005). As the TM of DDA:TDB liposomes is above 37 °C, 
upon in vivo administration the liposomal bilayers will remain in a rigid state. Whilst the TM 
of DOTAP liposomes is not agreed upon (-12 °C, (Hirsch-Lerner and Barenholz, 1998) and ~ 
0 °C (Simberg et al., 2004)), it is mutually accepted that it lies below 37 °C due to the 
presence of unsaturated hydrocarbon tails. Therefore, DOTAP liposome bilayers are fluid 
at 37 °C upon in vivo application. Liposomes composed of DC-Chol are not proposed to 
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have a specified TM (as DC-Chol doesn’t possess hydrocarbon chains) but the cholesterol 
planar ring backbone of DC-Chol may indeed reduce bilayer fluidity and in some instances 
even abolish transition temperatures (Bloom et al., 1991; Gregoriadis and Davis, 1979). 
 Consequently, it was of interest to investigate an analogue of DDA which exhibited a fluid 
bilayer upon in vivo administration but expressed the same head group and structure so 
that any receptor mediated liposome:cell interactions would be the same as for DDA 
liposomes. The lipid N,N-dioleyl-N,N dimethylammonium chloride (DODA) is a structural 
analogue of DDA with the exception of two unsaturated c=c bonds in the hydrophobic 
chains. Although little is documented about DODA, its TM is considered to be < 0 °C (Dennis 
Christensen, personal communication and (Christensen et al., 2009)) and therefore 
liposomes composed of DODA are predicted to have a fluid bilayer at 37 °C. Liposomes 
composed of DDA, DODA, DOTAP or DC-Chol provided an ideal comparison to determine 
whether changes in biodistribution and/or immune responses are a result of changes in 
bilayer fluidity (DDA vs DODA vs DOTAP), or changes in the lipid head-group (DDA vs 
DOTAP vs DC-Chol). The structure of these lipids is shown below in Table 5.1. 
 
Table 5.1 Cationic lipids referred to in Chapter 5 
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5.3 Results and Discussion 
5.3.1 Physicochemical characterisation of cationic liposomes and 
their ability to adsorb antigens 
The lipids DDA, DODA, DOTAP and DC-Chol were all combined in an 8:1 molar ratio with 
TDB to form liposomes. In correlation with results documented in Chapters 3 and 4, 
DDA:TDB liposomes were ~ 420 nm in size and expressed a zeta potential of ~ 45 mV 
(Figure 5.1, A). Upon addition of the TB antigen Ag85B-ESAT-6 (10 μg/ml) no significant 
changes in vesicle size, zeta potential or polydispersity were noted. Similarly, addition of 
Ag85B-ESAT-6 to DODA:TDB, DOTAP:TDB or DC-Chol:TDB liposomes did not affect their 
physicochemical properties at the concentrations used (Figure 5.1, A, B). Whilst DODA:TDB 
liposomes were of a similar size and surface charge to DDA:TDB liposomes, DOTAP:TDB 
liposomes were significantly bigger (~ 760 nm) and DC-Chol:TDB liposomes were 
significantly smaller (~ 220 nm) in size and formed a much more homogenous population 
(polydispersity of 0.21) compared to DDA:TDB liposomes (Figure 5.1, A). The vesicle size 
distribution of the liposome populations was confirmed by TEM which showed numerous 
small vesicles for DC-Chol:TDB liposomes whilst DOTAP:TDB liposomes were much more 
variable in their structure  (Figure 5.2). All liposomes studied expressed a zeta potential of 
between 40 – 50 mV due to the presence of the ammonium head group conferring a 
cationic charge (Figure 5.1, B).  
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Figure 5.1 Vesicle size (A, bars), polydispersity (A, values) and zeta potential (B) values for 
liposomes composed of the cationic lipids DDA, DODA, DOTAP and DC-Chol in combination 
with TDB. Characteristics before (closed bars) and after (open bars) addition of Ag85B-
ESAT-6 (10 μg/ml) are shown. Results denote mean ± SD of triplicate samples. H1, Ag85B-
ESAT-6.  
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Figure 5.2 TEM images of DC-Chol:TDB (A) and DOTAP:TDB (B) liposomes.  
 
All liposomes were studied over a 56-day period to identify any possible issues with 
stability. Liposomes were measured for size and zeta potential after storage at both 4 °C 
and 25 °C. The results obtained suggest that DC-Chol:TDB and DOTAP:TDB liposomes are 
susceptible to changes in temperature; storage at 4 °C caused a significant increase in the 
vesicle size of DC-Chol:TDB liposomes as early as 7 days post formation whilst DOTAP:TDB 
liposomes stored at 25 °C experienced a drop in zeta potential from ~ 55 mV to ~ 10 mV 
within the initial 10 days (Figure 5.3, C, d). The zeta potential of DOTAP:TDB liposomes 
stored at 25 °C continually decreased over the 56 day period reaching ~ -10 mV by the end 
of the study. In general, the stability of DDA:TDB and DODA:TDB liposomes was much 
better with both formulations having a vesicle size of ~ 550 nm after 56 days storage at 4 
°C or 25 °C.  
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Figure 5.3 Cationic liposomes were investigated for their stability over a 56-day period. 
The vesicle size (A, B, C, D) and zeta potential (a, b, c, d) of liposomes was measured using 
a Brookhaven ZetaPlus. The liposome formulations included DDA:TDB (A, a), DODA:TDB (B, 
b), DC-Chol:TDB (C, c) and DOTAP:TDB (D, d) which were all stored at 4 °C (○) or 25 °C (■). 
Results represent mean ± SD of triplicate samples.  
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To further characterise the liposomal systems, DDA:TDB, DC-Chol:TDB and DOTAP:TDB 
liposomes were investigated under the same conditions but with the addition of Ag85B-
ESAT-6 (10 μg/ml) to the liposomes. Figure 5.4 documents the changes noted in vesicle 
size and zeta potential; whilst the stability of DC-Chol:TDB liposomes is improved upon 
addition of Ag85B-ESAT-6, the same temperature dependent effects are noted for 
DOTAP:TDB liposomes.  
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Figure 5.4 Stability of liposomes over a 56-day period as measured by changes in vesicle 
size  (A, B C) and zeta potential (a, b, c) after addition of Ag85B-ESAT-6 (10 μg/ml). The 
liposome formulations DDA:TDB (A, a), DC-Chol:TDB (B, b) and DOTAP:TDB (C, c) were all 
produced at a final lipid:TDB concentration of 1.98:0.25mM and stored at 4 °C (○) or 25 °C 
(■). Significant differences in vesicle size and zeta potential over time (compared to day 
one) are shown. *p<0.05, **p<0.01, ***p<0.001. Results represent mean ± SEM of 
triplicate samples.  
 
The steep decrease in vesicle size and zeta potential observed after storage of DOTAP:TDB 
liposomes at 25 °C (Figure 5.3, d) could be explained by breakdown of the lipid 
components. The hydrolysis of lipids containing ester bonds (such as phospholipids and 
DOTAP) has been reported to affect the physical stability of liposomal systems (Gao and 
Huang, 1991; Koeber et al., 2007; Rabinovich-Guilatt et al., 2005; Vernooij et al., 2002; 
Zhong et al., 2010) resulting in a decrease in vesicle size and enhanced permeability of the 
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bilayer which is also dependent on the TM of the lipid (Zuidam et al., 1995). Cleavage of the 
positively charged head-group of DOTAP (Koeber et al., 2007) would result in a decrease in 
the net surface charge of the liposomes (Figures 5.3 and 5.4) which is known to decrease 
the stability of the system as the charge repulsion between adjacent liposomes is weaker 
(Martin, 1990). It is therefore possible that the significant decrease in vesicle size observed 
for DOTAP:TDB when stored at 25 °C and not at 4 °C is due to hydrolysis of ester linkages 
and unsaturated carbons present in the hydrocarbon chains which occurs when the 
liposome exists in its fluid phase.  
To further determine how changes in the measured physicochemical properties affect 
liposome stability, images of DDA:TDB, DC-Chol:TDB and DOTAP:TDB liposomes were 
taken at the corresponding time-points (Figure 5.5). With the exception of DOTAP:TDB 
liposomes stored at 25 °C, all liposomes remained stable without any aggregate formation. 
DOTAP:TDB liposomes aggregated at the latter time-points and clear phase-separation 
was noted by day 56 (Figure 5.5, insert).  
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Figure 5.5 Images of DDA:TDB (A), DC-Chol:TDB (B) and DOTAP:TDB (C) liposomes taken at 
various time-points over a 56-day period. Liposomes were stored at 4 °C or 25 °C. The 
photo insert shows a closer view of DOTAP:TDB liposomes after storage at 25 °C.  
 
5.3.2 Cationic liposome mediated toxicity studies 
Cationic liposomes are significantly more cytotoxic than neutral or anionic liposomes in 
vitro due to the charge mediated interactions between the cell (anionic) and the liposome 
(cationic) causing high levels of uptake and consequent lysis (Chapter 4). Assuming 
cytotoxicity is solely mediated by surface charge, it would be expected that more cationic 
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formulations express higher toxicity whilst lesser cationic formulations are less cytotoxic. 
The cytotoxicity of DDA:TDB, DODA:TDB, DC-Chol:TDB and DOTAP:TDB liposomes was 
consequently investigated to test this hypothesis as all 4 formulations expressed non-
significantly different zeta potentials and therefore their cytotoxic effects would be 
expected to be the same. In fact, it was noted that DODA:TDB liposomes were significantly 
more toxic than DDA:TDB, DC-Chol:TDB and DOTAP:TDB liposomes (Figure 5.6).  This was 
confirmed using both the neutral red (NR) and LDH assays which are complementary 
assays to determine cell viability and cell lysis respectively. Whilst DDA, DC-Chol and 
DOTAP based liposomes had no significant effect on cell viability at concentrations < 5 
μg/ml, DODA:TDB liposomes induced significant decreases in cell viability at 5 μg/ml. 
These results therefore suggest that in addition to the surface charge of liposomes having 
an effect on the cell viability, other factors such as membrane rigidity coupled with vesicle 
size may play a role. Another more likely possibility is that the toxicity noted with 
DODA:TDB liposomes is related to the counterion of DODA; whilst DDA has a bromide 
counterion (Br-), DODA was supplied with a chlorine counterion (Cl-). Whilst the effect of 
counterion has not been studied between DDA and DODA, or indeed using solely DODA, 
the physicochemical properties of DDA liposomes associated with either Br- or Cl- 
counterions have been studied in detail by Feitosa and colleagues (Feitosa and Alves, 
2008; Feitosa et al., 2006; Lopes et al., 2008). Within these studies a larger TM with more 
densely packed bilayers was noted for Cl- counterion DDA liposomes. As no such study has 
been conducted with DDA (Br-) and DODA (Cl-) liposomes, it is difficult to postulate the 
role of the counterion in the aforementioned cytotoxicity.    
157 
 
0.005 0.05 0.5 5 50
0
20
40
60
80
100
120
***
Lipid concentration (ug/ml)
C
e
ll
 v
ia
b
il
it
y
 (
%
)
0.005 0.05 0.5 5 50
0
10
20
30
40
50
60
70 DDA:TDB
DODA:TDB
DC:Chol:TDB
DOTAP:TDB
***
Lipid concentration (ug/ml)
S
p
e
c
if
ic
 c
e
ll
 l
y
s
is
 (
%
)
A
B
 
Figure 5.6 Cell viability measured using the neutral red (A) and LDH (B) assays to 
determine the highest lipid concentration that could be applied to RAW264 cells without 
significant loss of cell numbers. Results indicate the mean ± SD of three separate 
experiments in which four wells of a 96-well microplate were assayed per condition. A; cell 
viability was calculated as a % of cells without any liposomes therefore considered 100 % 
viable. B; Specific cell lysis is calculated as a % of maximum cell lysis as obtained by Triton® 
X-100. Two way ANOVA was used to determine significance levels (***, p< 0.001).  
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5.3.3 Studying the biodistribution of cationic liposomal vaccines 
5.3.3.1 Ag85B-ESAT-6 adsorption to cationic liposomes 
Biodistribution studies were conducted to determine whether cationic lipids expressing 
different physicochemical characteristics including head group, size and bilayer fluidity 
affected the strong Ag85B-ESAT-6 antigen depot-effect noted upon its administration with 
DDA:TDB liposomes (Chapters 3 and 4). The ability of the various cationic lipids to adsorb 
Ag85B-ESAT-6 was first investigated to ensure that antigen adsorption did indeed occur. 
As shown in Figure 5.7, all formulations measured high levels of Ag85B-ESAT-6 association 
ranging between 95 – 97 %. Following this initial adsorption, all formulations were placed 
in simulated in vivo conditions (50 % FCS, 37 °C) and the release profile of Ag85B-ESAT-6 
measured. After an initial release period in which DODA:TDB, DC-Chol:TDB and 
DOTAP:TDB liposomes all showed ~ 10 % loss of Ag85B-ESAT-6, no further significant 
decreases in Ag85B-ESAT-6 were noted (Figure 5.7). After 96 hours in simulated in vivo 
conditions all liposomes still showed high levels of Ag85B-ESAT-6 adsorption with > 80 % 
of the initial amount of Ag85B-ESAT-6 added being recovered associated to the cationic 
liposomes.  No significant differences in antigen adsorption to the cationic liposomes were 
noted (Figure 5.7) suggesting that surface adsorption of Ag85B-ESAT-6 to liposomes 
expressing a cationic surface charge is indeed due to electrostatic interactions and is not 
affected by other factors such as bilayer fluidity.   
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Figure 5.7 Determination of Ag85B-ESAT-6 antigen adsorption to cationic liposomes 
composed of DDA:TDB, DODA:TDB, DC-Chol:TDB and DOTAP:TDB. Ag85B-ESAT-6 was 
added at 10 μg/ml and left to adsorb for 1 hr. Liposomes were placed in simulated in vivo 
conditions (50 %  FCS, 37 °C) to determine the antigen release profile. ***p<0.001. 
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5.3.3.2 Determination of vaccine components at the site of injection  
Tissue from the site of injection (SOI) was removed on days  1, 4 and 14 p.i and assayed for 
the presence of 3H (liposome) and 125I (antigen) (Figure 5.8). Two distinct liposome 
drainage profiles were noted; DDA:TDB and DC-Chol:TDB liposomes exhibited a slower 
prolonged drainage from the SOI with 30 – 40 % of the injected dose recovered 14 days p.i 
(Figure 5.8, A). In contrast, DOTAP:TDB and DODA:TDB liposomes drained significantly 
faster from the SOI and on day 14 p.i between 3 – 10 % of the injected dose was 
recovered. These differences were deemed significant at all three time-points (Figure 5.8, 
A). With regards to the retention of Ag85B-ESAT-6 from the SOI, all liposomes were able to 
initiate a long term antigen depot with over 50 % of the injected dose recovered on day 1 
p.i (Figure 5.8, B). By day 14 p.i Ag85B-ESAT-6 could still be detected (between 1 – 7 % of 
the injected dose).  
It was interesting to note that whilst DOTAP:TDB and DODA:TDB liposomes both drained 
relatively quickly from the SOI, their simultaneously injected Ag85B-ESAT-6 antigen was 
well retained; this was seen at day 4 p.i where less than 27 % of the injected liposome 
dose remained in combination with 30 % of the injected antigen dose. This unusual finding 
whereby the amount of antigen present at the injection site surpassed the amount of 
liposomes raised the possibility that antigen and liposome dissociation was occurring, 
although this had not been noted to significantly high levels in the simulated in vivo study 
(Figure 5.7). Furthermore, these results were not due to experimental errors as repeated 
studies showed the same pattern (results not shown). As only DOTAP:TDB and DODA:TDB 
liposomes showed this trend, it appears that it is related to bilayer fluidity and it is 
conceivable that APCs take up antigen at the SOI whereas DOTAP:TDB and DODA:TDB 
liposomes may either degrade and/or passively drain from the SOI due to the high fluidity 
of their bilayer at 37 °C. Ultimately there are conditions that occur in vivo which have not 
been replicated in the simulated in vivo antigen release study. These include the constant 
flow of interstitial fluid draining to the lymphatics, tissue infrastructure and the presence 
of complement able to bind antigens or pathogenic substances. Therefore Ag85B-ESAT-6 
association with liposomes in vivo may indeed follow a different trend to what is observed 
in simulated stability studies. A further explanation to the loss of liposome yet retention of 
antigen at the SOI may be due to loss of the radiolabel itself from the liposomal 
membrane. 3H-DPPC is added to the liposomes at a low concentration of DPPC (25 
ng/dose) yet a high radioactivity so that minimal DPPC interference on the liposomal 
systems occurs. The critical micellar concentration (CMC) of DPPC is 0.46 mM and 
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consequently for micelle formation, all of the DPPC added per liposome dose would be 
required to escape from the liposomal membrane. Therefore whilst solely DPPC micelle 
formation seems unlikely, another possibility is that DPPC fuses into the cell membrane. 
However if this were the case, 3H-DPPC would be recovered from the SOI to higher 
amounts and for a longer period of time than is noted. A further possibility would be the 
loss of 3H itself from DPPC however dialysis of liposomes containing 3H-DPPC in conditions 
simulating the in vivo environment (50 % FCS, 37 °C) did not show any loss of radioactivity 
(Chapter 3, Figure 3.11). With all this in mind, it would appear that the decrease in 
liposomes draining from the SOI whilst antigen is retained is due to antigen dissociation 
from the liposomes and different drainage profiles.  
1 4 14
0
10
20
30
40
50
60
70
80
90
100
**
*
***
***
***
DDA:TDB:H1 DC-Chol:TDB:H1
Days post injection
%
 l
ip
o
s
o
m
e
 d
o
s
e
 a
t 
th
e
 S
O
I
1 4 14
0
10
20
30
40
50
60
70
80
90
100
DOTAP:TDB:H1
*
***
DODA:TDB:H1
**
**
Days post injection
%
 a
n
ti
g
e
n
 d
o
s
e
 a
t 
th
e
 S
O
I
A B
Figure 5.8 Biodistribution studies in which tissue from the site of injection (SOI) was 
removed and the presence of liposomes (A) and protein (B) determined. Liposomes 
investigated include DDA:TDB, DC-Chol:TDB, DODA:TDB and DOTAP:TDB, all associated 
with Ag85B-ESAT-6 antigen. Results denoted mean ± SD of 5 mice. H1, Ag85B-ESAT-6. 
*p<0.05, **p<0.01, ***p<0.001 
 
5.3.3.3 Determination of vaccine components in the local draining 
lymph node 
The popliteal lymph node (PLN) was removed to assess the proportion of liposome and 
antigen (Figure 5.9, A and B respectively) that had drained from the SOI to the local 
lymphoid organ. In a similar way to the results relating to vaccine presence at the SOI 
(Figure 5.8), there were 2 distinct patterns of liposome drainage to the PLN. DDA:TDB and 
DC-Chol:TDB liposomes showed a gradual increase in liposome presence which by day 14 
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continued to rise. In contrast, the movement of DODA:TDB or DOTAP:TDB liposomes to 
the SOI showed a peak in liposome presence at day 4 p.i, after which the levels dropped to 
below that noted on day 1 p.i. Injection of DOTAP:TDB liposomes led to the highest 
recovered liposome dose on days 1 and 4 p.i whereby between 0.008 – 0.01 % of the 
injected dose per mg of tissue was detected. Similar levels of liposome presence were 
noted for DDA:TDB liposomes by day 14 p.i, suggestive of a much slower drainage pattern 
but with equal amplitude. By day 14 p.i the presence of DDA:TDB liposomes was 
significantly higher (p<0.001) than that of DC-Chol:TDB, DODA:TDB or DOTAP:TDB 
liposomes (Figure 5.9, A).  
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Figure 5.9 Liposome (A) and Ag85B-ESAT-6 antigen (B) drainage kinetics from the SOI to 
the local draining popliteal lymph node (PLN), detected on days 1, 4 and 14 p.i. Results 
denote mean ± SD of 5 mice. H1, Ag85B-ESAT-6. **p<0.01, ***p<0.001 
 
In correlation with previous results documenting antigen presence in the PLN (Chapter 3 
and 4), the proportion of the injected dose was very low and difficult to compare between 
liposomal formulations. One notable exception to this was the administration of Ag85B-
ESAT-6 with DOTAP:TDB liposomes whereby significantly higher (p<0.001) amounts of 
Ag85B-ESAT-6 were detected on day 1 p.i (Figure 5.9, B). A similar antigen drainage profile 
has also been noted for DSPC:TDB liposomes associated with Ag85B-ESAT-6 (Chapter 4, 
Figure 4.12). The results are unusual as both DOTAP:TDB liposomes and DSPC:TDB 
liposomes also show similar liposomal drainage kinetics to the PLN even though their 
physicochemical characteristics are rather different. There is a possibility that the 
physicochemical characteristics of DOTAP:TDB liposomes change in vivo and it may be that 
the temperature affects the ester bonds resulting in hydrolysis and subsequent cleavage 
162 
 
of the positively charged head-group of DOTAP (Koeber et al., 2007). If this did occur, not 
only would the bilayer stability of DOTAP:TDB liposomes be severely altered but antigen 
dissociation would occur allowing free antigen to passively drain through the PLN as seen 
with non-Ag85B-ESAT-6 adsorbing DPSC:TDB liposomes (Chapter 4). Whilst this theory 
may indeed explain the results seen in vivo, unfortunately serum stability experiments 
designed to simulate the in vivo environment did not support this hypothesis as Ag85B-
ESAT-6 adsorption to DOTAP:TDB liposomes was found to be similar to the other cationic 
liposome formulations tested (Figure 5.7). 
 
5.3.3.4 Monocyte recruitment to the SOI 
In previous chapters the use of the dye pontamine blue has allowed monocyte influx to 
the SOI to be semi-quantified based on the intensity of blue staining recovered. Pontamine 
blue is readily uptaken by macrophages (Tilney, 1971) and can therefore give an indication 
to the ability of liposomes to induce innate immune cell influx to the injected tissue. As 
noted in Figure 5.10, injection of DDA:TDB, DC-Chol:TDB or DOTAP:TDB liposomes, all 
adsorbing Ag85B-ESAT-6, does not lead to high levels of blue staining on day 1 p.i. 
However, by day 4 p.i more significant blue staining was noted after injection of DDA:TDB 
and DOTAP:TDB liposomes whilst DC-Chol:TDB injection induced little pontamine blue 
staining. By day 14 p.i the staining intensity increased for DDA:TDB and DC-Chol:TDB 
liposomes whilst a slight decrease was noted after DOTAP:TDB liposome injection. These 
results correlate with the kinetics of liposome drainage to the PLN (Figure 5.9) and suggest 
a slower ability of DC-Chol:TDB liposomes to initiate monocyte influx to the SOI. Whilst the 
presence of pontamine blue cannot be quantified (as the tissue is radioactive and is 
required for quantification of the liposome and antigen dose at the SOI), the images in 
Figure 5.10 give a good indication as to the immunostimulatory abilities of the different 
liposome formulations. 
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Figure 5.10 Pontamine blue staining at the site of injection (quadriceps) after injection 
(i.m) of DDA:TDB (1), DC-Chol:TDB (2) or DOTAP:TDB (3) liposomes, all adsorbing Ag85B-
ESAT-6 antigen.  
 
5.3.4 Immunogenicity of cationic liposomes adsorbing Ag85B-ESAT-
6 antigen  
In addition to conducting biodistribution studies to identify the ability of cationic 
liposomes to induce a long term antigen depot-effect, the immune responses to the 
various cationic formulations including T cell proliferative responses and cytokine 
production were measured in C57Bl/6 mice. These data describe results obtained from 
experiments conducted in collaboration with Statens Serum Institute (SSI) using liposomes 
made at Aston University.  
5.3.4.1 T cell division in response to cationic liposomal vaccines 
In order to determine the efficiency of Ag85B-ESAT-6 adsorbing cationic liposomes to 
cause T cell division, splenocytes derived from Ag85B241-255 TCR transgenic mice were 
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fluorescently labelled with CFSE and injected into C57Bl/6 mice previously immunised with 
DDA:TDB, DC-Chol:TDB or DOTAP:TDB liposomes. Determination of the decrease in CFSE 
per cell gives an indication as to the level of cellular division (or proliferation) in response 
to Ag85B-ESAT-6; this method is described in more detail in Chapter 4 (Section 4.3.5.1). 
Injection of Ag85B-ESAT-6 alone was able to induce T cell division to significantly higher 
(p<0.01) levels than naïve unimmunised control mice (Figure 5.11, A, C). This however was 
only noted in the early stages of Ag85B-ESAT-6 exposure as at day 14 no significant 
increase in T cell division above levels of unimmunised mice was noted after immunisation 
with Ag85B-ESAT-6 alone. As expected, DDA:TDB, DC-Chol:TDB and DOTAP:TDB liposomes 
were also able to induce significantly higher levels of T cell division compared to naïve 
mice, however, significantly higher levels compared to immunisation with Ag85B-ESAT-6 
alone was only noted for DDA:TDB liposomes (Figure 5.11, A, C). Extended proliferative 
responses measured on day 14 p.i showed that only DOTAP:TDB and DDA:TDB liposomes 
were capable of causing significant increases in T cell division, measured by the % divided 
cells as opposed to the divisional index (Figure 5.11, B vs D).  
Comparison of the three cationic liposome formulations with each other suggests an equal 
ability of the liposomes to present Ag85B-ESAT-6 to APCs as no significant differences 
between liposome formulations were noted. However, whilst the results indicate that all 
three formulations were able to present antigen at the early time-points, the response 
was short-lived as by 14 days p.i no significant differences against mice immunised with 
only Ag85B-ESAT-6 were noted. These results demonstrate antigen presenting abilities for 
DDA, DC-Chol and DOTAP:TDB liposomes, however those attributed to DDA:TDB 
liposomes are superior in the initial stages of immunisation. Interestingly no particular 
trend with regards to liposome membrane rigidity is noted which is in contrast to the 
movement of liposome from the SOI (Figure 5.9, A).  
 
 
165 
 
 
Figure 5.11 Percentage dividing of- (A, B) and division index for- (C, D) the initial amount of 
Ag85B241-255 specific T cells 4 days after transfer into mice immunized three days (A, C) or 
14 days (B, D) previously with Ag85B-ESAT-6 alone (white) or in combination with 
DOTAP:TDB (black), DC-Chol:TDB (dashed) or DDA:TDB (grey) liposomes. Taken from 
(Henriksen-Lacey et al., 2010b). 
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5.3.4.2 Cationic liposomal vaccine induced cytokine responses 
The ability of cationic liposomes to induce a primarily Th1 or Th2 response was 
investigated by measuring IFN-γ (Th1) and IL-5 (Th2) production from peripheral blood 
mononuclear cells (PMBCs) of immunised mice. Samples were collected on day 7 and 21 
post the final injection (p.f.i) of triplicate immunisations with 2 week intervals. 
Immunisation with Ag85B-ESAT-6 alone did not induce any IFN-γ production and levels of 
IL-5 were low, albeit deemed significantly different on day 21 p.f.i (Figure 5.12, D). 
DOTAP:TDB liposomes were unable to stimulate significantly elevated levels of IFN-γ 
production on day 7 or 21 p.f.i compared to naïve control or Ag85B-ESAT-6 immunised 
mice (Figure 5.12 1, A, C). In contrast, DC-Chol:TDB liposomes were able to stimulate IFN-γ 
production but only at the early time-point as by day 21 p.f.i IFN-γ production was not 
deemed significantly higher than control or Ag85B-ESAT-6 immunised mice. All 
formulations were capable of IL-5 production and whilst low (< 8 pg/ml), this was 
significantly higher than naïve or Ag85B-ESAT-6 immunised mice at both day 7 and day 21 
p.f.i; no significant differences were noted between cationic liposome formulations. 
DDA:TDB liposomes were consequently the only cationic liposomal formulation able to 
stimulate IFN-γ production to relatively high levels over a continued period of time (Figure 
5.12, A, C).  
 
Whilst cationic charge and membrane rigidity play an important role in liposome retention 
at the SOI (Figure 5.8, A), the cytokine results suggest that there is another parameter 
which affects the ability of cationic liposomal adjuvants to stimulate long term T cell 
memory responses, such as that noted after immunisation with DDA:TDB liposomes. DC-
Chol:TDB liposomes, although able to stimulate immune responses, are poor inducers of 
long term memory T cells as highlighted by the disappearance of IFN-γ responses 21 days 
after the last immunisation. However results relating to liposome retention at the SOI, as 
well as the continued ability of DC-Chol:TDB immunised mice to produce IL-5 production, 
suggests that this formulation does indeed have immunostimulatory abilities due to a 
combination of prolonged presence at the SOI and an ability to improve Ag85B-ESAT-6 
presentation to T cells.    
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Figure 5.12 IFN-γ (A, C) and IL-5 (B, D) responses in mice (pooled PBMCs) one (A, B) and 
three (C, D) weeks after the last of three immunizations with 2 µg of Ag85B-ESAT-6 antigen 
alone (white) or combined with DOTAP:TDB (black), DC-Chol:TDB (dashed) or DDA:TDB 
(grey) liposomes. Results denote mean ± SEM. *p<0.05, **p<0.01, ***p<0.001. Taken 
from (Henriksen-Lacey et al., 2010b) with minor formatting modifications. 
 
 
In a separate experiment, the ability of DODA:TDB liposomes to stimulate cytokine 
production from PMBCs was investigated. In addition to analysing IFN-γ and IL-5 
production, characteristic of Th1 and Th2 immune responses respectively, IL-17 
production was also measured as restimulated splenocytes derived from DDA:TDB 
liposome immunised mice were previously shown to induce IL-17 production (Chapter 4, 
Figure 4.16). Both DDA:TDB and DODA:TDB liposomes were able to induce IFN-γ, IL-17 and 
IL-5 7 days p.f.i (Figure 5.13). Absent IFN-γ and IL-17 responses were noted for Ag85B-
ESAT-6 immunised mice. In correlation with Figure 5.12, DDA:TDB liposomes immunised 
mice exhibited a decline in IFN-γ but an increase in IL-5 production with time (day 7 vs day 
21 p.f.i). Remarkably considering their structural similarity, DODA:TDB liposomes failed to 
induce IFN-γ to even remotely similar levels as DDA:TDB liposomes; whilst the same 
pattern was noted for DODA:TDB liposomes, the amplitude of their response was 
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significantly lower with IFN-γ production being ~ 100-fold less on day 7 p.f.i. (Figure 5.13, 
A).  
 
 
Figure 5.13 Cytokine responses from PMBCs derived from mice immunised with Ag85B-
ESAT-6 alone or in combination with DODA:TDB or DDA:TDB liposomes. Mice received 3 
immunisations with 2 week intervals. Samples were collected on day 7 or 21 post the final 
immunisation and the mean ± SEM is shown. *p<0.05, **p<0.01, ***p<0.001. Taken from 
(Christensen et al., 2010b) with minor formatting modifications. 
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T cells derived from mice immunised with Ag85B-ESAT-6 combined with DODA:TDB and 
DDA:TDB liposomes were also analysed by multiparameter flow cytometry to investigate 
the stage of T cell differentiation. DDA:TDB liposomes induced predominantly 
multifunctional T cells being IFN- +TNF-α+IL-2+ (~ 30 %) and central memory T cells being 
TNF-α+IL-2+ (~ 32 %) (Figure 5.14). DODA:TDB liposomes primarily induced TNF-α+IL-2+ (~ 
42 %) and TNF-α+ (~ 28 %) central memory T cells, albeit to lower levels compared to the 
response noted from DDA:TDB immunised mice. The phenotype of T cells derived from 
DODA:TDB liposome immunised mice is remarkably similar to that derived from DSPC:TDB 
liposome immunised mice (Chapter 4, Figure 4.16, D) and suggests an inability of 
DODA:TDB liposomes to induce memory T cell production.   
 
  
 
Figure 5.14 Detection of cytokines produced from CD44High CD4+ T cells was used to 
determine the stage of T cell differentiation using the model derived by Seder et al. (Seder 
et al., 2008). Results denote mean ± SEM. Taken from (Christensen et al., 2010b) with 
minor formatting modifications. 
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5.4 Discussion and Conclusions 
The results shown in this chapter aimed to clarify the role of the lipid DDA in the positive 
immune responses which have been noted in numerous immunisation studies using the 
tuberculosis antigen Ag85B-ESAT-6. Liposomes composed of DDA combined with the 
immunomodulator TDB (DDA:TDB liposomes) form a strong liposome and antigen depot-
effect at the SOI, elicit Th1 cell-mediated immune responses characterised by IFN-γ and IL-
17 production, induce multifunctional and memory T cells, effectively present antigen to T 
cells (as measured by their proliferative ability upon subsequent exposure to antigen), and 
are also capable of inducing humoral immunity with high IgG1 and IgG2 titres. Although 
cationic charge has been noted as an important factor for the formation of the above 
responses (Chapter 4), it is unclear whether many of the observed effects are as a result of 
the lipid DDA itself, or possibly a synergistic combination between cationic lipid and TDB. 
By investigating the depot-forming and immunising abilities of other similar cationic 
liposomes as adjuvants it was hoped to gain a more detailed understanding of the 
mechanisms by which cationic liposomes act as adjuvants.  
 
Based on differences in membrane fluidity (defined by the inclusion of unsaturated 
hydrocarbon chains in the lipids) and previously documented immunostimulatory actions, 
three cationic lipids were chosen to form comparative cationic liposomes to DDA:TDB. All 
the cationic liposome formulations adsorbed TB antigen Ag85B-ESAT-6 to high levels (> 95 
%) due to the electrostatic interaction of Ag85B-ESAT-6 with the highly positive surface of 
the liposomes. Upon i.m injection of the cationic liposomal vaccines, two distinct profiles 
of liposome movement from the SOI were noted; liposomes possessing a rigid bilayer 
(DDA:TDB and DC-Chol:TDB) showed a lengthened retention profile whilst those with a 
fluid bilayer (DOTAP:TDB and DODA:TDB) drained significantly faster from the SOI. 
Liposome rigidity correlated with IFN-γ production at the early stages of immunisation (1 
week after the final injection), however, 3 weeks after the final injection IFN-γ production 
from rigid DC-Chol:TDB liposome immunised mice had waned whilst DDA:TDB liposome 
immunised mice retained the ability to produce IFN-γ. All cationic liposomes with 
documented immunostimulatory action (DDA-, DC-Chol- and DOTAP-based liposomes) 
were able to induce similar levels of IL-5 which were significantly higher than after 
immunisation with Ag85B-ESAT-6 alone. Liposomes composed of the lipid DODA, chosen 
for its fluid membrane structure as opposed to immunisation abilities, were also able to 
stimulate IL-5 production, However, the response took longer to establish with significant 
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levels only being noted 3 weeks after the final immunisation. Data obtained at the same 
time-point showed decreased IFN-γ and IL-17 responses indicative of a poor Th1 mediated 
immune response in mice immunised with DODA:TDB liposomes. The multifunctionality of 
DDA:TDB verses DODA:TDB liposomes was also investigated and showed a significantly 
stronger ability of DDA:TDB liposomes to induce both multifunctional and central memory 
T cells. Results not shown here but also undertaken at SSI described equal abilities of 
DDA:TDB and DODA:TDB liposomes to present antigen to T cells, as measured by their 
proliferative ability. Therefore whilst membrane rigidity plays a key role in the formation 
of memory responses, this is not due to differences between rigid and fluid liposomes to 
present antigen to APCs.  
 
Further to the work described here, recent findings analysing the role of membrane 
fluidity by comparing the aforementioned fluid DODA:TDB liposomes with rigid DDA:TDB 
liposomes highlighted the strong immunostimulatory abilities of DDA:TDB liposomes 
(Christensen et al., 2010b). Whilst the liposomes used in these studies were not produced 
at Aston University, this work formed part of a collaboration between Aston University, SSI 
and Arun Kamath and Claire-Anne Siegrist of the University of Geneva. In contrast to using 
radiolabelling, fluorescence labelling of liposomes and antigen was undertaken and the 
proportion of each component measured in the dendritic cell (DC) population found in the 
local draining lymph node. No significant differences in the proportion of local draining 
lymph node DCs containing DDA:TDB or DODA:TDB liposomes was observed. This is in 
contrast to our radiolabelled liposome results which show significant variance at all time-
points investigated. Examination of the mean fluorescence intensity (MFI) per DC showed 
that DC uptake of DDA:TDB liposomes was 4-5 fold more efficient than uptake of the fluid 
DODA:TDB liposomes, indicating that whilst similar numbers of DCs were involved in 
DDA:TDB or DODA:TDB liposome uptake, DCs that did take up DDA:TDB liposomes took up 
more per cell. However, liposome uptake is irrelevant if co-administered Ag85B-ESAT-6 
antigen is not uptaken by DCs for presentation on MHC molecules. Administration of 
Ag85B-ESAT-6 with DODA:TDB liposomes led to a significantly higher proportion of DCs 
containing Ag85B-ESAT-6 in the local draining lymph node 24 hrs p.i. Unfortunately this did 
not translate to an overall increased percentage of Ag85B-ESAT-6 dose in the lymph node 
at the same time-point when measured using radiolabelling. The observed discrepancies 
between radiolabelled and fluorescently labelled vaccine biodistribution in the lymph 
nodes may simply be due to various cells participating in vaccine uptake; as solely DCs 
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were analysed in the work conducted by Arun Kamath, passive draining or cellular uptake 
by cells other than DCs would not be included in the analysis.   
 
In support of the more immunogenic nature of rigid DDA:TDB liposomes compared to fluid 
DODA:TDB liposomes (as shown by cytokine production and multiparameter flow 
cytometry), work conducted by Arun Kamath provided evidence of the highly 
immunostimulatory nature of DDA:TDB liposomes compared to DODA:TDB liposomes. 
Increased levels of CD40 and CD86 activation markers on dendritic cells were noted, as 
was CD86 expressed on macrophages. Whilst DODA:TDB liposomes could also increase 
CD40 and CD86 upregulation compared to naïve controls, DDA:TDB liposomes were 
superior. As activation of DCs has been shown to increase their turnover rate (Hou and 
Van Parijs, 2004; Kamath et al., 2002; Obst et al., 2007), these results suggest that 
DDA:TDB liposomes are superior activators of DCs, very likely due to the lengthened 
exposure of DCs to Ag85B-ESAT-6 when delivered with DDA:TDB liposomes as opposed to 
DODA:TDB liposomes. 
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Chapter 6: Investigating the Role of Liposome Size on 
the Immunological Properties of an Established 
Tuberculosis Vaccine Adjuvant 
 
 
 
 
 
 
 
Papers relating to this chapter 
Henriksen-Lacey M, Devitt A and Perrie Y. The effect of vesicle size on the biodistribution 
and immunogenicity of DDA:TDB liposomes. Molecular Pharmaceutics, 2010, In 
preparation.
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6.1 Aims 
This final chapter documenting experimental findings relates to the effect of liposome size 
on the resulting biodistribution profile of liposomes and simultaneously injected antigen. 
The ability of various sizes of liposomes composed of the immunostimulatory combination 
‘DDA:TDB’ were investigated as vaccines for the induction of both humoral and cell-
mediated immune responses after immunisation with the tuberculosis antigen Ag85B-
ESAT-6.  
 
6.2 Introduction 
For the establishment of immunity against a particular pathogen, its antigenic components 
must enter the antigen presenting cell (APC) so that the antigen can be loaded onto MHC 
molecules for subsequent presentation to T cells. The same is true for vaccines carrying 
antigenic components and therefore vaccine design must consider the various methods by 
which the antigen may enter the cell. As described in Chapter 1, there are numerous 
uptake mechanisms designed to uptake pathogens and host-derived substances in the 
nano- (endocytosis) or micro- (phagocytosis) range. Many experiments use fluorescently 
labelled polystyrene microspheres to investigate particle uptake as they can be purchased 
in a variety of narrowly defined sizes, after which surface modifications such as addition of 
peptide antigens, toxoids or immunomodulatory substances can be achieved using 
conjugation technology. Another commonly used method is the use of size reduction 
techniques such as sonication, filtration or extrusion, all of which are suitable techniques 
for liposomes. Whilst the use of filtration and extrusion results in vesicles of a defined size, 
dependent on the duration and power of sonication or the extrusion filter pore size, the 
resulting population is not necessarily homogeneous. Furthermore, in the case of 
extrusion loss of material is also common due to either non-specific or specific interactions 
with the membrane. Although sonication generally does not lead to any loss of material, 
there is no physical size limiting device therefore the population of resulting vesicles may 
be more heterogeneous than observed after extrusion. In addition, the forces involved in 
sonication may have a more degradative effect on the material.  
The role of vesicle size for antigen uptake and activation of the immune response remains 
debated with many studies offering contradictory indications as to whether smaller or 
larger vesicles are superior. In fact, it appears that vesicle size plays a significant role in 
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biasing the immune response towards Th1 or Th2 immunity (Brewer et al., 1998; Fifis et 
al., 2004; Mottram et al., 2006). Recently Mann and colleagues revisited the Th1/Th2 
paradigm using heterogeneous sized bilosomes (liposomes incorporating bile salts) for oral 
delivery in an influenza model (Mann et al., 2009). In correlation with results from Brewer 
and colleagues (Brewer et al., 1998), smaller vesicles enhanced Th2 responses whilst larger 
liposomes induced high levels of IFN-γ and IgG2 antibodies, characteristic of Th1 
responses. Importantly, larger liposomes also gave better protection in the ferret 
challenge model of influenza (Mann et al., 2009). Particle size has also been shown to have 
a significant effect on vesicle trafficking to lymph nodes and uptake by APCs (Brewer et al., 
2004; Foged et al., 2005; Oussoren et al., 1997). Manolova et al. recently described the 
trafficking of small nanoparticles and virosomes (20-200 nm) to the local draining lymph 
nodes (LN) after injection into the footpads of mice (Manolova et al., 2008). Although 
larger (0.5 - 2 μm) particles remained at the site of injection (SOI), only these larger 
particles were shown to be uptaken by dendritic cells (DCs) at the SOI whereas small (< 
200 nm) particles freely drained to the LN wherein they were efficiently uptaken by 
phagocytic cells (DCs and macrophages). Previous in vitro studies investigating the 
phagocytic abilities of macrophages compared to monocyte-derived DCs have shown that 
large (4.5 μm) positively charged vesicles are more efficiently phagocytosed than smaller 
(1 μm) negatively charge vesicles (Thiele et al., 2001). Furthermore, these cationic vesicles 
are able to induce DC maturation as measured by CD83 expression. As monocyte-derived 
DCs are noted for their plasticity and ability to accumulate in LNs after infection 
(Steinman, 2008), vaccines composed of larger cationic liposomes may provide an ideal 
method to target and stimulate this population of DCs.  
The discrepancies noted in comparing studies on particulate size and resulting immune 
responses are partly due to the variable vesicles compared; whilst a defined size range 
may be documented, differences in vesicle composition, antigens, animal models (or 
indeed in vitro cell lines) will all have an effect. Therefore, by keeping all of these 
parameters the same but altering just the vesicle size, it is possible to offer a direct 
comparison of the effect of vesicle size. It has continually been shown that liposomes 
composed of DDA and TDB produce a strong antigen depot-effect which is independent on 
the route of injection (Chapter 3), dependent on the cationic surface charge and antigen 
adsorption (Chapter 4) and dependent on the rigidity of the liposome bilayer (Chapter 5). 
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Therefore the aim of this work was to investigate whether rigid cationic liposomes (i.e. 
DDA:TDB) which were of various size distributions, would have similar abilities to cause an 
antigen depot-effect at the SOI. To investigate this, DDA:TDB liposomes were produced to 
three different sizes, termed small, medium and large herein. Small liposomes were 
produced using the usual lipid-film hydration method followed by a sonication step to 
reduce the mean vesicle diameter. Medium liposomes were the same as the DDA:TDB 
liposomes documented in previous chapters. Large liposomes were produced using a 
novel method effectively leading to increased lipid packing in the bilayers and a larger 
vesicle size (see Chapter 2, Section 2.2.1 for method). After investigations relating to 
buffer molarity (Chapter 3) it was discovered that by using a PBS buffer as opposed to Tris 
buffer the size of the liposomes could be controlled and upon hydration of DDA:TDB lipid 
films with PBS buffer at 10 mM, large vesicles formed (Chapter 3). Therefore as a final 
formulation in some of the described studies, extra large DDA:TDB liposomes produced 
using PBS buffer to hydrate lipid films were also included.  
 
6.3 Results and Discussion 
6.3.1 Characterisation of DDA:TDB liposomes of varying size 
distributions 
DDA:TDB liposomes, produced using the lipid-hydration method, were made to four 
different size ranges by use of sonication (small liposomes), increased lipid packing (large 
liposomes) or substituting Tris buffer with PBS buffer (10 mM) for rehydration of lipid films 
(extra large liposomes); medium liposomes were produced without any alteration to the 
usual technique. Medium DDA:TDB liposomes were slightly larger than that noted in 
previous chapters (possibly due to use of a different lipid batch) and expressed a mean 
vesicle size of 685 nm (Figure 6.1, A). Sonication effectively reduced the size range of these 
medium vesicles to ~ 175 nm, whilst the use of the lipid-packing technique resulted in 
vesicles approximately 2-fold larger than normal with a mean vesicle size of 1.5 μm (Figure 
6.1, A). The largest vesicles produced were on the limit of accurate measurement using the 
dynamic light scattering technique (DLS), however the value obtained showed vesicles of 
between 2 – 3 μm formed. The sizes measured using DLS were supported by TEM imaging 
which also showed the heterogeneous nature of the vesicles produced (Figure 6.2)  
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Figure 6.1 Physicochemical characteristics of DDA:TDB liposomes prior and post addition 
of Ag85B-ESAT-6 antigen. Liposomes were made to four different sizes, termed small, 
medium, large and extra large followed by addition of Ag85B-ESAT-6 to a final protein 
concentration of 10 μg/ml liposomes. Vesicle size (A; bars), polydispersity (A; values) and 
zeta potential (B) were all measured using a Brookhaven ZetaPlus. Results denote mean ± 
SD of 3 samples. (*p<0.05). 
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Figure 6.2 Transmission electron microscopy showing liposomes produced to the small (A), 
medium (B), large (C) and extra large (D) defined size ranges.  
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It is particularly interesting to note that the method used to produce large liposomes does 
actually result in vesicles of an increased diameter and not simply vesicle aggregates, 
which is a difference that DLS cannot differentiate between. All liposomes expressed a 
positive surface charge which varied between 28 – 47 mV depending on the liposome size; 
although not significantly different from one another, the most cationic liposomes were of 
a medium size (+47 mV) whilst extra large liposomes were least cationic (+28 mV) (Figure 
6.1). 
The stability of these liposomes over a 28-day period when stored at 4 °C and 25 °C was 
addressed. However, as the extra large liposomes were too large to be accurately 
measured by DLS, they were not included in this study. Furthermore, medium liposomes 
have been characterised in Chapters 3 and 5 and have been shown to remain stable over a 
56-day period regardless of the storage temperature or presence of Ag85B-ESAT-6. They  
were therefore not repeated. Figures 6.3 and 6.4 address the changes in physicochemical 
characteristics noted for small and large liposomes respectively. Whilst small liposomes 
without Ag85B-ESAT-6 are relatively stable over the 28-day period (Figure 6.3, A,B), 
addition of Ag85B-ESAT-6 caused liposomes stored at 25 °C to significantly increase in 
vesicle size becoming approximately 4-fold larger by day 28 post formation. No similar 
temperature dependent changes were noted for their zeta potential (Figure 6.3, b). Large 
DDA:TDB liposomes also increased in size when stored at 25 °C but not at 4 °C, although it 
should be noted that it was difficult to measure these vesicle sizes accurately due to the 
large size of the formulation (Figure 6.4, A, a). In general it appears that storage of small 
and large DDA:TDB liposomes at 4 °C hinders any Ag85B-ESAT-6 antigen-induced 
variations in vesicle size noted. At higher temperatures (25 °C) thermal instabilities in the 
liposome bilayer can occur leading to loss of adsorbed Ag85B-ESAT-6 and/or electrostatic-
mediated aggregation and potentially fusion of adjacent liposomes. The finding that 
significant temperature and antigen mediated changes in vesicle size are noted for small 
and large DDA:TDB liposomes, but not for normal sized DDA:TDB liposomes (Chapter 5, 
Figure 5.4), also suggests that these small and large DDA:TDB liposomes are more 
thermodynamically unstable due to their unnatural structure.  
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Figure 6.3 Small DDA:TDB liposomes were stored at 4 °C (○) or 25 °C (■) for 28 days. 
Periodically the vesicle size (A, a) and zeta potential (B, b) of liposomes both without (A, B) 
or with Ag85B-ESAT-6 (a, b) was measured using a Brookhaven ZetaPlus. Results denote 
mean ± SD of triplicate samples. 
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Figure 6.4 Large DDA:TDB liposomes were stored at 4 °C (○) or 25 °C (■) for 28 days. 
Periodically the vesicle size (A, a) and zeta potential (B, b) of liposomes both without (A, B) 
or with Ag85B-ESAT-6 (a, b) was measured using a Brookhaven ZetaPlus. Results denote 
mean ± SD of triplicate samples. 
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6.3.2 Investigation into the protein adsorption abilities of small and 
large liposomes 
The ability of the small and large DDA:TDB liposomes described above to adsorb antigen 
were investigated with both radiolabelling and fluorescence labelling techniques. 
Radiolabelled Ag85B-ESAT-6 was used to determine the proportion of Ag85B-ESAT-6 
adsorption and subsequent release in simulated in vivo conditions, thereby providing 
complementary data for biodistribution studies. In addition, fluorescent labelling of 
liposomal bilayers was used to gain a more visual idea of how protein interacts with the 
liposomes as well as to support visual data obtained from TEM.   
In correlation with the high levels of Ag85B-ESAT-6 adsorption noted for medium DDA:TDB 
liposomes (Chapters 3, 4 and 5), both small and large DDA:TDB liposomes are capable of 
adsorbing large amounts of Ag85B-ESAT-6, thereby demonstrating the importance of 
cationic surface charge and not liposome geometry (Figure 6.5). However it was noted 
that unlike the medium DDA:TDB liposomes, both small and large liposomes exhibited 
significantly faster rates of Ag85B-ESAT-6 dissociation upon exposure to 50 % FCS at 37 °C, 
thereby simulating the in vivo environment (Figure 6.5). After 96 hrs in these conditions, ~ 
75 % of Ag85B-ESAT-6 remained adsorbed to the liposomes.  
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Figure 6.5 Ag85B-ESAT-6 adsorption and release kinetics from small and large DDA:TDB 
liposomes placed in conditions simulating the in vivo environment (37 °C, 50 % FCS). 
Results denote mean ± SD of triplicate experiments. Medium size liposome data is taken 
from Figure 3.10, Chapter 3. 
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Rather than the physical geometry of the liposome, these increased rates of antigen loss 
may have been due to batch variation in the radiolabelled Ag85B-ESAT-6 as both small and 
large liposomes follow a very similar kinetic pattern. It is also likely that the liposomes 
exhibited a type of ‘burst-release’ pattern as after 24 hrs in simulated in vivo conditions 
the antigen release stabilised. 
In order to gain a clearer understanding of the geometry of the large DDA:TDB liposomes 
as well as to  further investigate how protein affects these structures, both small and large 
DDA:TDB liposomes were fluorescently labelled using Rho-DPPE which incorporates into 
the lipid bilayer. Liposomes were then mixed with FITC-labelled ovalbumin and viewed 
under the Rho- and FITC- filters of a fluorescent microscope. In general, small liposomes 
were too small to be clearly defined, even when using the highest magnification (x100). 
Figure 6.6 shows a series of z-stack images of small and large DDA:TDB liposomes (Rho-
labelled, red) with added OVA (FITC-labelled, green) to a final concentration of ~ 100 
μg/ml. By using z-stacks it is possible to see the multilamellar nature of the large 
liposomes (columns B and C) whereas small liposomes appear to be unilamellar (column 
A). Furthermore, the z-stack images give a good cross-sectional view of how protein 
associates with cationic liposomes; it appears that protein is also within the liposomes 
although this could be due to invaginations in the liposome bilayer and consequently 
depending on the level of the z-stack it may appear that protein is within the vesicles 
when it is actually still surface bound.  
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Figure 6.6 A series of z-stack images showing small (column A) and large (columns B and C) 
Rho-labelled DDA:TDB liposomes with FITC-labelled OVA. The bottom left image marks the 
presence of liposomes (closed arrow), aggregates of protein ± liposomes (open arrow) and 
an artefact (circle).   
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6.3.3 Attempted determination of liposome-mediated intracellular 
lysosomal activity 
The NAG assay can be used to quantify cellular lysosomal activity due to liposomal uptake. 
As lysosomes are involved in the breakdown of extracellular matter taken up via an 
endocytotic route, quantification of the amount of NAG present intracellularly may give an 
indication to the endocytotic ability of the cell. NAG is one of the enzymes involved in the 
degradation of glycolipids and proteins and therefore is of interest in studies in which 
liposomes adsorbing protein are added to cells. There is little literature on the use of the 
NAG assay to measure cellular activity and most research is based on its use to measure 
elevated levels of NAG present in urine of people with renal disorders. 
Attempts to measure NAG in the supernatant of cells exposed to various concentrations of 
liposomes were unsuccessful (Figure 6.7, A). Firstly, the absorbance values derived from 
the assay were very low (< 0.2 units) suggestive of background levels. Control wells set up 
as positive (cells lysed with Triton-X100) and negative (no liposomes) also gave very low 
absorbance readings ranging between 0.143 and 0.192 (results not shown). 
Simultaneously conducted experiments to determine cell viability upon addition of small 
or large DDA:TDB liposomes at 4 °C or 37 °C showed that control wells in which nothing 
had been applied were capable of NR uptake whilst those which had been lysed by Triton-
X100 released all their NR into the surrounding medium (Figure 6.7, B). This confirms the 
ability of Triton-X100 to successfully lyse cells as well as confirming the ability of cells to 
pinocytose. The results relating to the NAG assay therefore suggest that there was no NAG 
present in the cells as all the non-cellular controls relating to the assay effectiveness (p-
Nitrophenol standard and NAG control enzyme) worked very well with high absorbance 
values derived (between 0.7 and 2.4 depending on the control). Whilst Figure 6.7, A shows 
slightly higher absorbance values for cells in which liposomes were applied at 4 °C as 
opposed to 37 °C, when the controls are considered these variances are insignificant.  
To confirm that liposomes were indeed taken up by cells, fluorescently labelled small and 
large liposomes associated with FITC-labelled OVA antigen were added to cells and images 
taken. As seen in Figure 6.8, red (indicative of liposomes) and green (indicative of OVA) 
staining can clearly be seen within the cells and both are uptaken simultaneously by the 
cells (Figure 6.8, C).  
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Figure 6.7 Small and large DDA:TDB liposomes were added to J774 cells at concentrations 
ranging from 0.05 – 50 μg/ml and left to incubate with the cells at 4 °C or 37 °C for 4 hrs. 
A; supernatants were removed and cell monolayers lysed. The supernatant was 
subsequently assayed for the presence of NAG by measurement of a colour change 
detected at 405 nm. B; cells were assayed directly for NR uptake (measured at 560 nm) as 
an indicator of cell viability. Results denote the mean ± SD.  
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Figure 6.8 DDA:TDB liposome uptake by THP-1 cells. Liposomes were labelled with 
rhodamine-DPPE (A; red) and mixed with FITC-OVA (B; green); photos of liposomes, 
protein and cells were taken using a fluorescent microscope and overlaid with phase 
contrast images to produce the above images (C; liposome+OVA+phase contrast). 
 
6.3.4 Biodistribution of small, medium and large DDA:TDB 
liposomes 
To determine the role of liposome size on the antigen (and liposome) depot-effect at the 
SOI, DDA:TDB liposomes were produced with the inclusion of 3H-DPPC in the bilayer 
membrane and 125I-labelled Ag85B-ESAT-6 antigen as previously outlined (Chapter 2, 
sections 2.2.2 and 2.4.3). The SOI and various other tissues were collected and the 
percentage of the administered dose (% dose) quantified. Figure 6.9 shows the proportion 
of liposomes (A) and Ag85B-ESAT-6 antigen (B) retained at the SOI following i.m injection. 
Regardless of the liposome size (small, medium or large), all liposomes were well retained 
with between 40 – 50 % of the injected dose recovered after 14 days. It is interesting to 
note that even at the earliest time-point of 6 hrs (0.25 days) the entire dose is not 
recovered. Although this may be due to passive draining of the liposomes from the 
injection site, it is more likely to be due to difficulties collecting the entire dose. Analysis of 
the proportion of  Ag85B-ESAT-6 recovered shows very high retention (~ 80 % for small 
liposomes) at the earliest time-point of 6 hrs, followed by a gradual decrease reaching 
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levels of between 1 – 10 % of the dose, depending on the liposome size (Figure 6.9, B). 
Significantly different results are only noted between small and medium liposomes 
analysed 4 days p.i (p<0.01) suggesting that small liposomes are able to cause a longer 
Ag85B-ESAT-6 retention profile at the SOI. This is also supported by Ag85B-ESAT-6 
recovery on day 14 p.i being the highest (10.6 % dose) after injection with small DDA:TDB 
liposomes (Figure 6.9, B).  
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Figure 6.9 Pharmacokinetics of small, medium and large DDA:TDB liposomes administered 
with Ag85B-ESAT-6 antigen via the i.m route. Tissue from the site of injection (SOI) was 
collected 6 hrs (0.25 days), 1 day, 4 days or 14 days p.i. Results denote mean ± SD of 3 or 4 
mice. **p<0.01.  
 
In addition to investigating the ability of different sized DDA:TDB liposomes to retain 
Ag85B-ESAT-6 at the SOI, various tissues were assayed and the % dose of both liposome 
and antigen components determined. The results show that vesicle size plays a role in the 
clearance of liposomes to the local popliteal lymph node (PLN) with larger liposomes 
appearing in the PLN faster than small liposomes (Figure 6.10, A). Furthermore, small 
liposomes are also detected in the spleen at significantly lower levels than their medium 
or large counterparts (Figure 6.10, B). Interestingly, significantly higher quantities of 
liposomes are detected in the PLN as opposed to the spleen even though the PLN is 
considerable smaller (the mean spleen weight is ~ 80 mg whilst a popliteal lymph node 
weighs ~ 1-2 mg).  
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Figure 6.10 Biodistribution of DDA:TDB liposomes (small, medium or large) administered 
with Ag85B-ESAT-6 antigen (protein). Vaccines were given via the i.m route and tissues 
including the popliteal lymph node (PLN) (A) and spleen (B) collected 6 or 24 hrs p.i. 
Results denote mean ± SD of 4 mice. *p<0.05, **p<0.01, ***p<0.001. 
 
6.3.5 Studies addressing immunogenicity of various sizes of 
DDA:TDB liposomes  
The aim of the study was to determine whether different sized DDA:TDB liposomes (small, 
medium, large and the previously described extra large) would have varying abilities to 
immunise mice and whether a polarised Th1 or Th2 immune response would ensue, based 
on previous reports showing liposome size to be a determining factor (Brewer et al., 1998; 
Mann et al., 2009). 
6.3.5.1 Antibody responses against adjuvanted Ag85B-ESAT-6 
The ability of small, medium, large and extra large DDA:TDB liposomes to induce IgG 
(total), IgG1 and IgG2 antibody isotypes was investigated using ELISAs. Blood was collected 
on days 0, 13, 28, 36 and 49 and mice were injected with vaccines on days 1, 14 and 29. As 
expected, all PBS injected mice (naïve control group) did not mount any measurable IgG 
response over the experimental period (Figure 6.11). The results obtained for ICF and 
liposome immunised mice were not significantly different from each other however there 
were notable trends (Figure 6.11): 
 In general, mice immunised with liposome adjuvanted Ag85B-ESAT-6 mounted 
total IgG and IgG2 responses to higher titres compared to ICF immunised mice. 
 Furthermore, in the case of IgG2, two doses of liposome adjuvanted Ag85B-ESAT-6 
vaccine were sufficient to mount the maximum IgG2 titre.  
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 Finally, for ICF immunised mice, three immunisations were required to reach 
maximal IgG2 titres (Figure 6.11, C).   
Whilst it is difficult to draw any conclusions with regards to the efficiency of the different 
sized liposomes to induce humoral immune responses, all liposome vaccine formulations 
induced high levels of both IgG1 and IgG2 antibodies. The results observed do not show 
any Th1 or Th2 antibody bias as a result of variable liposome size but instead show a mixed 
Th1/Th2 antibody response unlike the predominantly Th2 response noted upon 
immunisation with currently used aluminium salt adjuvants. 
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Figure 6.11 Antibody responses detected in the serum of immunised mice injected on days 
1, 14 and 29 (depicted with arrows) with various liposomal vaccine formulations adsorbing 
Ag85B-ESAT-6 antigen. Mice were bled on days 0, 13, 28, 36 and 49 and IgG (A), IgG1 (B) 
and IgG2b (C) titres measured. Results show the mean ± SD reciprocal endpoint dilution 
(log10) of 3 (Incomplete Freund’s adjuvant, ICF), 4 (naïve unimmunised) or 5 (liposomes) 
mice.  
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6.3.5.2 Splenocyte proliferation ex vivo in response to Ag85B-ESAT-6 
On day 49 all mice were terminated and their spleens removed for assessment of 
proliferative ability in response to Ag85B-ESAT-6 antigen. Splenocytes were restimulated 
with 0.05, 0.5 and 5 μg/ml Ag85B-ESAT-6 in addition to the positive control stimuli, ConA 
(5 μg/ml). Figure 6.12 shows the proliferative ability of splenocytes in response to ConA. 
All mice responded to ConA although 7 mice showed poor levels of proliferation which 
resulted in ~ 1000 fold less 3H-thymidine uptake compared to naïve unimmunised mice. 
The average 3H-thymidine uptake was between 10,000 – 100,000 counts per minute 
(CPM). Splenocytes derived from unimmunised mice or those immunised with extra large 
liposomes or ICF responded to nearly equal proliferative levels with a very small standard 
deviation noted between mice (Figure 6.12).  
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Figure 6.12 Splenocyte proliferation in response to the positive control stimuli ConA. 
Splenocytes were derived on day 49 of the study and restimulated ex vivo with ConA (5 
μg/ml) to induce proliferation. 3H-thymidine was applied to the cells 72 hrs after exposure 
to ConA. After a further 24 hrs cells were harvested and the proportion of 3H-thymidine 
incorporated in the cells measured using standard scintillation counting. Results are shown 
for individual mice as the mean counts per minute (CPM) of triplicate wells of a 96-well 
plate. 
 
In addition to inducing splenocyte proliferation with the non-specific stimulator ConA, 
splenocytes were also exposed to previously encountered Ag85B-ESAT-6 antigen. Figure 
6.13 shows the results for individual spleens whilst Figure 6.14 gives an overview for all 
liposomal vaccine formulations. The results expressed in Figure 6.13 outline two 
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immediate findings; firstly baseline levels of splenocyte 3H-thymidine uptake are < 2000 
CPM as proliferation (or rather uptake) is still noted in the absence of Ag85B-ESAT-6 
restimulation (Figure 6.13, A); secondly, all unimmunised and ICF immunised mice did not 
respond to Ag85B-ESAT-6 restimulation to levels above background (Figure 6.13). With 
regards to spleens derived from mice immunised with liposomal vaccines (small, medium, 
large or extra large DDA:TDB liposomes adsorbing Ag85B-ESAT-6 antigen), in general there 
was a liposome size and Ag85B-ESAT-6 concentration dependent increase in proliferation 
noted (Figure 6.14). Whilst  small DDA:TDB liposomes failed to induce levels of 
proliferation deemed significantly higher than naïve unimmunised mice upon 
restimulation with 0.05 or 0.5 μg/ml Ag85B-ESAT-6 (Figure 6.13, B and C), all other 
formulations could do so and showed increases in proliferation to be related to increases 
in liposome size. The same liposome size-dependent increase in splenocyte proliferation 
was noted upon restimulation with 0.5 and 5 μg/ml Ag85B-ESAT-6 (Figure 6.13, C, D). 
Immunisation of mice with small DDA:TDB liposomes did induce significant levels of 
splenocyte proliferation however the highest concentration of Ag85B-ESAT-6 for 
restimulation was required (5 μg/ml) (Figure 6.13, D). Regardless of the concentration of 
Ag85B-ESAT-6 used to restimulate splenocytes, no significant differences in proliferation 
were noted between medium and large DDA:TDB liposomes (Figure 6.13). Furthermore, 
irrespective of the Ag85B-ESAT-6 restimulation concentration, mice immunised with extra 
large DDA:TDB liposomes responded with the highest proliferative ability (Figures 6.13, 
6.14). Taken together, these results show a liposome size-dependent immunising ability of 
DDA:TDB liposomes to induce splenocyte proliferation upon restimulation with previously 
experienced Ag85B-ESAT-6 antigen. 
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Figure 6.14 Overview of splenocyte proliferation measured using 3H-thymidine 
incorporation after restimulation ex vivo with Ag85B-ESAT-6 at concentrations ranging 
between 0 – 5 μg/ml. Significance is measured against naïve unimmunised mice (not 
shown). *p<0.05, **p<0.01, ***p<0.001. The “*/**” noted at 0.05 μg/ml Ag85B-ESAT-6 
restimulation refers to large (*) and medium (**) liposomes.  
 
6.3.5.3 Cytokine production from ex vivo restimulated splenocytes 
The supernatants of restimulated splenocytes were assayed for the presence of cytokines 
IL-2, IL-5, IL-6, IL-10 and IFN-γ. The same experimental setup as used to determine 
splenocyte proliferation was used with Ag85B-ESAT-6 being applied to cells at 0.05, 0.5 
and 5 μg/ml, in addition to ConA stimulation as a positive control. Whilst Figures 6.15 to 
6.19 show cytokine production for individual spleens, Figure 6.20 gives a conclusive 
overview of the results derived from each experimental group.  
Figure 6.15 shows the production of IL-2 from splenocytes in the absence of a stimulant 
(A), after restimulation with Ag85B-ESAT-6 at 0.05, 0.5 or 5 μg/ml (B, C and D respectively), 
and finally in the presence of ConA (E). Baseline levels of IL-2 were approximately 230 
pg/ml for all immunisation groups investigated (Figure 6.15, A). Upon re-stimulation of 
splenocytes with Ag85B-ESAT-6 there were significant increases in IL-2 production for all 
liposome-injected mice, regardless of liposome size; naïve unimmunised mice and ICF 
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immunised mice did not respond to Ag85B-ESAT-6 at any of the concentrations added. 
Between the liposome-injected groups the only trend noted was an approximate 2-fold 
decrease in IL-2 production by splenocytes derived from mice immunised with extra large 
liposomes. This was significant compared to IL-2 production by medium and large 
liposome immunisation groups upon restimulation with the highest Ag85B-ESAT-6 
concentration (Figure 6.20, A). Small, medium and large liposome injected mice all 
produced between 1000 – 2600 pg/ml IL-2 when restimulated with 0.05 - 5 μg/ml Ag85B-
ESAT-6. The use of ConA as a positive control resulted in significant IL-2 production only 
from small liposome injected mice (Figure 6.15, E).  
IL-2 is commonly described as a Th1 mediating cytokine and has roles as both a pro- and 
anti-inflammatory cytokine. It is an important mediator of T cell expansion upon TCR and 
antigen binding and has been shown to act in an autocrine manner stimulating further IL-2 
receptor expression, the activation of which leads to induction of effector and regulatory T 
cells (Lan et al., 2008). With this in mind, the low IL-2 production noted from Ag85B-ESAT-
6 restimulated splenocytes derived from ICF immunised mice suggests a poor ability of ICF 
to present Ag85B-ESAT-6 and prime T cells. Similarly, splenocytes derived from mice 
immunised with extra large liposomes show the lowest IL-2 production upon Ag85B-ESAT-
6 restimulation therefore indicating poorer Ag85B-ESAT-6 presenting abilities of this 
vaccine.  
The next cytokine investigated was IL-5 which plays an important role in steering naïve T 
cells towards a Th2 phenotype. IL-5 is present in high amounts in pro-inflammatory 
disorders such as allergies and asthma. IL-5 is also one of the principle cytokines used to 
detect immune responses after experimental administration of mineral salt adjuvants due 
to their Th2 polarising abilities. Figure 6.16 shows IL-5 production from splenocytes in the 
absence of a stimulant (A), after restimulation with Ag85B-ESAT-6 at 0.05, 0.5 or 5 μg/ml 
(B, C and D respectively), and in the presence of ConA (E). Unlike IL-2 production, there 
appeared to be no ‘background’ level of IL-5 production as many splenocyte cultures were 
totally unresponsive even in the presence of Ag85B-ESAT-6 or ConA stimuli. Whilst levels 
of IL-5 production were approximately 10-fold lower than IL-2 production in responding 
splenocyte cultures, a similar pattern was noted with splenocytes derived from extra large 
liposome injected mice being the poorest cytokine producers when compared to the other 
liposome injected mice. This was considered significant when compared to the large 
liposome group at the highest Ag85B-EAT-6 restimulation concentration (Figure 6.20, B). 
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Levels of IL-5 from Ag85B-ESAT-6 restimulated splenocytes derived from ICF injected or 
unimmunised mice were non-existent (< 15 pg/ml) even in the presence of ConA 
stimulation. ConA stimulation induced the highest IL-5 production from splenocytes 
derived from small liposome injected mice (~ 320 pg/ml) (Figure 6.16, E) although this was 
deemed non-significantly different from other liposomal formulations. Taken together, 
these results suggest that when combined with Ag85B-ESAT-6, DDA:TDB liposomes and 
ICF do not stimulate the Th2 arm of the immune response, however the poor IL-5 
response noted upon ConA stimulation may also suggest a bias in this mouse strain 
towards Th1 responses (Charles et al., 1999).  
The following cytokine investigated was IL-6 which is an important cytokine for B cell 
differentiation towards antibody secreting plasma cells, as well as playing a role in the 
differentiation of T cells to a Th1 or Th2 phenotype (Jones, 2005). IL-6 is therefore an 
important cytokine for detection of humoral immune responses as well as cell-mediated 
immunity. Whilst IL-6 has been implicated in IL-2 promotion and therefore Th1 immune 
responses, the critical finding that IL-6 promotes autocrine actions of IL-4 (Th2 cytokine) as 
well as inhibiting IFN-γ production suggests its involvement in predominantly Th2 
responses (Diehl and Rincón, 2002; Dienz and Rincon, 2009). However it does appear to be 
a rather complex relationship, also highlighted by the recent finding that IL-6 is involved in 
naïve T cell differentiation towards the Th17 phenotype (McGeachy and Cua, 2008).  
IL-6 was detected in the supernatant of splenocytes derived from mice immunised with 
and restimulated with the same experimental conditions as noted for IL-2 and IL-5. Figure 
6.17 shows their response in the absence (A) or presence of Ag85B-ESAT-6 (B, C, D) or 
ConA (E). Unstimulated splenocyte IL-6 production was between 20 – 250 pg/ml with no 
particular trend noted between immunisation groups (Figure 6.17, A). These background 
levels of IL-6 were maintained in splenocytes derived from ICF immunised and naïve 
unimmunised mice upon restimulation with Ag85B-ESAT-6. In contrast, stimulation of the 
same splenocyte populations with ConA caused ~ 2-fold higher levels of IL-6 production 
highlighting the ability of ConA to restimulate splenocytes irrespective of the vaccine used 
to immunise mice with (Figure 6.17, E). With regards to splenocytes derived from 
liposome-immunised mice, whilst no trend was noted between the liposomal groups, all 
groups responded to Ag85B-ESAT-6 restimulation producing levels of IL-6 approximately 3 
- 6 fold higher than ICF or naïve groups. Peak IL-6 production was noted by splenocytes 
derived from mice immunised with medium and large liposomes and restimulated with 
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the highest Ag85B-ESAT-6 concentration (1100 pg/ml; Figure 6.17, D). No significant 
differences in IL-6 production were observed between liposome formulations (Figure 6.20, 
C).  
The final cytokine of the interleukin family investigated was IL-10 which is also known to 
have dual Th1/Th2 differentiating abilities as well as being involved in establishing 
humoral immune responses (Mocellin et al., 2004). To further complicate matters, IL-10 
production has been detected from IL-6 stimulated Th17 cells and has been shown to 
regulate Th1 and Th17 responses in a type of negative feedback loop thereby preventing 
host-derived excessive inflammatory responses (Heo et al., 2010; McGeachy and Cua, 
2008). In addition to this important link between IL-6 and IL-10 responses, IL-10 has also 
been shown to be inhibitory to IL-2 and IFN-γ production from Th1 cells (Fiorentino et al., 
1989), as well as inhibiting cell proliferation (Mocellin et al., 2004). Analysis of IL-10 
production from splenocytes is therefore of particular interest with regards to their 
proliferative ability (discussed in section 6.2.5.2).  
Figure 6.18 shows IL-10 production from splenocytes derived from naïve unimmunised 
mice, ICF and liposomal immunised mice, either in the absence (A) or presence of Ag85B-
ESAT-6 (B, C, D) or ConA (E). Generally low but variable of IL-10 were detected from 
unstimulated splenocytes with no trend or significant differences between immunisation 
groups noted (Figure 6.18, A). In contrast, the use of ConA to stimulate splenocytes to 
produce cytokines was successful as high levels of IL-10 were noted from splenocytes 
derived from liposome immunised mice (~ 1100 pg/ml; Figure 6.18, B). Levels of IL-10 from 
ConA stimulated ICF and naïve splenocytes were lower (~ 200 pg/ml) but were still 
significantly higher than background (i.e no stimulation). Re-exposure of liposome 
immunised mouse splenocytes to Ag85B-ESAT-6 lead to the interesting finding that IL-10 
production was liposome size dependent; regardless of the Ag85B-ESAT-6 restimulation 
concentration, a trend was noted whereby splenocytes derived from mice injected with 
the smallest liposomes produced the highest levels of IL-10 (~ 350 pg/ml) whereas those 
receiving the largest of liposomes produced the least IL-10 (~ 80 pg/ml). Whilst these 
results were only deemed significant between small versus large and extra large groups 
when restimulated with 0.05 μg/ml Ag85B-ESAT-6 (Figure 6.20, D), the trend was clearly 
visible and applied over the three concentrations of Ag85B-ESAT-6 used to restimulated 
splenocytes (Figure 6.18, B, C, D). Whilst there was no similar liposome size-dependent 
trend noted in the production of IL-2, IL-5 or IL-6, liposome size (and Ag85B-ESAT-6 
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restimulation concentration) had a significant effect on the proliferative ability of 
splenocytes (Figure 6.14). Interestingly, the relationship between IL-10 production and 
splenocyte proliferation as a result of immunisation with various sized liposomes was an 
inverse one: high IL-10 production gave low proliferation and vice versa. This result 
correlates nicely with described cell proliferation inhibitory actions of IL-10 (Mocellin et 
al., 2004).  
The last and perhaps the most important cytokine investigated was IFN-γ which is a 
commonly used marker to determine the efficacy of tuberculosis vaccines (Agger and 
Andersen, 2001). In the same format as for the previous cytokines, Figure 6.19 shows IFN-
γ production from unstimulated (A), and (re-)stimulated (B, C, D, E) splenocytes derived 
from naïve, ICF or liposomal immunised mice. Interestingly no splenocyte samples 
produced IFN-γ when cultured in the absence of Ag85B-ESAT-6 or ConA (Figure 6.19, A). 
This was the only cytokine studied for which this was noted and consequently suggests its 
production is infection-mediated and highly dependent on splenocyte activation. In 
accordance with this thought, splenocytes derived from naïve unimmunised mice also 
failed to produce IFN-γ when exposed to Ag85B-ESAT-6. Unexpectedly splenocytes derived 
from ICF immunised mice which had been previously exposed to Ag85B-ESAT-6 in vivo also 
failed to recognise Ag85B-ESAT-6 upon re-exposure and no IFN-γ response was detected 
across the range of concentrations tested. Both ICF immunised and naïve unimmunised 
mouse splenocytes did however respond to the positive stimuli ConA with IFN-γ produced 
to ~1500 pg/ml (Figure 6.19, E). Without exception, production of IFN-γ from splenocytes 
derived from liposomal immunised mice was significantly higher than any other cytokine 
investigated; on average between 7000 - 27000 pg/ml IFN-γ was detected after re-
exposure to Ag85B-ESAT-6. Splenocytes derived from mice immunised with medium sized 
liposomes resulted in the highest mean IFN-γ production regardless of the concentration 
of Ag85B-ESAT-6 used for restimulation (Figure 6.19, B, C D). The same was also true upon 
exposure to ConA as opposed to Ag85B-ESAT-6 (Figure 6.19, E). Medium sized liposomes 
induced significantly higher (p<0.01 and p<0.001) levels of IFN-γ from restimulated 
splenocytes (0.5 μg/ml Ag85B-ESAT-6) compared to splenocytes derived from small, 
medium and large liposomes (Figure 6.20, E). 
IFN-γ is an important correlate of protective immunity and numerous TB vaccine studies 
have shown IFN-γ production and vaccine efficacy to be analogous (Agger and Andersen, 
2001). In terms of TB infection, IFN-γ plays an important role in both primary and 
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subsequent Mycobacterium tuberculosis (M.tb) infection. Mice lacking IFN-γ producing 
cells are susceptible to primary M.tb challenge whilst upon secondary infection IFN-γ is 
capable of limiting M.tb growth (Goldsack and Kirman, 2007; Serbina and Flynn, 2001). 
Importantly however, not all vaccines which offer protection against M.tb challenge also 
induce high levels of IFN-γ (Badell et al., 2009) therefore highlighting the need to look at 
the overall immune response including other cytokines, antibody isotypes and ultimately 
protection in challenge studies.  
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Figure 6.15 IL-2 cytokine production from culture splenocytes derived from unimmunised 
mice (naïve) or those immunised with Ag85B-ESAT-6 combined with Incomplete Freund’s 
adjuvant (ICF) or DDA:TDB liposomes produced to various vesicle sizes (small, medium, 
large or extra large. Mice received 3 injections with 2-week intervals and splenocytes were 
obtained 3 weeks post the final immunisation. Splenocytes were restimulated for 48 hrs in 
the presence of media alone (A), Ag85B-ESAT-6 at 0.05 μg/ml (B), 0.5 μg/ml (C) or 5 μg/ml 
(D), or in the presence of 5 μg/ml ConA (E) to act as a positive control. Cytokines were 
detected from splenocyte supernatants and measured using sandwich ELISAs.   
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Figure 6.16 Legend as for Figure 6.15 but for detection of IL-5 cytokine. 
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Figure 6.17 Legend as for Figure 6.15 but for detection of IL-6 cytokine. 
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Figure 6.18 Legend as for Figure 6.15 but for detection of IL-10 cytokine. 
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Figure 6.19 Legend as for Figure 6.15 but for detection of IFN-γ cytokine. 
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Figure 6.20 Conclusion graphs showing IL-2 (A), IL-5 (B), IL-6 (C), IL-10 (D) and IFN-γ (E) 
production from splenocytes restimulated with Ag85B-ESAT-6 at 0.05, 0.5 or 5 μg/ml. 
Results are shown for mice immunised with small, medium, large or extra large DDA:TDB 
liposomes using the same experimental method described for Figure 6.15.  
 
6.4 Discussion and Conclusion 
The role of liposome size remains undetermined in the ensuing immune responses upon 
liposome adjuvanted immunisation. Although there are reports showing that large 
liposomes are superior to small liposomes for induction of Th1 responses (Brewer et al., 
1998; Mann et al., 2009), the wide range of conflicting data with regards to liposomes in 
general merited an investigation into the role of DDA:TDB liposome size in the current TB 
model using Ag85B-ESAT-6. In addition to investigating whether liposome size altered the 
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kinetics of vaccine movement upon i.m injection, the resulting humoral and cell-mediated 
immune responses in mice were investigated.  
The results indicate that altering the size of DDA:TDB liposomes does indeed affect the 
biodistribution and immune responses in mice immunised with Ag85B-ESAT-6. Significant 
differences observed must be solely a property of the vesicle size as this was the only 
characteristic altered in the liposomal vaccines investigated. The only potential exception 
to this relates to the extra large liposomes which were formed using PBS buffer as 
opposed to Tris buffer to rehydrate the lipid films; therefore significant differences in the 
immune response relating to this formulation may be argued to be salt-induced as 
opposed to solely size induced. Regardless, the choice of production methods to form 
DDA:TDB liposomes did indeed result in four significant different sized vesicles, ranging 
from 200 nm to over 3 μm, which all  expressed a cationic surface charge. Levels of Ag85B-
ESAT-6 adsorption were high (~ 96 %) due to electrostatic interactions between the 
liposomes and antigen. Although extra large PBS formed liposomes were not investigated 
in vitro, results relating to small and large DDA:TDB liposomes (medium DDA:TDB 
liposomes were described in Chapter 3) showed no overt cytotoxicity when applied at 5 
μg/ml and liposome endocytosis by cells was observed.  
The ability of DDA:TDB liposomes to cause an antigen depot-effect was again observed 
regardless of whether small, medium or large liposomes were used as the Ag85B-ESAT-6 
delivery vehicle. No major differences were noted in liposome draining from the SOI 
suggesting that the liposome depot effect is more significantly governed by liposome 
charge and rigidity rather than draining of different vesicle sizes. In correlation with 
previous experiments (Chapters 3, 4 and 5), the local popliteal lymph node showed higher 
levels of liposomes than antigen. The very interesting finding that smaller liposomes 
drained slower to the lymph node than larger liposomes was observed at two early time-
points (6 hrs and 24 hrs p.i). This further supports the observation that liposome 
movement from the injection site is not due to vesicle size related draining from the tissue 
(otherwise smaller liposomes would be expected in the lymph node quicker). As DDA:TDB 
liposomes are immunostimulatory due to the inclusion of the mycobacterial glycolipid 
TDB, faster draining and increased presence of large DDA:TDB liposomes in the lymph 
node may result in heightened immune responses to simultaneously administered Ag85B-
ESAT-6. However only two time-points were studied in this experiment and previous 
results have show rapid liposome draining to the lymph node to be disadvantageous for 
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the formation of immune responses (DSPC:TDB and DOTAP:TDB liposomes, Chapters 4 and 
5 respectively). Consequently it is also possible that this faster draining of large DDA:TDB 
liposomes may suggest an earlier peak and subsequent decrease in liposomes presence 
within the lymph node.  
The ability of Ag85B-ESAT-6 adsorbing small, medium, large and extra large DDA:TDB 
liposomes to induce humoral immunity characterised by IgG antibodies was investigated 
and compared to the response given upon injection of Incomplete Freund’s adjuvant (ICF) 
in combination with Ag85B-ESAT-6. Unfortunately no significant differences were detected 
between immunisation groups, however, IgG, IgG1 and IgG2 antibody titres for liposome 
adjuvanted Ag85B-ESAT-6 vaccines were ≥ ICF antibody titres. In addition to investigating 
the humoral immune response, the cell-mediated response was measured by detecting 
levels of splenocyte proliferation and cytokine production upon restimulation with Ag85B-
ESAT-6 antigen. Levels of splenocyte proliferation were highly dependent on both the size 
of the liposome and the concentration of Ag85B-ESAT-6 used to restimulated cells. 
Increases in vesicle size and Ag85B-ESAT-6 concentration caused significant increases in 
splenocyte proliferation. These results provide strong reasoning to suggest that larger 
liposomes are better at presenting antigen to APCs and inducing memory T cell formation. 
The results relating to cytokine production from the same restimulated splenocytes only 
show a liposome size mediated effect in the production of IL-10 from restimulated 
splenocytes, however, IL-10 production is an inverse relationship with splenocyte 
proliferation. As IL-10 is noted to have inhibitory actions on splenocyte proliferation 
(Mocellin et al., 2004), it is possible that the poorer proliferative ability of splenocytes 
derived from small liposome immunised mice is due to IL-10 inhibition. This is also 
supported by the finding that the highest level of IL-10 production corresponds with the 
lowest level of splenocyte proliferation, regardless of the liposome size or Ag85B-ESAT-6 
restimulation concentration. With the exception of IL-10, there were no other notable 
results relating to liposome size mediated cytokine production. In correlation with 
numerous other immunisation studies using DDA:TDB liposomes combined with Ag85B-
ESAT-6 (Agger et al., 2008b; Davidsen et al., 2005; Linderstrøm et al., 2009), levels of IFN-γ 
were high and similar levels were produced regardless of the concentration of Ag85B-
ESAT-6 applied to splenocytes for restimulation. Splenocytes therefore respond to this 
antigenic signal to a high affinity as the difference in the amount of Ag85B-ESAT-6 applied 
to the cells was 100-fold. In  addition to the characteristic Th1 cytokine IFN-γ, IL-2 was also 
produced to relatively high levels (1000 – 3000 pg/ml) and the combined presence of 
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these cytokines suggests the induction of central memory T cells which posses 
multifunctional abilities (Seder et al., 2008).  
It is also pleasing to see that none of the liposomal formulations induced high levels of IL-5 
which is often measured as the predominant Th2 mediating cytokine and is present in high 
amounts upon immunisation with aluminium mineral salts. The differences in liposome 
size in this study do therefore not bias the immune response in a Th1/Th2 way, as 
measured by IgG1/IgG2 antibody titres and IFN-γ and IL-5 cytokine production. However 
there does appear to be an increased ability of larger liposomes to induce memory T cells 
(as noted in proliferation studies) although this may also be due to inhibitory actions of IL-
10 limiting proliferation in splenocyte samples collected from mice immunised with 
smaller liposomes. IL-10, expressed constitutively by a range of cells including 
mononuclear phagocytes, natural killer cells and CD4+ T cells, is able to affect activation 
and proliferation of T cells via a number of mechanisms (all reviewed in detail by Moore et 
al. (Moore et al., 2001)). Firstly IL-10 has been shown to inhibit transport of antigen loaded 
MHC Cl II molecules to the cell surface thereby limiting the number of TCRs that can 
become activated. Furthermore IL-10 can down-regulate expression of co-stimulatory 
molecules CD45, CD80 and CD86 which further limits the ability of successful T cell 
activation to occur. Finally IL-10 indirectly blocks the co-stimulatory signal CD80/86 (on 
APCs) with CD28 (on T cells) thereby inhibiting T cell activation (Akdis and Blaser, 2001). 
However, with regards to this last mechanism, inhibition of T cell activation is only noted 
for T cells which require the CD28 co-stimulatory signal and therefore implies that T cells 
which have already experienced antigen (i.e. memory T cells) are not affected by IL-10 as 
CD28 co-stimulation is not required (Mocellin et al., 2004). These combined actions 
suggest a targeted role of IL-10 towards naïve T cells or those which are derived from 
immunised mice in which antigen has been poorly presented and consequently contain a 
poor memory T cell population. Collectively this suggests that smaller DDA:TDB liposomes 
are less efficient at Ag85B-ESAT-6 presentation to APCs than larger DDA:TDB liposomes.  
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Chapter 7: General Discussion 
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Cationic lipids such as DDA have been known to have immunostimulatory actions for over 
40 years (Gall, 1966). However, it is only within the last 5 - 10 years that the molecular 
mechanisms by which liposomes composed of cationic lipids act are starting to be 
understood. Liposomes composed of DDA in combination with the highly 
immunomodulatory glycolipid TDB are in Phase I trials as vaccine adjuvants designed to 
improve immune responses towards TB vaccination. Of the various methods by which 
adjuvants are proposed to improve immune responses towards simultaneously 
administered antigen (Schijns, 2000), DDA:TDB liposomes have been proposed to fulfil at 
least three mechanisms including improved antigen delivery to APCs, induction of an 
antigen depot-effect at the SOI and local tissue damage upon injection leading to release 
of endogenous DAMPS. More recently the involvement of a fourth mechanism involving 
exogenous PAMPs has been identified; TDB has been shown to bind to the cellular 
receptor Mincle initiating a series of intracellular cascades resulting in innate immune 
activation with resultant Th1/Th17 immune responses (Ishikawa et al., 2009; Schoenen et 
al., 2010; Werninghaus et al., 2009). 
The duration of antigen exposure to the host is known to have an effect on the efficiency 
of the resulting immune response (Obst et al., 2007). As subunit vaccine antigens are 
generally small inert peptides or proteins that do not contain pathogenic stimuli, their 
administration without any carrier molecule leads to their rapid removal by the host and 
therefore little, if any, immune response is mounted. In order to increase the duration of 
antigen presentation to APCs and subsequently T cells for the initiation of memory 
responses, liposomes can be used to simultaneously delivery antigen. Whilst liposomes 
composed of DDA have been noted to cause an antigen depot-effect at the SOI (Holten-
Andersen et al., 2004), this has not been quantified, nor has its role on the 
immunogenicity of vaccines composed of DDA been established. Therefore, the general 
aim of this thesis was to investigate which physicochemical parameters of DDA-based 
liposomes lead to the desirable immune responses noted in immunisation studies. By 
altering parameters such as liposomal charge and size, membrane fluidity and stability, or 
the direct substitution of DDA with other lipids with documented immunostimulatory 
actions, the properties which define DDA-based liposomes as successful adjuvants were 
consequently investigated. 
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7.1 DDA:TDB Liposomes as a Mediator of the Antigen Depot-
effect and Long Term Immune Responses 
In correlation with described observations of DDA:TDB liposome deposition at the SOI 
(Holten-Andersen et al., 2004), we have shown and indeed quantified the DDA:TDB depot-
effect and note that even after 2 weeks p.i more than one third of the administered 
liposome dose can be recovered from the SOI (Henriksen-Lacey et al., 2009). Furthermore, 
significant antigen retention at the SOI was observed, however, this was highly dependent 
on antigen adsorption to the DDA:TDB liposomes as a model antigen which showed poor 
adsorption to DDA:TDB liposomes was not efficiently retained at the SOI (Henriksen-Lacey 
et al., 2010c). Addition of stabilising cholesterol to DDA:TDB liposomes had little effect on 
either liposome or antigen movement from the SOI, suggesting that whilst cholesterol may 
be required to improve liposome stability thereb extending the shelf-life, upon in vivo 
administration little change in the physicochemical nature of the vesicles is observed. 
Although not reported here, the inclusion of cholesterol in DDA:TDB liposomes has been 
shown to decrease the IFN-γ response (Christensen et al., 2009), suggesting that 
cholesterol has an effect on the cell-mediated immune response.  
The liposome and antigen depot-effect noted upon injection of DDA:TDB liposomes 
adsorbing Ag85B-ESAT-6 antigen was not limited to i.m injection as similarly strong depots 
were observed after s.c injection (Henriksen-Lacey et al., 2009). In addition, 
immunogenicity studies showed little difference in the cell-mediated immune responses 
when DDA:TDB liposomes were administered via the i.m, s.c or i.d routes of injection 
(Mohanan et al., 2010). Therefore the depot-effect does not appear to be tissue specific 
although local cell populations and proximity to local lymph nodes may have an effect on 
the immune responses noted.  
The ability of DDA:TDB liposomes to induce long term immunity in mice has recently been 
described by Lindenstrøm and colleagues, again using the TB model antigen Ag85B-ESAT-6 
(Linderstrøm et al., 2009). Their findings also highlight the Th1 polarising nature of 
DDA:TDB liposomes and their ability to induce production of multifunctional memory T 
cells which are vital against secondary TB infection. Such T cells isolated > 1 year after 
immunisation retained their proliferative ability (divisional abilities were ~ 10 times higher 
than non-vaccinated controls), and mice did not succumb to disease in Mycobacterium 
tuberculosis  challenge experiments (Linderstrøm et al., 2009). These results show the 
strong ability of cationic DDA:TDB liposomes to act as an adjuvant for Ag85B-ESAT-6 
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antigen and the authors raised the importance of long-term slow release of antigen after 
administration. It is mutually accepted that antigen dose and drainage kinetics are 
important factors in the resulting immune response. However, whilst some argue for 
escalating doses (Johansen et al., 2008), it is also clear that single or multiple 
administration of depot-forming adjuvants is able to induce the desired response 
(Linderstrøm et al., 2009). 
 
7.2 The Role of Liposome Charge 
Liposomes expressing a cationic surface charge aggregate with serum proteins and 
consequently, upon in vivo injection, it was hypothesised that the strong retention of 
DDA:TDB liposomes at the injection site may have been due to serum protein-mediated 
liposome aggregation. This was also the basis for the hypothesis that simultaneously 
administered antigen, regardless of its adsorption efficiency to DDA:TDB liposomes, is also 
retained at the SOI due to cationic liposomal aggregation. To determine the role of 
liposome charge in the liposome and antigen deposition noted at the SOI, the cationic lipid 
DDA was substituted with DSPC therefore donating a neutral/slightly anionic surface 
charge to the liposomes due to the zwitterionic nature of DSPC. As hypothesised, 
DSPC:TDB liposomes exhibited significantly faster rates of removal from the SOI, as did 
simultaneously administered (although not adsorbed due to lack of electrostatic 
interactions) Ag85B-ESAT-6 antigen. This corresponded with a poor ability of neutral 
DSPC:TDB liposomes to induce T cell proliferation, cause IFN-γ production and induce 
production of T cells with memory ability (Henriksen-Lacey et al., 2010c). In vitro studies 
comparing DDA:TDB and DSPC:TDB liposomes highlighted the importance of liposomal 
surface charge for cellular uptake and activation of DCs to induce Il-1β production; whilst 
DDA:TDB liposomes efficiently associated (both uptaken and adsorbed) to macrophages, 
the lipid concentration administered was vital as toxicity was observed. The results 
consequently suggest that IL-1β production by DCs may well be due to DC uptake of 
DDA:TDB liposomes but not DSPC:TDB liposomes. Whilst this feature had no relation to 
the depot-effect (as studies were conducted in vitro using microplates), it does suggest 
that if even if exposure of DSPC:TDB liposomes to APCs was prolonged, no improvements 
in liposome uptake would be observed. The cationic charge of DDA:TDB liposomes 
therefore prolongs its retention at the SOI as well as increasing its uptake by APCs.  
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7.3 The Importance of Antigen Choice for the Depot-effect and 
Eliciting Immune Responses 
Numerous immunisation studies use model antigens such as OVA to study humoral and 
cell-mediated immunity. The reasons for this are numerous; OVA is inexpensive and 
readily available, there is a lot of literature regarding its use, and there are many research 
techniques available such as transgenic mice or fluorescently labelled OVA. However we 
have shown that the immune response derived from Balb/c mice immunised with 
DDA:TDB liposomes and OVA is not typical of the strong Th1 polarising nature of DDA:TDB 
liposomes observed in other immunisation studies (Christensen et al., 2010a; Davidsen et 
al., 2005; Holten-Andersen et al., 2004; Vangala et al., 2007). When Balb/c mice were 
immunised with DDA:TDB liposomes adsorbing OVA, no detectable IgG2 response was 
observed and splenocytes were extremely poor at cytokine production in response to 
ConA or restimulation with OVA. Similar poor cell-mediated immune responses were 
observed in a collaborative study conducted at University Hospital of Zurich (Mohanan et 
al., 2010). As explained later (section 7.6), substitution of Balb/c mice for the more Th1 
polarising mouse strain C57Bl/6 (Charles et al., 1999), in addition to substituting OVA for 
the immunogenic antigen Ag85B-ESAT-6 (Olsen et al., 2001), re-established the strong Th1 
immune responses typically elicited by DDA:TDB liposomes adsorbing Ag85B-ESAT-6.  
The role of antigen was also investigated in biodistribution studies whereby the 
importance of antigen adsorption to DDA:TDB liposomes was questioned. DDA:TDB 
liposomes adsorb strongly to Ag85B-ESAT-6 and initiate high levels of Ag85B-ESAT-6 
retention at the injection site; would antigens which displayed poor adsorption abilities to 
DDA:TDB liposomes also be well retained? To answer this, two antigens were chosen 
which expressed medium and poor adsorption abilities to DDA:TDB liposomes. Whilst 
simultaneous administration of antigen expressing medium adsorption abilities to 
DDA:TDB liposomes was retained at the SOI to the same efficiency as Ag85B-ESAT-6, the 
poorly adsorbing antigen showed a similar drainage profile to antigens administered 
without a delivery system (Henriksen-Lacey et al., 2010c). Therefore a degree of antigen-
liposome association was required although the importance of this was  not translated 
into immunisation studies. Regardless, the role of antigen in establishing immune 
responses but also prolonging its own exposure to APCs is significant and should be 
considered when designing costly in vivo experiments.  
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7.4 Comparison of Fluid Verses Rigid Liposomes as Effective 
Adjuvants 
As it was established that cationic charge and antigen adsorption were both important 
factors for a liposome and antigen depot-effect at the SOI, the role of liposomal 
membrane fluidity was consequently investigated. Membrane fluidity can be altered by 
the inclusion of unsaturated hydrocarbon chains into the lipid, thereby altering the VDW 
forces between adjacent lipid monomers and disrupting the bilayer organisation. A direct 
comparison against DDA:TDB liposomes was made using DODA which is an unsaturated 
analogue of DDA and is therefore hypothesised to contain fluid bilayers at physiological 
temperatures. The increase in bilayer fluidity noted with DODA-based liposomes caused 
faster liposome drainage from the SOI and a subsequent faster appearance of liposomes in 
the local lymph nodes. However, this did not correlate with improved immune responses 
as mice immunised with DODA:TDB liposomes produced little IFN-γ and IL-17 from 
restimulated splenocytes. Furthermore, the T cells derived from these mice displayed low 
levels of memory T cells. Analysis of DCs from DODA:TDB liposome injected mice also 
showed a significantly lower uptake of DODA:TDB liposomes and reduced abilities to 
stimulate upregulation of co-stimulatory markers when compared to DDA:TDB liposome 
injected mice (Christensen et al., 2010b). Liposome rigidity therefore plays an important 
role in prolonging cellular exposure to liposomes which has significant effects on APC 
activation and long term memory induction.  
 
7.5 Choosing the Correct Immunostimulatory Cationic Lipid 
Whilst DDA-based liposomes express numerous characteristics which make them efficient 
adjuvants for subunit vaccines, it is interesting to note that no direct immunostimulatory 
actions have been attributed to the lipid DDA (Korsholm et al., 2006; Vangasseri et al., 
2006). In contrast, cationic lipids such as diC14-amidine, DOTAP and DC-Chol have been 
shown to have immunomodulatory properties including upregulation of co-stimulatory 
molecules and chemokine induction (Cremel et al., 2006; Tanaka et al., 2008; Vangasseri et 
al., 2006; Yan et al., 2007). DOTAP and DC-Chol are cationic liposome forming lipids and 
therefore it was presumed that they would also express an ability to form a liposome 
depot at the SOI. However, our results showed that although DC-Chol-based liposomes did 
indeed form a liposome depot similar to that noted by DDA, DOTAP-based liposomes 
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drained rapidly from the SOI. In fact, DOTAP:TDB liposomes expressed a similar liposome 
and antigen depot-effect to DODA:TDB liposomes, presumably due to the unsaturated 
nature of both lipids and therefore a similar bilayer fluidity in vivo. DC-Chol-based 
liposomes had a similar biodistribution to DDA:TDB liposomes which suggests a rigid 
nature to the vesicles. The results relating to the immune responses of these liposomal 
formulations were interesting as the previously documented immunostimulatory abilities 
of DOTAP-based liposomes did not translate to increased levels of IFN-γ in immunisation 
studies. Furthermore, whilst DC-Chol:TDB liposomes were strong inducers of early IFN-γ 
production, they failed to maintain this for a longer period (Henriksen-Lacey et al., 2010b). 
A study is currently ongoing to investigate the functionality of T cells derived from mice 
immunised with DOTAP:TDB and DC-Chol:TDB liposomes (personal communication, 
Dennis Christensen). Therefore it appears that whilst DOTAP-based liposomes are efficient 
stimulators of DCs, they are poor at antigen presentation and activation of cell-mediated 
immune responses. The opposite was noted for DDA:TDB liposomes. 
 
7.6 Investigating the Role of Vesicle Size  
Throughout we have highlighted the strong immunogenic properties of DDA:TDB 
liposomes which make these vesicles suitable adjuvants for Ag85B-ESAT-6 antigen 
delivery. As a final investigation, the importance of vesicle size was analysed to determine 
whether changes in DDA:TDB vesicle size altered their ability to cause a liposome and 
antigen depot-effect, and successfully immunise mice with Ag85B-ESAT-6. Whilst no 
differences in the depot-effect were noted across the size ranges studied, significant size-
related differences in liposome draining to the local lymph nodes, splenocyte proliferation 
and IL-10 cytokine production from restimulated splenocytes were noted. Larger 
liposomes drained faster to the lymph node and splenocytes derived from mice 
immunised with larger liposomes proliferated to higher levels upon restimulation ex vivo. 
By contrast, the smallest liposomes of ~ 200 nm showed a slower drainage profile to the 
lymph node and, upon restimulation of splenocytes derived from small liposome 
immunised mice, lower levels of splenocyte proliferation were noted. Liposomes of all size 
ranges elicited similar levels of IgG (IgG1 and IgG2) antibodies and IFN-γ, indicative of 
successful humoral and cell-mediated immune responses respectively. Whilst these results 
therefore suggest an improved ability of larger liposomes to present antigen to APCs 
which in turn can stimulate improved memory T cell, it was interesting to note that 
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restimulation of splenocytes derived from mice immunised with small DDA:TDB liposomes 
resulted in elevated levels of IL-10. In fact, there was an inverse correlation between IL-10 
production and splenocyte proliferation. As IL-10 is documented to inhibit cell 
proliferation (Mocellin et al., 2004; Moore et al., 2001), it remains possible that 
splenocytes derived from small DDA:TDB liposome immunised mice show increased 
production of IL-10 which in turn inhibits their own proliferation. Alternatively the 
opposite may occur in which splenocytes derived from larger DDA:TDB liposome 
immunised mice produce an IL-10 receptor agonist which blocks IL-10  mediated inhibition 
of proliferation as well as autocrine IL-10 production.  
 
7.7 Conclusions and Further Thoughts 
It is evident that cationic liposomes have a special ability to improve immune responses 
towards simultaneously administered antigens. Whilst a model to define the required 
characteristics of a successful cationic liposomal adjuvant has not been finalised in these 
characterisation studies, we have identified a number of physicochemical properties which 
appear to improve immune responses to the vaccine antigen. The ideal liposome in this 
respect appears to have: 
 a cationic surface charge that shows strong adsorption to the vaccine antigen 
 exhibits a rigid bilayer 
 is large (> 1 or 2 μm) in size  
This combination leads to a strong liposome and antigen depot-effect, efficient liposome 
and antigen draining to the local lymph node, uptake and activation by DCs, strong 
humoral immune responses with IgG2 antibody isotypes, IFN-γ production and most 
importantly, long lasting immune responses which are characterised by memory T cells. 
Throughout the studies DDA:TDB liposomes were superior to other liposome formulations 
in their abilities to immunise mice with Ag85B-ESAT-6. The results retaining to DDA:TDB 
vesicle size illustrate an interesting finding as the immunogenicity of ‘normal’ DDA:TDB 
liposomes appears to be augmented upon increasing their vesicle size. These results merit 
further characterisation of the immune responses elicited by the larger version of 
DDA:TDB liposomes. Experiments such as determination of the route of endocytosis would 
be of interest as vesicle size-dependent internalisation is well documented (Brewer et al., 
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2004; Brewer et al., 1998; Mann et al., 2009). Furthermore, determination of the role 
played by IL-10, if any, in splenocyte proliferation could be of interest for therapeutic 
vaccines. The detection of the pro-inflammatory cytokine IL-1β from DCs stimulated with 
DDA:TDB liposomes also raises the question of whether DDA:TDB liposomes and adjuvants 
such as aluminium salts share more features than originally though. Aluminium salts are 
known to cause an antigen depot-effect and stimulate the inflammasome complex which 
is involved in IL-1β production. DDA:TDB liposomes also cause an antigen-depot effect and 
stimulate IL-1β production. Consequently, are some of the adjuvantal effects noted by 
DDA:TDB liposomes a result of local tissue damage causing release and production of 
alarmins? Full production of active IL-1β also requires TLR signalling (Marrack et al., 2009; 
Monie et al., 2009) and although no binding of DDA:TDB liposomes to TLRs has yet been 
discovered, TDB is known to bind to the C-type lectin Mincle (Ishikawa et al., 2009; 
Schoenen et al., 2010). Therefore perhaps there is a potential role for Mincle to stimulate 
the inflammasome? A further interesting correlation between DDA liposomes and 
aluminium salts is their shared inability to stimulate upregulation of co-stimulatory 
molecules on DCs (Korsholm et al., 2006; Sun et al., 2003), however incorporation of TDB 
to DDA liposomes can overcome this problem.  
To finalise, cationic liposomes remain a complex system whereby small changes in the 
physicochemical characteristics result in large changes in the observed immune responses 
towards vaccine antigens. The results presented in this thesis come at an interesting time 
as DDA:TDB liposomes are in clinical trials. Hopefully the results presented in this thesis 
will expand our understanding of how DDA:TDB liposomes work.  
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